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Abstract 
Neisseria gonorrhoeae is a public health concern due to increasing numbers of cases of 
gonorrhoea and the ability of the organism to develop antimicrobial resistance. N. gonorrhoeae 
can harbour β-lactamase plasmids that encode TEM-1 penicillinase, but do not produce extended-
spectrum β-lactamases (ESBLs). ESBLs are active against the last remaining option for gonorrhoea 
monotherapy, ceftriaxone. The aim of this research was to establish what resistance mechanisms 
in N. gonorrhoeae could abolish the effectiveness of ceftriaxone for the treatment of gonorrhoea. 
Investigations into the genetic diversity of blaTEM alleles in gonococcal isolates from 2012 detected 
a high proportion of blaTEM-135 alleles (27%). Only a single specific mutation near the β-lactamase 
active site could result in TEM-135 penicillinase evolving into an ESBL.  
Electroporation was established for the transformation of native gonococcal resistance plasmids 
into N. gonorrhoeae, and was then used in attempts to transfer the enteric plasmid pEK204 
(harbouring blaCTX-M-3 and blaTEM-1) into gonococcal strains. Electroporation and natural 
transformation were additionally used to transform gonococci with blaCTX-M-3 and blaTEM-10 genes. 
Five transformants were detected using blaTEM-10 and these all showed increased minimum 
inhibitory concentrations of ceftriaxone. The lack of success in uptake of pEK204 and blaCTX-M-3 was 
probably due to large plasmid size and lack of recombination site, respectively. Nevertheless, 
gonococcal β-lactamase plasmids were successfully transferred into clinical strains of the 
multidrug-resistant clone N. gonorrhoeae ST1407, suggesting that this could also happen in 
natural mixed gonococcal infections.  
In summary, it is encouraging that no further blaTEM alleles were detected and that                          
N. gonorrhoeae was not able to express a CTX-M-type ESBL. However, the expression of TEM-10 
ESBL is concerning and this work is the first report of ESBL activity in gonococci, albeit in vitro. It is 
essential to continue antimicrobial susceptibility surveillance and to develop molecular 
surveillance to detect rapidly the emergence of an ESBL in N. gonorrhoeae. 
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1 Introduction 
 Gonorrhoea 1.1
1.1.1 Epidemiology 
The Gram-negative bacterium, Neisseria gonorrhoeae, is the aetiological agent of the sexually 
transmitted infection (STI) gonorrhoea. Gonorrhoea is a significant public health problem 
worldwide,  with an estimated 106.1 million new cases diagnosed globally each year (World 
Health Organization, 2008). In England, gonorrhoea is the second most common bacterial STI, 
after chlamydia (Public Health England, 2015). During 2014, 34,958 cases of gonorrhoea were 
reported as part of routine surveillance to Public Health England (PHE), which is a 19% increase 
from the previous year (29,419 cases in 2013) (Public Health England, 2015). In England 
gonorrhoea is more prevalent in urban areas, in particular London, and the burden of gonorrhoea 
within England is in men who have sex with men (MSM), young heterosexuals and persons of 
black ethnicity (Public Health England, 2015). Gonorrhoea is the most common STI in MSM, and 
this patient group demonstrated a 32% increase in 2014 (13,629 to 18,029 diagnoses). Fifty-five 
percent of heterosexuals diagnosed with gonorrhoea were aged 15-24 years (Public Health 
England, 2015). Overall, recent increases in gonorrhoea diagnoses may be due to increases in the 
amount of testing in STI clinics, such as testing of extra-genital sites including pharyngeal and 
rectal testing in MSM (Haidari, Perry, & White, 2014), the widespread use of molecular tests 
which are more sensitive than culture, particularly from extra-genital sites (Haidari et al., 2014) 
and also continual high-risk sexual behaviours, such as no condom usage and high rates of partner 
change (Chen, Ghani, & Edmunds, 2008; Public Health England, 2015).  
1.1.2 Clinical manifestation 
N. gonorrhoeae is an obligate human pathogen, which infects the mucosa of the lower genital 
tract and subsequently presents as urethritis in men and cervicitis in woman (Ison & Lewis, 2003). 
As many as 50% of women remain asymptomatic (Ison & Lewis, 2003), leading to undiagnosed 
and untreated infection which in turn can allow the organism to ascend to the upper genital tract. 
This can lead to pelvic inflammatory disease, ectopic pregnancy and infertility (Ison & Lewis, 
2003). A complication in men is epididymitis which can also lead to infertility (Ison & Lewis, 2003). 
As well as the lower genital tract, N. gonorrhoeae can colonise the rectum, primarily through anal 
intercourse or secondary infection from cervical colonisation, and can colonise the pharynx as a 
result of oral sex. Rarely, N. gonorrhoeae can also enter the bloodstream causing fever and 
disseminated infection in the skin as well as  other tissues, and septic arthritis in joints (Rice, 
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2005). The conjunctiva of neonates can become infected during birth if the mother is infected, 
and conjunctival colonisation can occur in adults through self-inoculation. N. gonorrhoeae eye 
infections need prompt and effective treatment to prevent corneal scarring or perforation (Ison & 
Lewis, 2003). HIV transmission and acquisition has been shown to increase in the presence of 
gonococcal infection (Fleming & Wasserheit, 1999; Mlisana et al., 2012), which is an obvious 
important public health concern. 
1.1.3 Diagnostics 
Sensitive and specific gonorrhoea testing is important to confirm diagnosis and is generally 
recommended for patients with symptoms, partners of patients who have been diagnosed with 
gonorrhoea and also patients with risk factors that are identified with gonorrhoea infection 
(Public Health England, 2014b). Microscopy may be used to diagnose gonorrhoea directly from 
genital smears; Gram or methylene blue staining is used to identify diplococci within 
polymorphonuclear leukocytes. Microscopy can be very sensitive in men with urethral discharge; 
however, the technique can have low sensitivity in women and asymptomatic patients, and is not 
recommended for smears from extra-genital sites such as the rectum or pharynx due to 
contaminating organisms and other Neisseria species that have the same microscopic profile.      
N. gonorrhoeae can be isolated using culture, which can have high sensitivity and specificity, again 
particularly in symptomatic men, and when performed with appropriate collection, transport and 
incubation procedures, and additionally allows the organism to be tested for antimicrobial 
susceptibility which can direct patient management and inform antimicrobial susceptibility 
surveillance studies.   
Commercial nucleic acid amplification tests (NAATs) are available, are increasingly used, and 
employ a variety of amplification methodologies to detect different gonococcal nucleic acids 
directly (Toby, Saunders, & Ison, 2015). Overall, NAATs are more sensitive than culture (Public 
Health England, 2014b), can be used with non-invasive specimens such as urine, are quicker than 
culture and are also amenable to automation. However, care must be taken when using NAATs in 
a low prevalent population as there is an increased likelihood of a false-positive result (Public 
Health England, 2014b). This is also a risk with  specimens from the pharynx and the rectum due 
to cross-reactivity with other Neisseria that have genetic homology with N. gonorrhoeae (Public 
Health England, 2014b). A supplementary NAAT is generally recommended to confirm an initial 
positive result due to these potential problems of low prevalence and cross-reactivity (Public 
Health England, 2014b). Unfortunately the gonococcal NAATs currently available are for species 
identification purposes only and do not detect any markers of antimicrobial resistance, so it is 
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recommended that a culture specimen is taken alongside a NAAT specimen from patients 
suspected to have gonorrhoea (Public Health England, 2014b). Non-commercial NAATs are 
available for the detection of antimicrobial resistance determinants, however the specificity and 
sensitivity can be low (Unemo & Shafer, 2014). 
1.1.4 Patient management 
Repeat gonococcal infections can occur in the same patients as there is little adaptive 
immunological response as well as a poor humoral response to gonococcal infection (Jerse, Bash, 
& Russell, 2014). Vaccine development has been hampered due to the lack of correlates of 
protection for gonorrhoea (Jerse et al., 2014),  along with the unavailability of good animal 
models and due to the obligate human pathogen status of N. gonorrhoeae. The ability of the 
organism to evade the immune system through differing expression of surface antigens and point 
mutations, (Virji, 2009) and the  intracellular nature of the organism also creates difficulties for 
vaccine development.  
With no available vaccine, antibiotic treatment is an extremely important tool in the management 
of gonorrhoea not only to prevent sequelae from infection, but also to interrupt transmission. The 
current recommended first line treatment for gonorrhoea in the UK is dual therapy with 
ceftriaxone 500 mg (increased from 250 mg in 2011) intramuscular plus azithromycin 1 g orally; 
orally administered cefixime with azithromycin may be given, but only if the patient refuses an 
injection (Bignell & Fitzgerald, 2011). Treatment is often given empirically to patients who are 
symptomatic or are contacts of gonorrhoea-positive partners. To ensure compliance with 
antimicrobial therapy, it is administered as a single dose of each agent before the patient leaves 
the clinic and before the antimicrobial susceptibility profile of the infecting isolate is known. 
Therefore, antimicrobial susceptibility surveillance of circulating gonococci is important to inform 
treatment guidelines and to ensure effective treatment. The World Health Organization (WHO) 
recommends that gonorrhoea treatment should be at least 95% effective, so no more than 5% of 
gonococcal isolates should be resistant to the antimicrobial used for first line treatment (Tapsall, 
2001). Effective partner tracing, prevention, epidemiological surveillance and sensitive, specific 
and timely diagnostics are also important tools in the management of gonorrhoea. 
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 History of gonococcal treatment, the emergence of antimicrobial 1.2
resistance and resistance mechanisms in N. gonorrhoeae  
The development of resistance to antimicrobial agents previously used for therapy is often as a 
result of chromosomal mutations acquired through selection or the acquisition of resistance 
determinants (genes, parts of gene and plasmids). This section will describe the antimicrobials 
previously used to treat gonorrhoea, when antimicrobial resistance first emerged and the 
resistance mechanisms responsible.  
1.2.1 Sulphonamides 
The sulphonamides were the first antimicrobials available for gonorrhoea treatment in 1937 but 
resistance was quick to emerge and resistance was prevalent towards the end of the second 
world war (Kampmeier, 1983). Sulphonamide resistance is due to the mutations in 
dihydropteroate synthetase resulting in reduced affinity for sulphonamide or due to the dilution 
of sulphonamide through excessive p-aminobenzoic acid synthesis (Johnson & Morse, 1988). 
1.2.2 Penicillin  
Chromosomal penicillin resistance 
Penicillin was introduced for gonorrhoea treatment in 1943 (Unemo & Nicholas, 2012), but the 
organism quickly became less susceptible to this new antibiotic and subsequently the treatment 
doses were increased to counteract emerging resistance (Lewis, 2010). Chromosomal resistance 
in gonococci results from stepwise changes in loci accumulating in low level resistance/reduced 
susceptibility, then intermediate resistance and finally high-level resistance (Ropp, Hu, Olesky, & 
Nicholas, 2002).  Penicillin inhibits penicillin-binding protein (PBP) enzymes by the formation of an 
acyl-enzyme complex, which subsequently prevents peptidoglycan synthesis. Accordingly, the first 
step in acquiring reduced susceptibility to penicillin are mutations in PBP-2 which is encoded by 
penA, resulting in decreased affinity for penicillin (Dougherty, Koller, & Tomasz, 1980; Spratt, 
1988). Uptake and subsequent recombination of the PBP transpeptidase domain from other 
closely related Neisseria species, as well as amino acid insertions and substitutions, resulted in 
altered mosaic forms of PBP-2 (Spratt, 1988). Subsequent mutations in other genes contribute to 
the accumulative penicillin resistance, such a mutations in mtrR, which encodes a transcriptional 
regulator (MtrR) in the gonococcal multiple transferable resistance (mtr) system. This results in 
increased expression of the MtrC-MtrD-MtrE efflux pump and subsequent resistance to 
antimicrobial agents (Hagman et al., 1995). Outer membrane permeability to penicillin and other 
antimicrobials, such as tetracycline, ciprofloxacin and extended-spectrum cephalosporins is 
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reduced by mutations in the porin PorB1b, encoded by penB, which reduces antimicrobial influx 
into the periplasm, but only when mutations in mtrR are present (Gill et al., 1998; Olesky, Zhao, 
Rosenberg, & Nicholas, 2006; Zhao et al., 2009). The fourth resistance determinant is a mutated 
ponA (Ropp et al., 2002), which encodes PBP-1, resulting in a lower rate of acylation with 
penicillin due to a missense mutation (Ropp et al., 2002). The mutation in ponA, together with as 
yet an unidentified further resistance determinant/s (Ropp et al., 2002; Zhao, Tobiason, Hu, 
Seifert, & Nicholas, 2005), are required to move the isolate from intermediate resistance to high-
level resistance (Ropp et al., 2002). Type IV pili in N. gonorrhoeae are required for DNA uptake 
(Biswas, Sox, Blackman, & Sparling, 1977), adhesion to epithelial cells (Kallstrom, Liszewski, 
Atkinson, & Jonsson, 1997) and for twitching motility (Wolfgang et al., 1998) (see Section 1.5.1). 
PilQ is required for the formation of pili (Zhao, Tobiason, Hu, Seifert, & Nicholas, 2005) and 
mutations in laboratory isolates in pilQ reduces influx of penicillin. However, the presence of this 
mutation in clinical isolates is unlikely as pili formation is disrupted when this mutation is present 
(Whiley et al., 2010).   
Plasmid-mediated penicillin resistance  
Plasmid-mediated high-level resistance to penicillin was first detected in 1976 in the United 
Kingdom (Phillips, 1976) and the United States (Ashford, Golash, & Hemming, 1976). Resistance is 
conferred through the production of the TEM-1 β-lactamase (blaTEM-1), which hydrolyses the β-
lactam ring of penicillin (Bush & Jacoby, 2010). The β-lactamase gene in N. gonorrhoeae is 
encoded by a TnA (ampicillin)-like transposon, Tn2 (Chen & Clowes, 1987; Pagotto et al., 2000a), 
which frequently encodes for β-lactamase in enteric bacteria (Elwell, Roberts, Mayer, & Falkow, 
1977; Roberts, 1989). The regions flanking blaTEM-1 in N. gonorrhoeae include about 40% of the Tn2 
sequence (Elwell et al., 1977; Fayet, Froment, & Piffaretti, 1982; Roberts, Elwell, & Falkow, 1977) 
resulting in a non-transposable Tn2 (Fayet et al., 1982) suggesting that these gonococcal plasmids 
evolved from a deletion event in a plasmid with a full transposon sequence (Fayet et al., 1982). As 
well as TEM-1, the TEM-135 penicillinase has been sporadically detected in N. gonorrhoeae (Chen 
et al., 2013; Muhammad et al., 2014; Nakayama et al., 2012; Ohnishi, Ono, Shimuta, Watanabe, & 
Okamura, 2010a; Srifeungfung et al., 2009). This variant was first reported in N. gonorrhoeae from 
Thailand in 2009 (Srifeungfung et al., 2009), although a recent retrospective study found that 
TEM-135 has been present in N. gonorrhoeae since at least 1984 (Muhammad et al., 2014). The 
TEM-135 enzyme differs from TEM-1 by one amino acid substitution (M182T), and was first 
identified in an isolate of Salmonella enterica subsp. enterica serovar Typhimurium from a rabbit 
in Italy (Pasquali, Kehrenberg, Manfreda, & Schwarz, 2005).  
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The quick dissemination of this high-level penicillin resistance rendered this once highly effective 
antimicrobial unusable by 1987 (Ropp et al., 2002). The epidemiological links (i) to West Africa for 
the patient infected with the penicillinase-producing N. gonorrhoeae (PPNG) isolated in Great 
Britain (Phillips, 1976) and (ii) to Asia for US personnel returning from Southeast Asia ( Ashford et 
al., 1976) resulted in these two β-lactamase plasmid types becoming known as ‘African’ and 
‘Asian’ plasmids, respectively. Since then six other different β-lactamase plasmids have been 
identified, again named according to their epidemiological origin; Toronto (Yeung, Dillon, Pauze, & 
Wallace, 1986), Rio (Van Embden, Dessens-Kroon, & Van Klingeren, 1985), Nîmes (Gouby, Bourg, 
& Ramuz, 1986), New Zealand (Brett, 1989), Johannesburg (Muller, Fayemiwo, & Lewis, 2011) and 
Australian (Trembizki, Buckley, Lawrence, Lahra, & Whiley, 2014). Although they share a high 
degree of sequence identity; the major differences are due to insertions or deletions of repeat 
regions, and the Toronto and Rio plasmids were found to have the same sequence (Pagotto et al., 
2000a).  It was initially postulated that the Asian and African plasmids may have emerged 
independently (Elwell et al., 1977), however, subsequent sequencing has shown that the large 
repeats within the plasmid DNA allows for DNA re-arrangement, deletions and insertions in non-
TnA coding regions which could have produced the different plasmid types (Pagotto et al., 2000a). 
Further sequence analysis has shown that the African, Toronto/Rio and Johannesburg plasmids 
resulted from deletion events in the Asian plasmid and the Nîmes and New Zealand plasmids 
resulted from insertion events into the African plasmid (Muller et al., 2011; Pagotto et al., 2000a).  
Transfer of the β-lactamase plasmids between strains of N. gonorrhoeae occurs via conjugation 
when the conjugative plasmid is additionally present (Baron, Saz, Kopecko, & Wohlhieter, 1977; 
Roberts, 1989). It is unclear exactly how gonococci acquired these plasmids harbouring blaTEM-1  as 
the plasmids are not gonococcal in origin (Roberts et al., 1977). One hypothesis is that the 
gonococcal β-lactamase plasmids originated in Haemophilus species (Brunton, Clare, & Meier, 
1986; Chen & Clowes, 1987), as supported by sequence homology between the gonococcal and 
Haemophilus β-lactamase plasmids (Roberts et al., 1977). There is, however, a strong link to 
Enterobacteriaceae due to the presence of the TnA (Fayet et al., 1982), Insertion Sequence 5 (IS5) 
(Pagotto et al., 2000a), as well as the plasmids being able to be transferred and replicate in 
Escherichia coli and other genera (Dillon & Yeung, 1989). Therefore, the movement of these 
plasmids from enteric bacteria via Haemophilus species seems the most likely evolutionary route. 
Transfer of these resistance plasmids from Haemophilus species could have occurred through 
conjugation, or alternatively through transformation, which has been shown to result in plasmid 
deletions (Sox, Mohammed, & Sparling, 1979) providing some explanation for the truncated 
transposon in the gonococcal β-lactamase plasmids. 
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1.2.3 Tetracycline 
Chromosomal tetracycline resistance 
Tetracyclines were used in the early years of gonorrhoea antimicrobial therapy. Tetracyclines 
inhibit protein synthesis and resistance is conferred by a mutation in the chromosomal gene that 
encodes for the S10 ribosomal protein, which results in ribosomal protection from the 
tetracycline (Hu, Nandi, Davies, & Nicholas, 2005). Mutations in other chromosomal genes, such 
as mtrR and penB (Olesky et al., 2006)  as well as pilQ, results in accumulative resistance to 
tetracycline (Zhao et al., 2005).  
Plasmid-mediated tetracycline resistance 
High-level plasmid-mediated tetracycline resistant N. gonorrhoeae (TRNG) evolved from the 
insertion of a tet(M) determinant (Morse, Johnson, Biddle, & Roberts, 1986), which confers 
ribosomal protection (Chopra & Roberts, 2001), into the 24.5 MDa gonococcal conjugative, self-
transferable plasmid (Knapp, Johnson, Zenilman, Roberts, & Morse, 1988; Morse et al., 1986).  
TRNG were first identified in the USA in 1985 (Centers for Disease Control and Prevention, 1985; 
Knapp et al., 1987) and the Netherlands (Roberts, Wagenvoort, van Klingeren, & Knapp, 1988) and 
it is these locations that have been used to name the TRNG plasmids as ‘American’ and ‘Dutch’ 
type plasmids which are now distributed globally (Roberts, 1989). These 25.2 MDa plasmids are 
still able to move between strains and facilitate the movement of the β-lactamase plasmids 
(Dillon & Yeung, 1989), and gonococcal isolates can harbour both the tetracycline and β-
lactamase producing plasmids (Gascoyne-Binzi, Hawkey, & Heritage, 1994). Restriction 
endonuclease mapping revealed differences in the tetracycline plasmids, including sizes (Dutch 
40.5 kb and American 42.8 kb) (Gascoyne, Heritage, Hawkey, Turner, & van Klingeren, 1991). It is 
unclear how these two different plasmid types evolved, but two possibilities were originally 
proposed (Gascoyne et al., 1991) such as evolving from two different progenitor conjugative 
plasmids with a recombination event with the tet(M) resistance determinant or recombination of 
the American plasmid with a conjugative plasmid to create the Dutch plasmid. However, 
sequencing of the tet(M) genes from the two plasmid types showed 96.8% identity, as well as 
different levels of sequence homology with Tn1545, Tn916 and Ureaplasma urealyticum tet(M) 
genes, which suggests the two plasmids have different origins (Gascoyne-Binzi, Heritage, & 
Hawkey, 1993) and were not recombination events of the American plasmid with a conjugative 
plasmid resulting in the Dutch plasmid. More recent sequence analysis has revealed that the 
Dutch and American TRNG plasmids are conjugative plasmids with either a Dutch or American 
backbone, and contain either a Dutch or American tet(M) determinant, so using the tet(M) as a 
marker to differentiate between the plasmid types is insufficient (Pachulec & van der, 2010). It 
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has also been suggested that transposition (class II) of a Tn916-like transposon into the 
conjugative plasmid has resulted in some deletions in the transposon resulting in subsequent loss 
of transposition functions but leaving the tet(M) determinant intact (Gascoyne et al., 1991; 
Swartley, McAllister, Hajjeh, Heinrich, & Stephens, 1993).  
1.2.4 Azithromycin 
Azithromycin was developed in the 1980s and is a macrolide antimicrobial that inhibits protein 
synthesis by binding to the 50S ribosomal subunit. Azithromycin is not recommended as first-line 
monotherapy for gonorrhoea as resistance can be rapidly selected, but azithromycin (2 g orally) is 
a second-line treatment option, and is now used in dual therapy (1 g orally) with ceftriaxone 
(Bignell & Fitzgerald, 2011). Again, increased efflux due to mtrR gene mutations confers some 
resistance, but the other resistance mechanisms are modification the ribosomal target through 
expression of rRNA methylases (Roberts et al., 1999) or mutations in the peptidyltransferase loop 
in domain V of the 23S rRNA (Chisholm, Dave, & Ison, 2010; Ng, Martin, Liu, & Bryden, 2002). The 
A2059G substitution in three to four of the 23S rRNA alleles can result in very high-level 
azithromycin resistance (> 256 mg/L) (Chisholm et al., 2010) which has been detected sporadically 
worldwide (Chisholm & Ison, 2008; Cole et al., 2010; Galarza et al., 2009; Starnino & Stefanelli, 
2009) and can be selected for in the laboratory when just one allele carries the A2059G mutation 
(Chisholm et al., 2010). 
1.2.5 Ciprofloxacin 
From 1989 to 2004 ciprofloxacin was first-line treatment for gonorrhoea in the UK (Ross & Maw, 
2002), and like penicillin was extremely effective. Low dosages were used initially, until reported 
treatment failures in 1990 (Gransden, Warren, Phillips, Hodges, & Barlow, 1990) and decreasing 
susceptibility was recorded in the UK (Ison, Martin, Ivens, Philip, & Greene, 2001).  The continual 
rise in ciprofloxacin resistance meant that ciprofloxacin was no longer recommended for first line 
treatment in the UK from 2004 (Bignell, 2004). 
Ciprofloxacin targets type II topoisomerases DNA gyrase (super-coils linear DNA and is encoded by 
gyrA and gyrB) and topoisomerase IV (encoded by parC and parE) which along with adenosine 
triphosphate hydrolysis are involved in the breaking and re-joining of the bacterial double-
stranded DNA (Belland, Morrison, Ison, & Huang, 1994). Resistance is accumulative, with 
susceptibility decreasing with a single mutation in gyrA, and resistance increasing dramatically 
with multiple concomitant mutations in gyrA and parC (Belland et al., 1994).  
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1.2.6 Extended-spectrum cephalosporins  
Extended-spectrum cephalosporins (ESCs) (oral cefixime or intramuscular ceftriaxone) became the 
recommended treatment options for gonorrhoea in the UK in 2004 (Bignell, 2004) due to 
increasing ciprofloxacin resistance levels. Since then, and like all the other previous antimicrobials, 
susceptibility to the ESCs has been decreasing in England and Wales (Public Health England, 2013) 
and globally (Bala, Kakran, Singh, Sood, & Ramesh, 2013; Cole et al., 2015a; Dillon, Trecker, & 
Thakur, 2013; Kirkcaldy, Kidd, Weinstock, Papp, & Bolan, 2013; Lahra, Lo, & Whiley, 2013). The 
current UK treatment recommendations were updated in 2011 (Bignell & Fitzgerald, 2011) in 
response to emerging cefixime resistance (Public Health England, 2013) and global treatment 
failures; treatment failure to cefixime was first detected in Hawaii in 2001 (Wang et al., 2003) and 
Japan in 2002 (Yokoi et al., 2007), and since then treatment failures with cefixime and ceftriaxone 
have been detected in Europe (Golparian et al., 2014; Unemo, Golparian, & Hestner, 2011a; 
Unemo, Golparian, Potocnik, & Jeverica, 2012; Unemo, Golparian, Stary, & Eigentler, 2011c; 
Unemo, Golparian, Syversen, Vestrheim, & Moi, 2010) and the UK (Forsyth, Penney, & Rooney, 
2011; Ison, Hussey, Sankar, Evans, & Alexander, 2011). More recently, gonococcal strains 
demonstrating high-level ceftriaxone and cefixime resistance have emerged, firstly in Japan 
(Ohnishi et al., 2011), and a strain with the same molecular type caused treatment failure in 
France (Unemo et al., 2011b) and was detected in two sexual contacts in Spain (Camara et al., 
2012). 
Decreased susceptibility to cefixime is mainly due to mosaicism in the penA gene, resulting in up 
to 60 amino acid changes in PBP-2 compared with the wild type sequence (Takahata, Senju, Osaki, 
Yoshida, & Ida, 2006). This results in conformational changes in the -lactam binding pocket of 
the PBP-2 protein and decreased affinity for cefixime (Osaka et al., 2008; Tomberg, Unemo, 
Davies, & Nicholas, 2010). The mosaic penA genes are comprised of gene fragments obtained 
through recombination from N. gonorrhoeae together with fragments derived from commensal 
Neisseria species, usually found in the throat, and which can be less susceptible to cephalosporins 
(Ameyama et al., 2002; Ito et al., 2005). DNA exchange in the throat between Neisseria species 
can occur because of the competence of N. gonorrhoeae which allows the organism to acquire 
DNA through horizontal gene transfer. Pharyngeal gonorrhoea can be more difficult to treat 
compared with genital infections (Unemo & Nicholas, 2012) which can impose greater selection 
for these less susceptible strains in the pharynx.  
The mosaic penA gene seems less involved in decreased susceptibility to ceftriaxone, where a 
specific A501V substitution in a non-mosaic penA (Takahata et al., 2006) along with other 
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mutation variants (Whiley, Limnios, Ray, Sloots, & Tapsall, 2007) in PBP-2 appear to play a role. 
The A501V substitution is specific to gonococci at this present time suggesting that this resistance 
emerged through selection in gonococci rather than via acquisition from other Neisseria (Unemo 
& Nicholas, 2012). The first strain displaying high-level cefixime and ceftriaxone resistance 
isolated in Japan contained a penA mosaic but with 12 amino acid alterations when compared 
with the more commonly described penA mosaic X (Ohnishi et al., 2011). Three amino acid 
changes (A311V, V316P, and T483S) have been verified to contribute to the high-level ceftriaxone 
and cefixime resistance in the Japanese strain (Tomberg, Unemo, Ohnishi, Davies, & Nicholas, 
2013). A combination of a mosaic penA and an A501P substitution was detected in the high-level 
resistant strain from France (Unemo et al., 2011b) resulting in much higher MICs (cefixime 4 mg/L, 
ceftriaxone 1-2 mg/L). Sustained transmission of these high-level resistant strains has not been 
detected, suggesting reduced biological fitness (Unemo et al., 2011b).   
Transformation of the penA gene from strains displaying decreased susceptibility to ESCs into 
susceptible recipients resulted in raised ESC minimum inhibitory concentrations (MICs) in the 
recipients but not to the same as the level in the donor strain. For both cefixime and ceftriaxone, 
mutations in mtrR and penB also play additive roles in conferring further reductions in 
susceptibility (Osaka et al., 2008; Zhao et al., 2009). PenA, mtrR and penB seem to play an equal 
role in ceftriaxone decreased susceptibility, whereas for cefixime penA plays more of a dominant 
role (Zhao et al., 2009). These differences may be due to differences in the net charge of cefixime 
and ceftriaxone and this may affect the ability of the two antimicrobials to permeate the 
periplasmic space (Zhao et al., 2009). The addition of these resistant determinants in 
transformation studies still do not transform a recipient strains MIC to the donor levels indicating 
an unknown resistance (factor X) determinant is present in strains displaying decreased 
susceptibility to ESCs (Ohnishi et al., 2011; Unemo et al., 2011b; Zhao et al., 2009). 
With no other long-term treatment options available (Unemo, 2015), the risk of untreatable 
gonorrhoea is real, particularly with the emergence of the high-level ceftriaxone and cefixime 
strains which also display resistance to other antimicrobials. This threat has prompted the 
development of national, regional and global action plans to combat the spread of multi-drug 
resistant gonorrhoea (European Centre for Disease Prevention and Control, 2012; Health 
Protection Agency, 2013; Ndowa, Lusti-Narasimhan, & Unemo, 2012).  
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 Summary of N. gonorrhoeae antimicrobial resistance prevalence; 1.3
globally and within England and Wales 
1.3.1 Penicillin  
Penicillin resistance remains high globally even though resistance emerged many years ago and 
penicillin is no longer used for treatment (Bignell & Unemo, 2013). Penicillin resistance levels 
globally range from 13.2% in the US (2012 data) (Kirkcaldy et al., 2013), 24% in South America and 
the Caribbean (pooled 1990-2011 data) (Dillon et al., 2013), 32% in Russia (2010 data) (Unemo et 
al., 2013), up to 66% in the Western Pacific Region (2011 data) (Lahra et al., 2013), and are close 
to 100% in the South-East Asia region (2009–2012 data) (Bala et al., 2013). The total penicillin 
resistance (combined chromosomal and plasmid-mediated resistance) in England and Wales has 
been increasing since 2011 with 18.4% penicillin resistance observed in 2013 (Figure 1.1). PPNG 
prevalence in England and Wales was 6.7% in 2013 (Public Health England, 2014a) which is low 
compared with some countries in South-East Asia, where PPNG rates may be as high as 100% 
(Bala et al., 2013; Public Health England, 2014a). 
 
Figure 1.1 Percentage of gonococcal isolates resistant to ciprofloxacin (> 0.5 mg/L), penicillin (> 1 
mg/L) and tetracycline (> 1 mg/L) from GRASP clinics, 2009 to 2013 (data taken from the GRASP 
2013 report (Public Health England, 2014a)).  
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in 2013 (Figure 1.1) (Public Health England, 2014a) even though tetracycline is no longer used for 
the treatment of gonorrhoea (Bignell & Unemo, 2013).  
1.3.3 Ciprofloxacin 
Ciprofloxacin resistance in N. gonorrhoeae is high globally. Latest resistance data revealed 13.5% 
in the US (2012 data) (Kirkcaldy et al., 2013), 14.8% in  South America and the Caribbean (pooled 
1990-2011 data) (Dillon et al., 2013), 53% in Russia (2010 data) (Unemo et al., 2013), 53% across 
Europe (2013 data) (Cole et al., 2015a), up to 99% in the Western Pacific Region (2012 data) and 
up to 100% in the South-East Asia region (2009–2012 data) (Bala et al., 2013). Within England and 
Wales ciprofloxacin resistance levels were at 29% in 2013 (Public Health England, 2014a) which is 
an increase from 2012 (25%) but still lower than 2009-2011 (34-35%) (Figure 1.1).  
1.3.3.1 Azithromycin 
There is no overall increasing or decreasing trend in azithromycin resistance within England and 
Wales (Figure 1.2) (Public Health England, 2014a) or other regions (Bala et al., 2013; Cole et al., 
2015a; Dillon et al., 2013; Kirkcaldy et al., 2013; Lahra et al., 2013), but resistant strains are 
circulating. The most recent 2013 GRASP data revealed azithromycin resistance at 1.6% which 
included three isolates with azithromycin MICs of > 256 mg/L (Public Health England, 2014a).  
 
Figure 1.2 Percentage of gonococcal isolates resistant to ceftriaxone (> 0.064 mg/L), cefixime (> 
0.064 mg/L)  and azithromycin (> 0.5 mg/L) from GRASP clinics, 2009 to 2013 (data taken from the 
GRASP 2013 report (Public Health England, 2014a)).  
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1.3.4 Extended-spectrum cephalosporins  
Isolates with elevated ceftriaxone MICs increased from 0.05-0.3% in the US (2006–2012) 
(Kirkcaldy et al., 2013), increased from 0.7% in 2007 to 1% in 2011 in  South America and the 
Caribbean (Dillon et al., 2013), up to 25% in the Western Pacific Region (2011) (Lahra et al., 2013) 
and a wide range of 0.1% to 84.2% in the South-East Asia region (2009–2012 data) (Bala et al., 
2013). In addition  ceftriaxone MICs are increasing across Europe (Cole et al., 2015a), Russia 
(Unemo et al., 2013) and  in England and Wales (Public Health England, 2013). For cefixime, 
elevated MICs increased from  0.1-1.1% in 2006 to 2012 in the US (Kirkcaldy et al., 2013) and the 
resistance levels across Europe are currently at 4.7% in 2013, which is a slight increase from 3.9% 
in 2012 (Cole et al., 2015a). In England and Wales isolates with increased cefixime MICs increased 
rapidly from 1.2% in 2008 to 17.1% 2010, however levels have decreased again to 5.2% in 2013 
(Figure 1.2) (Public Health England, 2014a).   
 Molecular epidemiology of N. gonorrhoeae 1.4
The molecular epidemiology of N. gonorrhoeae has been studied extensively, most recently using 
the Neisseria gonorrhoeae multi-antigen sequence typing (NG-MAST) molecular method. NG-
MAST is a sequence-based typing method, which exploits sequence variation in two hypervariable 
gonococcal genes; tpbB, which encodes the subunit B of the transferrin-binding protein, and porB, 
which is the gene for the outer membrane porin (Martin, Ison, Aanensen, Fenton, & Spratt, 2004). 
The hypervariable nature of these genes makes the technique highly discriminatory. Additionally 
NG-MAST is reproducible, objective and there is a web-based database, which allows results to be 
shared internationally (www.ng-mast.net). NG-MAST has been used most frequently to identify 
associations between sequence types (STs), antimicrobial resistance and sexual orientation, along 
with the molecular investigation of sexual networks (Chisholm et al., 2013; Choudhury et al., 
2006; Cole et al., 2013; Ison et al., 2013b). 
Examples of how NG-MAST can be used for public health purposes are available in many studies 
(Unemo & Dillon, 2011), including a study in England and Wales that established that the majority 
of gonococcal isolates with decreased susceptibility to cefixime from 2007 to 2011 belonged to a 
clonal group of isolates that were all the same or closely related to ST1407; genogroup 1407 (G1407),  
and were associated with infection in MSM (Ison et al., 2013b). A NG-MAST genogroup consists of 
isolates with the same ST or ≥ 99% similar (Chisholm et al., 2013). A European study used isolates 
collected in 2010 by the European Gonococcal Antimicrobial Surveillance programme that were 
NG-MAST typed and the data analysed, like the previous study, in the context of epidemiological 
information and therapeutically relevant resistance profiles (Chisholm et al., 2013). The study 
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elucidated that the gonococcal population in Europe is highly heterogeneous but some main 
genogroups predominate. The study generated a base-line for NG-MAST STs and genogroups, 
which is of importance to support outbreak investigations. One of the key findings from this 
European study was that G1407 was also most predominant across Europe in 2010 (23% of all 
isolates and found in 20 of the 21 participating countries) and was associated with both MSM and 
heterosexual networks (Chisholm et al., 2013). As well as decreased susceptibility/resistance to 
cefixime, G1407 is a multi-drug resistant gonococcal clone with decreased 
susceptibility/resistance to azithromycin, ceftriaxone and ciprofloxacin, and was responsible for 
most of the decreased susceptibility/resistance to cefixime, which was until 2011, the 
recommended first-line antimicrobial for monotherapy in Europe. The high prevalence of this 
multi-drug resistant gonococcal clone in Europe, including in England and Wales, and globally, is 
of concern. Representatives of the G1407 genogroup were responsible for two of the UK cefixime 
treatment failures (Ison et al., 2011), along with other treatment failures that have occurred in 
Europe (Unemo et al., 2011b; Unemo et al., 2012; Unemo et al., 2011c; Unemo et al., 2010). 
Worryingly, only a single amino acid substitution (A501P) in the mosaic penA gene (Unemo et al., 
2011b) would be required to render G1407 strains highly resistant to ceftriaxone (Unemo et al., 
2011b) which is the last remaining option for empiric monotherapy of gonorrhoea (Bignell & 
Fitzgerald, 2011). 
 Mechanisms of DNA and plasmid transfer in N. gonorrhoeae  1.5
1.5.1 Transformation 
Chromosomal DNA transformation 
N. gonorrhoeae are naturally competent, i.e.  they are able to take up and recombine Neisserial 
DNA into their genome. This competence allows the spread of antimicrobial resistance 
determinants throughout the gonococcal population and enables the gonococcus to adapt to 
selection pressure. The acquisition of external DNA can result in the horizontal transfer of 
chromosomal genes to create either mosaic alleles (sections of DNA from independent alleles) or 
complete gene replacement of identical alleles (Maiden, Malorny, & Achtman, 1996). 
Chromosomal DNA is available for transformation due to the autolytic nature of N. gonorrhoeae 
(Hebeler & Young, 1975)  and the ability of the gonococcus to donate DNA via a type IV secretion 
system (Hamilton, Dominguez, Schwartz, Hackett, & Dillard, 2005) which is encoded by the 
gonococcal genetic island (GGI). The GGI is a 57 kb DNA element present in approximately 80% of 
N. gonorrhoeae (Dillard & Seifert, 2001). Neisserial DNA is recognised by a genus-specific non-
palindromic DNA uptake sequence (DUS), which was initially thought to be 10 bp (Goodman & 
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Scocca, 1988), but investigation of a whole sequenced genome has identified a more prevalent 12 
bp DUS which results in more efficient transformation (Ambur, Frye, & Tonjum, 2007; Smith, 
Gwinn, & Salzberg, 1999).  There are up to 2,000 copies of the DUS in the gonococcal genome, 
which is approximately 1% of the genome (Smith et al., 1999).   The 12-mer DUS may also have a 
role in transcription as 50% are found at the end of genes as inverted repeats (Ambur et al., 
2007). 
Chromosomal DNA enters the gonococcus as double-stranded DNA (dsDNA) until homologous 
recombination with the gonococcus genome finalises the transformation progress (Biswas & 
Sparling, 1981). The exact role of single-stranded DNA (ssDNA) in gonococcal transformation 
remains unclear, even though at some point during the transformation process ssDNA must be 
available for recombination. Transformation studies have detected that donor DNA is mainly 
dsDNA, so detection of DNase I-resistant ssDNA (Chaussee & Hill, 1998) suggests that ssDNA 
formation occurs in the periplasm. Single-stranded DNA can also be used for transformation albeit 
less efficiently (Duffin & Seifert, 2010). 
The pioneering work on gonococcal genetics by Sparling in 1966 (Sparling, 1966) revealed that N. 
gonorrhoeae can transform DNA throughout their whole growth cycle, but transformation is 
dependent upon the presence of pili  (Biswas, Sox, Blackman, & Sparling, 1977) which are variably 
expressed and can undergo variation through recombination (Segal, Billyard, So, Storzbach, & 
Meyer, 1985). N. gonorrhoeae harbour type IV pili on their outer membrane, which are composed 
of pilin (PilE) subunits (Nassif, Pujol, Morand, & Eugene, 1999) and PilC which is a pilus-associated 
protein involved in pili assembly and adherence (Rudel et al., 1995). As well as competence, pili 
are involved in adhesion to epithelial cells via the membrane cofactor protein CD46 (Kallstrom, 
Liszewski, Atkinson, & Jonsson, 1997) and are required for twitching motility (Wolfgang et al., 
1998). As pili are required for transformation, it is important that piliated colonies are selected for 
transformation work. Other proteins involved in the uptake of DNA across the cell envelope and 
integration into the chromosome include PilT, which is involved in twitching motility (Wolfgang et 
al., 1998), ComA (Facius & Meyer, 1993), ComE (Wolfgang, van Putten, Hayes, & Koomey, 1999) 
and ComP (Chen & Gotschlich, 2001) which are involved in the facilitation and translocation of 
DNA through the two bacterial membranes and into the cytoplasm, and RecA for recombination 
into the chromosome (Koomey & Falkow, 1987). The actual receptor for the binding of the DUS 
and transforming DNA and the exact role pili play in transformation remains to be elucidated 
(Hamilton & Dillard, 2006). 
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Plasmid transformation 
N. gonorrhoeae can acquire plasmids through transformation, albeit much less efficiently than 
chromosomal DNA (Sox et al., 1979). Plasmid transformation can result in deletions, particularly if 
there are no other plasmids present for homologous recombination (marker rescue) (Biswas, 
Graves, Sox, Tenover, & Sparling, 1982). N. gonorrhoeae can produce restriction enzymes and 
methylases so transformed plasmids are subjected to host-mediated restriction (Stein, Gregoire, 
& Piekarowicz, 1988), even though this does not inhibit the transformation of chromosomal DNA 
(Stein, 1991). During transformation the plasmids are first linearised to enable uptake and then 
re-circularisation and homologous recombination takes place (Biswas, Burnstein, & Sparling, 
1986). The presence of the 12 bp DUS can increase plasmid transformation by two-fold (Ambur et 
al., 2007).   
1.5.2 Conjugation 
Some N. gonorrhoeae are also able to transfer plasmids, but not chromosomal DNA, efficiently 
through conjugation (Biswas, Thompson, & Sparling, 1989b). The transfer of plasmids between 
gonococci is made possible of the presence of the 24.5 MDa conjugative plasmid in the donor 
strain, which is self-transferable and is required to mobilise β-lactamase plasmids (Baron et al., 
1977; Sox, Mohammed, Blackman, Biswas, & Sparling, 1978). The gonococcal tetracycline 
resistance plasmids (25.2 MDa) can also transfer the β-lactamase plasmids (Roberts & Knapp, 
1988b).  The tetracycline plasmids have been detected in other bacterial species, including            
N. meningitidis, Eikenella corrodens and Kingella denitrificans (Knapp et al., 1988) and can be 
transferred to different Neisseria species (Roberts & Knapp, 1988a) so have  a broader host range 
than the conjugative plasmid which cannot be transferred and maintained to other Neisseria 
species (Genco, Knapp, & Clark, 1984; Roberts & Knapp, 1988b). Plasmid DNA is not restricted 
when conjugally transferred (Stein et al., 1988) and piliation is not required for conjugation.  
 Extended-spectrum β-lactamases  1.6
In Gram-negative bacteria, -lactamase production is the most common form of resistance to     
-lactam antibiotics (Bonnet, 2004) which include the penicillins and the cephalosporins. As 
previously described, plasmid-mediated high-level resistance to penicillin is conferred through the 
production of TEM-1 or TEM-135 in N. gonorrhoeae. Both these penicillinases have no hydrolytic 
activity against ESCs, but these antibiotics are substrates for extended-spectrum -lactamases 
(ESBLs), which are produced by other bacteria. ESBLs are diverse plasmid-mediated enzymes 
which fortunately have not been documented in N. gonorrhoeae as ESBL expression would render 
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all cephalosporins useless for the treatment of gonorrhoea. The CTX-M (Cefotaximase-Munich) 
family of ESBLs are the leading cause of ESC resistance in E. coli in the UK and globally which is of 
major public health concern and of great therapeutic challenge (Bonnet, 2004; Livermore et al., 
2007). Cefotaxime is an oxyimino-cephalosporin which was made available for use in the 1980’s 
due to emerging -lactam resistance. The usual antibiotic resistance story developed due to the 
production of ESBLs selected by increased use of cefotaxime (Bonnet, 2004) and other 
cephalosporins. The first clinical cefotaxime resistant E. coli was detected in Germany in 1989 and 
designated CTX-M-1 (Bauernfeind, Grimm, & Schweighart, 1990). Cefotaxime resistance has been 
globally widespread since 1995 (Bonnet, 2004) with the CTX-M enzymes being the most common 
ESBLs globally (Canton & Coque, 2006). Since then a large variety of CTX-M ESBLs have been 
identified and sequenced globally (more than 165 variants described to date) (Lahey Clinic, 2015)  
and are contained within five different phylogenetic clusters based upon sequence identity    
(CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25) (Canton & Coque, 2006; Lahey Clinic, 
2015). As well as antibiotic selection the widespread distribution of cefotaxime resistance can be 
attributed to the ability of CTX-M plasmids to be transferred by conjugation, and even for those 
plasmids lacking the genes required for conjugation, transfer can still occur through 
transformation (Bonnet, 2004). As well as the mobilisation of the plasmids the blaCTX-M genes are 
themselves also mobile allowing transfer to other plasmids and the plasmid’s host chromosome.  
This mobility is due to insertion sequences such as ISEcp1 (Canton & Coque, 2006).  
Within the UK, ESBL-producing E. coli are dominated by variants of the uropathogenic ST131 
lineage and most express CTX-M-15 -lactamase (Lau et al., 2008). CTX-M-15 was detected in 
2001 in India (Karim, Poirel, Nagarajan, & Nordmann, 2001) and is now the most widespread   
CTX-M enzyme globally (Clermont et al., 2008; Coque et al., 2008). CTX-M-15 differs from         
CTX-M-3 by one amino acid substitution (ASP240GLY) (Poirel, Gniadkowski, & Nordmann, 2002), 
conferring greater hydrolytic activity against ceftazidime, another oxyimino-cephalosporin.  Even 
though only one amino-acid substitution separates CTX-M-15 and CTX-M-3, Enterobacteriaceae 
have most likely acquired different plasmids encoding these enzymes on separate occasions 
(Woodford et al., 2009). Infection with E. coli can cause life threatening bacteraemia, however, 
the majority of infections are in the urinary tract and are associated with the elderly, long hospital 
stays and heavy antibiotic use (Oteo, Perez-Vazquez, & Campos, 2010). However, this ESBL 
ecology is changing as ESBLs are also reported (i) in E. coli causing community-onset urinary tract 
infections (UTIs), often with healthcare contact, prior antibiotic use, co-morbidities and foreign 
travel as a risk factor (Oteo et al., 2010); (ii) in some patients with community-onset infections 
with no obvious risk factors (Rodriguez-Bano et al., 2010) and (ii) in E. coli colonising the guts of 
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healthy individuals (Rodriguez-Bano, Lopez-Cerero, Navarro, Diaz, & Pascual, 2008). This 
increasing prevalence of ESBL E. coli in the community setting, as opposed to the traditional 
elderly patient groups, may provide N. gonorrhoeae with increasing opportunities for exposure to 
ESBL-producing E. coli in the urogenital tract and rectal N. gonorrhoeae infections may be exposed 
to enteric bacteria with plasmid-encoded antimicrobial resistance determinants.  Patients with 
community-acquired UTI caused by an ESBL-producing E. coli have been shown to also have 
clonally related faecal isolates. In addition, clonally-related faecal isolates have been identified in 
the relatives of patients with community-acquired UTI and between sexual partners (Rodriguez-
Bano et al., 2008). How healthy individuals in the community acquire ESBL-producing E. coli has 
not been elucidated.  
As well as transfer of ESBLs from E. coli, development of ESBLs could occur within the gonococcal 
blaTEM. As previously discussed, TEM-135 has been detected in N. gonorrhoeae (Chen et al., 2013; 
Muhammad et al., 2014; Nakayama et al., 2012; Ohnishi et al., 2010a; Srifeungfung et al., 2009) 
and, even though TEM-135 lacks ESBL activity, the M182T substitution does increase enzyme 
stability (Orencia, Yoon, Ness, Stemmer, & Stevens, 2001), and only one additional amino acid 
change is required for ESC hydrolysis. This is demonstrated by the three ESBLs that differ from 
TEM-135 by one amino acid substitution (TEM-20, TEM-106 and TEM-126) (Lahey Clinic, 2015). 
Therefore, the potential evolution of blaTEM-1 and blaTEM-135 into ESBLs in N. gonorrhoeae needs to 
be monitored closely.  
 The transfer of chromosomal and plasmid DNA from E. coli to              1.7
N. gonorrhoeae 
1.7.1 Transfer of native non-gonococcal plasmids from E. coli and other genera to       
N. gonorrhoeae  
There is no published research on the transfer of enteric plasmids into N. gonorrhoeae, however, 
there has been some research performed on the conjugal transfer of other non-gonococcal 
plasmids into N. gonorrhoeae. The Haemophilus ducreyi plasmid, pHD131, was successfully 
transferred and maintained from E. coli to N. gonorrhoeae by transformation (Piffaretti & Soldati, 
1990) but the transformation efficiency was low. Plasmid pHD131 contains an entire functional 
copy of the TEM-1-encoding transposable element, TnA, whereas the gonococcal β-lactamase 
plasmid carries a deleted TnA gene (Roberts et al., 1977). The experiments by Piffaretti et al. 
(1990) demonstrated that N. gonorrhoeae can harbour an intact TnA, and the deleted TnA in       
N. gonorrhoeae could be due to deletion events from when the β-lactamase plasmids entered the 
gonococcus via transformation, rather than the inability of N. gonorrhoeae to harbour a full TnA 
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gene. Plasmid deletions like the aforementioned have previously been observed in plasmids 
entering the gonococcus by transformation (Sox 1979), yet no plasmid deletions were observed 
by Piffaretti et al. (1990). It should be noted that pHD131 was also transferred to N. gonorrhoeae 
by conjugation with E. coli, however, the mobilising element pUB307 was also present in E. coli to 
facilitate conjugation. 
1.7.2 Transfer of native and modified gonococcal β-lactamase plasmids from E. coli to 
N. gonorrhoeae  
Flett, Humphreys, and Saunders (1981) were unsuccessful in trying to mobilise a gonococcal         
β-lactamase plasmid in a triparental mating (from N. gonorrhoeae to E. coli and then back to        
N. gonorrhoeae). This lack of success was attributed to the N. gonorrhoeae restriction barrier; 
production of a restriction endonuclease that cleaved the β-lactamase plasmid after it was 
propagated in E. coli. No restriction barrier was present when a chimeric β-lactamase plasmid 
(pFT180), created from a gonococcal β-lactamase plasmid and the N. gonorrhoeae cryptic 
plasmid, was able to transform N. gonorrhoeae after propagation in E. coli (Stein, Young, Tenover, 
& Clark, 1983b). It should be noted however that different E. coli and N. gonorrhoeae strains were 
used in the two studies (Flett et al., 1981; Stein et al., 1983b). It was suggested by the authors 
(Stein et al., 1983b), that this plasmid could be used as a shuttle vector. In fact pFT180 was 
subsequently developed into a smaller shuttle cloning vector called pLES2 with additional markers 
and additional restriction sites for cloning which can replicate in both N. gonorrhoeae and E. coli 
(Stein, Silver, Clark, & Young, 1983a). Gonococcal genes have been inserted into pLES2 (and its 
derivatives), grown in E. coli, and then transformed into N. gonorrhoeae in a number of studies 
that include the investigation of the nutritional requirements of N. gonorrhoeae (Stein, Silver, 
Clark, & Young, 1984), the uptake of specific restriction fragments by N. gonorrhoeae (Burnstein, 
Dyer, & Sparling, 1988), plasmid transfer from N. gonorrhoeae to N. cinerea (Genco & Clark, 1988) 
and the effect of the gonococcal uptake sequence on the transformation of plasmid DNA (Elkins, 
Thomas, Seifert, & Sparling, 1991).  
Conjugation for plasmid transfer is advantageous because it avoids deletions (Sox et al., 1979) and 
piliation is not required (Biswas et al., 1977). One study involved the broad host range conjugative 
plasmid pUB307, which is a derivative of the incompatibility group P (IncP) RP1 plasmid, and was 
able to promote the transfer of gonococcal resistance plasmids and the shuttle vector pLES2 from 
E. coli to N. gonorrhoeae (Piffaretti, Arini, & Frey, 1988) via conjugation. IncP plasmids like these 
may have provided TnA sequences in N. gonorrhoeae, as pUB307 contains incomplete TnA DNA, 
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similar to the gonococcal β-lactamase plasmids. It should be noted that pUB307 does not enter 
the gonococcus and cannot be maintained.  
1.7.3 Transfer of cosmid cloning vectors and other artificial plasmids from E. coli to   
N. gonorrhoeae  
As well as pLES2, cosmid cloning vectors and other plasmids have been used to transfer genes 
from E. coli into N. gonorrhoeae. Gonococcal IgA1 protease was studied by the insertion of the 
gonococcal IgA1 protease gene into recombinant plasmids that were propagated in E. coli.  
Recombinant IgA1 protease genes were also re-introduced into N. gonorrhoeae and  subsequent 
homologous recombination resulted in transformants that ceased to produce the IgA1 protease 
(Koomey, Gill, & Falkow, 1982). The study used an inserted β-lactamase gene in a cosmid vector 
to encourage homologous recombination in the gonococcus, and a restriction enzyme was added 
to the plasmid DNA before transformation to separate the cloned DNA from the cloning vector. 
The cosmid cloning vector pREG153 was used to create gene banks in N. gonorrhoeae, such as to 
isolate the recA gene (Koomey & Falkow, 1987). It should be noted that after cloning in                  
N. gonorrhoeae and transformation in E. coli, the plasmids in this study were not re-introduced to 
N. gonorrhoeae after propagation in E. coli.  
Gonococcal fragments were cloned into the cloning vector pBR322 and transformed into              
N. gonorrhoeae to correctly identify the gonococcal uptake sequence (Goodman & Scocca, 1988). 
A cosmid vector was used with a cloned nalidixic acid gene to investigate the factors that affect 
the DNA to be transformed (Stein, 1991). The authors noted the following; when the size of the 
DNA to be transformed decreases then the transforming efficiency also decreases, homologous 
recombination is performed within the gonococcus, host mediated restriction was not a barrier to 
transform chromosomal DNA, the uptake sequence greatly increases transformation efficiency, 
and linear (plasmid DNA cut with restriction enzymes) and native plasmids in their supercoiled 
DNA state transform at the same efficiency. A gene probe on a cosmid vector was used to screen 
a range of Gram-negative isolates, including N. gonorrhoeae, for gyrA mediated quinolone 
resistance by transformation of the gyrA probe (Power, Munoz Bellido, & Phillips, 1992). Plasmid 
vectors were used to investigate DNA methylation in N. gonorrhoeae by cloning a mutated 
methylase gene and demonstrating that the gonococcal recipient was susceptible to cleavage due 
to the mutated methylase gene  (Stein, Chien, & Seifert, 1992). Conjugation studies with shuttle 
vector pLEE10 were performed to investigate the genes which produce products involved in 
lipooligosaccharide biosynthesis (Sandlin, Apicella, & Stein, 1993). Four new plasmids were 
created to deliver cassettes into Neisseria species to construct insertional mutants and 
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transcriptional fusions (Zhou & Apicella, 1996). Cloning plasmids were used to create mutants 
using selectable markers, other than antibiotic resistance markers, so the transformed                  
N. gonorrhoeae can be used for human challenge (Johnston & Cannon, 1999). A gonococcal 
shuttle vector (pFP10) which was stable in both N. gonorrhoeae and E. coli and required no other 
plasmids for maintenance, was produced from an origin of replication from a gonococcal               
β-lactamase plasmid (Pagotto, Salimnia, Totten, & Dillon, 2000b) to express the green fluorescent 
protein (GFP). pLES94 vector was used (Silver & Clark, 1995) to create a translational lacZ reporter 
system that enabled the study of gonococcal gene regulation. The plasmid is transformable and 
not replicable, but is able to integrate into the proAB gene position in the gonococcal 
chromosome and not in the gene location that is being studied so the gene of interest is not 
inactivated.  
1.7.4 Shuttle mutagenesis using transposon insertions 
Gonococcal mutagenesis can be performed by shuttle mutagenesis using transposons. The 
procedure involves plasmid transfer from E. coli to N. gonorrhoeae. Transposon insertions are 
introduced into the gonococcal genome to disrupt genes and the subsequent phenotype is then 
studied. Briefly, a cloned gene from N. gonorrhoeae is placed in a cloning plasmid vector and then 
transferred into E. coli, normally by transformation. A transposon, normally a mini-transposon 
(mTn) is then inserted into the cloned gene. The cloned gene with the inserted mTn is then 
transferred back into the gonococcus by transformation and the mTn can be integrated into the 
gonococcal genome by homologous recombination. There have been a number of studies 
involving N. gonorrhoeae and shuttle mutagenesis, including a study to investigate the gonococcal 
pilin gene (Seifert, Ajioka, Paruchuri, Heffron, & So, 1990). The study showed that mTn insertions 
stop piliation and subsequently lower transformation frequency. However, transformation 
competence is still present, so the study demonstrated that pilin expression is not always 
essential for DNA transformation. Boyle-Vavra & Seifert (1993) showed that fragments with a 
larger homologous DNA region in relation to the heterologous insertion DNA transform more 
efficiently than smaller homologous segments of DNA. This is most probably due to more efficient 
homologous recombination. The transposon mTnEGNS, which confers erythromycin resistance 
and was used to mutate the gonococcal genome randomly and create a size-restricted plasmid 
library (Mehr & Seifert, 1997).  
Conjugation has also been used in shuttle mutagenesis; a Hermes shuttle vector system (Kupsch 
et al., 1996) has been designed which exploits a site in the tetracycline resistance plasmid (Knapp 
et al., 1988) that is permissive for plasmid propagation and conjugation. These sequences are 
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inserted in an E. coli vector which can then provide cloned genes via homologous recombination 
into the tetracycline resistance plasmid. The modified tetracycline resistance plasmid can then be 
mobilised via conjugation and thus introduce new genes into gonococcal recipients. The Hermes 
shuttle system was also used to insert an intact comL, which encodes a peptidoglycan-linked 
lipoprotein, to replace a mutant comL gene (Fussenegger, Facius, Meier, & Meyer, 1996). Another 
conjugation experiment involved a derivative of a kanamycin resistance transposon, Tn1545, 
which was sub-cloned into pLES2. Direct transposition of the transposon from the shuttle vector 
into the N. gonorrhoeae chromosome allowed for random mutagenesis and kanamycin was used 
as a selection marker (Nassif, Puaoi, & So, 1991).  
To summarise, there is no reported evidence that naturally-occurring plasmids can be transferred 
into N. gonorrhoeae from E. coli or other Enterobacteriaceae, with just one group successfully 
transferring a Haemophilus ducreyi plasmid (pHD131) from E. coli to N. gonorrhoeae (Piffaretti & 
Soldati, 1990). There is no published research on the cloning of ESBL genes into N. gonorrhoeae, 
or the introduction of plasmids encoding ESBLs into N. gonorrhoeae, indicating that the work 
presented in this thesis is novel and innovative. There is evidence that native and modified 
gonococcal plasmids, along with smaller, artificially produced cloning vectors can be transferred 
by transformation and conjugation from E. coli into N. gonorrhoeae. These plasmids generally 
have to contain the gonococcal uptake sequence, are not representative of the natural 
environment and may need ‘helper’ plasmids to facilitate conjugation. They do, however, show 
that N. gonorrhoeae can uptake plasmids by transformation. Additionally, as these plasmids are 
previously propagated in E. coli, the studies show that host restriction does not always play a role 
in the regulation of transformation.  
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2 Aims 
The overall aim of this thesis is to establish what resistance mechanisms in Neisseria gonorrhoeae 
could abolish the effectiveness of cephalosporins, such as ceftriaxone which is the last remaining 
option for gonorrhoea monotherapy. This thesis will attempt to achieve the following objectives:  
 Establish electroporation conditions for the transformation of native gonococcal               
β-lactamase and tetracycline resistance plasmids into a panel of N. gonorrhoeae strains.  
 
 To investigate whether extended-spectrum β-lactamase genes can be transferred into, 
maintained and expressed by various N. gonorrhoeae strains.   
 
 To investigate the genetic diversity of blaTEM alleles, antimicrobial susceptibility and 
molecular epidemiological characteristics of penicillinase-producing N. gonorrhoeae 
isolates from England and Wales.  
 
 To establish if gonococcal β-lactamase plasmids can be successfully transferred into         
N. gonorrhoeae strains which belong to a successful multi-drug resistant clone (ST1407). 
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3 General methods 
 Neisseria gonorrhoeae culture 3.1
Neisseria gonorrhoeae isolates stored in Microbank cryobeads (Pro-lab Diagnostics, 
Bromborough, UK) were retrieved from -80oC storage onto GCVIT agar consisting of GC agar base 
(Becton Dickinson, Oxford, UK) with 1% Vitox (Oxoid, Basingstoke, UK).  All agar plates were dried 
in a hot room for approximately 20 min to remove excess moisture.  Retrieved and subsequently 
sub-cultured isolates were incubated for 18–24 h at 35-37oC in 5% CO2. Purity was confirmed by 
the Gram-stain to detect Gram-negative cocci. Cytochrome C oxidase was detected by the PYO-
Test (Medical Wire and Equipment, Corsham, UK) which is comprised of impregnated paper strips 
with the redox dye N, N, N’, N’-tetramethyl-p-phenylenediamine dihydrochloride, which acts as 
an artificial electron acceptor for the enzyme oxidase. In the presence of the cytochrome oxidase 
enzyme, which is produced by N. gonorrhoeae, the redox dye is converted to indophenol blue 
which is detected by the rapid colour change (colourless to deep purple). 
3.1.1 Isolate archiving 
The bacterial growth was gathered from a whole plate of overnight growth and re-suspended in 
the Microbank cryobead fluid. The cryovial was closed tightly and inverted five times to mix the 
organisms with the fluid. Using a fine-tip pastette as much liquid as possible was removed and 
discarded. The cryovial was closed tightly and store at -80oC. 
 Antimicrobial susceptibility testing 3.2
3.2.1 E-tests 
Minimum inhibitory concentrations (MICs), which are the lowest concentrations of individual 
antimicrobials to inhibit growth completely, were determined by E-tests (BioMérieux, Marcy 
l'Etoile, France). E-tests are plastic strips with a predefined antimicrobial gradient dried on one side 
that is released into the medium once placed on to the surface of an agar plate, while the other 
side of the strip is printed with an MIC scale in mg/L.  
The bacterial isolates were sub-cultured once before susceptibility testing was performed. 
Suspensions of cultures aged 18–20 h were prepared to a density equivalent to McFarland’s 
standard 0.5 (approximately 104 CFU/µl) in sterile saline (0.85% w/v). Using GCVIT medium, the 
entire agar surface was swabbed evenly using a sterile cotton swab in three directions to produce a 
semi-confluent lawn. After 10 min the E-test was applied to the agar surface and the plates were 
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incubated for 18–24 h at 35-37oC in 5% CO2. The MIC was established by reading where the 
inhibition of growth (ellipse) intersected the MIC scale on the E-test strip.  
3.2.2 Agar dilution  
MICs determined by agar dilution were performed according to the GRASP agar dilution 
methodology (Chisholm et al., 2011) using Diagnostic Sensitivity Test agar (Oxoid) supplemented 
with 5% lysed horse blood (TCS Biosciences, Buckingham, UK) and 1% Vitox. Doubling dilutions of 
the antimicrobial being investigated was added to the melted supplemented agar. The plates 
were allowed to set at room temperature for a minimum of 1 h.   
Bacterial suspensions were prepared as described above for the E-test and were transferred into 
multipoint inoculator wells (Mast Group, Bootle, UK). The series of plates containing two-fold 
increasing concentrations of each antimicrobial were inoculated using the multipoint inoculator 
(Mast Group) with 1 µl inoculator pins which deliver approximately 104 CFU. Antimicrobial-free 
control plates were also inoculated. After 48 h incubation at 35-37°C in 5% CO2, the MIC was 
determined as the lowest antimicrobial concentration to inhibit growth completely. Three control 
strains were included in every run (WHO A, WHO J and A24).  
3.2.3 -lactamase detection  
All isolates were tested for -lactamase production using the chromogenic reagent, Nitrocefin 
(Oxoid). A drop of nitrocefin was applied to the surface of a N. gonorrhoeae culture grown on a 
GCVIT plate for 18–24 h and the colour was noted after one minute. Nitrocefin is a chromogenic 
cephalosporin and changes colour from yellow to red in the presence of β-lactamase as the amide 
bond in the -lactam ring is hydrolysed by the -lactamase. In the absence of β-lactamase the 
nitrocefin remains yellow.  
 Molecular methods 3.3
3.3.1 DNA lysates 
Gonococcal DNA was extracted from fresh overnight cultures for use in PCR reactions by the 
preparation of DNA lysates. Bacterial suspensions were prepared in phosphate buffered saline 
(PBS) to an equivalent McFarland’s standard of 0.5 from bacterial cultures aged 18-24 h. The 
suspensions were boiled for 10 min to lyse the bacteria and cellular debris was removed by 
centrifugation for 5 min at 10,000 rpm.  The supernatant, containing the gonococcal DNA, was 
removed and stored at -20oC. 
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3.3.2 Visualisation of PCR products 
PCR products were run on 0.8 to 2% E-gels (Life Technologies, Paisley, UK), which are pre-cast 
agarose gels which contain an ion generating system, a pH balancing system and ethidium 
bromide for nucleic acid staining. In addition to the PCR products the E-gel low range DNA ladder 
(Life Technologies), the 1 kb Plus DNA ladder (Life Technologies) or the 1 kb Hyperladder (Bioline, 
London, UK) were run to confirm PCR product size. To detect DNA the E-gels were visualised 
under UV using the InGenius LHR2 gel imaging system (Syngene, Cambridge, UK). Gel images were 
captured using the GeneSnap (Syngene) software. 
3.3.3 General sequencing reactions 
At least 10 µl of the PCR product to be sequenced was transferred to a MicroAmp Optical 96-well 
semi-skirted reaction plate (Life Technologies). The PCR products, along with an aliquot of the 
appropriate forward and reverse primers (5 pmol/µl) were sent to the in-house sequencing 
service at Public Health England (PHE) for purification of the PCR product (i.e. removal of residual 
dNTPs, primers, Taq DNA polymerase and buffer) and subsequent Sanger sequencing. All 
sequence data were analysed and edited in BioNumerics V.6.1 (Applied Maths, St-Martens-Latem, 
Belgium). 
3.3.4 NG-MAST methodology 
DNA lysates were prepared as previously (see Section 3.3.1). The N. gonorrhoeae multi-antigen 
sequence typing (NG-MAST) method requires the amplification of two different alleles; porB and 
tbpB (Martin et al., 2004). A separate master mix for the porB and tbpB PCRs was prepared (Table 
3.1 and Table A1, Appendix One).  
Table 3.1 NG-MAST PCR master mix ingredients and concentrations. 
Component and concentration Volume required for one reaction 
dNTPs X10 (2 mM) (Life Technologies)  5 l 
PCR buffer with MgCl2 X10 (Qiagen, 
Manchester, UK) 
5 l 
PorB-F/TbpB-F primer (100 pmol/l stock) 0.5 l  
PorB-R/TbpB-R primer (100 pmol/l stock) 0.5 l  
MgCl2 (1.5 mM) (Qiagen) 3 l  
Nuclease-free water (Severn Biotech, 
Kidderminster, UK)  
33.5 l 
Taq polymerase (Qiagen)   0.5 l (2.5 Units) 
DNA lysate 2 l  
Total volume 50 l  
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PCR amplification was performed on a DNA Engine Tetrad thermocycler (Bio-RAD, Hemel 
Hempstead, UK). The porB PCR was run with the following cycling conditions: 95oC for 4 min, then 
30 cycles of 95oC for 30 s, 52oC for 30 s and 72oC for 1 min, with a final elongation of 72oC for 10 
min. For the tbpB PCR the cycling conditions were the same as the porB PCR other than annealing 
was at 69oC and a total of 25 cycles were performed. Products were run on 1.2% E-gels along with 
an E-Gel low range DNA ladder as previously described (see Section 3.3.2). The porB PCR product 
size is between 600 and 650 bp and the tbpB PCR product is approximately 570 bp. The PCR 
products were sent to PHE’s centralised sequencing service for purification and sequencing (see 
Section 3.3.3). Sequence data were imported into BioNumerics V.6.1 for analysis and editing. 
Allele numbers were obtained via the online NG-MAST database (www.ng-mast.net) for the 
trimmed porB (490 bp from the start sequence 5’ TTGAA 3’) and the trimmed tbpB (390 bp from 
the start sequence 5’ CGTCTGAA 3’) sequence. Once allele numbers were obtained for porB and 
tbpB then a sequence type (ST) was assigned via the online NG-MAST database for each allele 
number combination. 
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4 Establishing a panel of gonococcal strains and electroporation 
conditions 
 Background 4.1
Neisseria gonorrhoeae is a naturally-competent organism, which means that it can transform 
chromosomal DNA with high efficiency (Dillard, 2011). The competence of N. gonorrhoeae is 
dependent upon the presence of type IV pili (Biswas et al., 1977), and the presence of a 12 bp 
gonococcal DNA uptake sequence (DUS) on the DNA to be transformed (Ambur et al., 2007; Smith 
et al., 1999). Plasmid DNA can also be transformed into gonococci, however plasmid 
transformation is inefficient, can result in deletions in the DNA (Sox et al., 1979) and the plasmids 
can be subjected to host-mediated restriction (Stein et al., 1988). Plasmids are normally 
transferred between gonococci via conjugation, so piliation and the presence of the DUS are not 
required. The conjugal transfer of plasmids between gonococcal isolates is however reliant upon 
the presence of the 24.5 MDa self-conjugative plasmid (Baron et al., 1977; Sox et al., 1978), which 
is able to mobilise smaller, non-conjugative plasmids.  
Electroporation is a common laboratory method used to achieve DNA transformation. 
Electroporation uses an electrical current, administered by a brief pulse of high-voltage electricity, 
to increase the permeability of the bacterial cell membranes by forming pores to enable the 
transfer of DNA (chromosomal or plasmid) into the cell. Parameters of electroporation include the 
field strength (kV), which is the maximum voltage applied to the bacterial cells divided by the 
distance between the electrodes on the cuvette, the resistance (Ω) and the capacitance (µF).    
Due to the natural competence of N. gonorrhoeae, electroporation has not been used a great deal 
to transform gonococci. To date only two publications describe its use in N. gonorrhoeae; the first 
by Genco, Chen, Arko, Kapczynski, and Morse (1991) who described the use of electroporation to 
transform chromosomal DNA to investigate the gonococcal iron uptake pathway. The second was 
by Dillard (2011) who described the methodology of electroporation, but no data regarding the 
use of electroporation were presented. Electroporation with N. gonorrhoeae eliminates the need 
for piliated gonococci and the presence of the DUS.   
The aim of work presented in this chapter was to establish electroporation conditions for the 
transformation of native gonococcal β-lactamase and tetracycline resistance plasmids into a 
selection of N. gonorrhoeae strains, with the overall aim to establish electroporation as a viable 
technique for plasmid transfer in N. gonorrhoeae. As the transfer of non-gonococcal plasmids via 
natural transformation is unlikely because of factors including the absence of the DUS and 
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plasmid incompatibility, it is hypothesised that electroporation might also be a useful tool to 
investigate whether N. gonorrhoeae can acquire resistance plasmids from enteric bacteria. An 
example of which is plasmid pEK204, which harbours the extended-spectrum β-lactamase (ESBL), 
CTX-M-3. In addition, the identification of piliated gonococcal colonies for natural transformation 
studies was also investigated using transmission electron microscopy to observe the presence of 
pili. 
 Methods 4.2
4.2.1 Selection and characterisation of Neisseria gonorrhoeae strains  
A panel of N. gonorrhoeae strains was required to serve either as recipients for blaCTX-M-3 in 
electroporation and natural transformation studies or as donors for β-lactamase and tetracycline 
resistance plasmids. To establish the most appropriate panel of strains, the antimicrobial 
susceptibility profiles and the plasmid profiles of a selection of gonococcal isolates were collated 
from published literature, including for the WHO N. gonorrhoeae isolates (Unemo, Fasth, 
Fredlund, Limnios, & Tapsall, 2009) and strains used in previous transformation studies (Biswas, 
Lacks, & Sparling, 1989a; Biswas et al., 1977; Biswas & Sparling, 1981; Chaussee & Hill, 1998; 
Duffin & Seifert, 2010, 2012; Rudel et al., 1995; Sparling, 1966).  Antimicrobial susceptibility 
testing by E-test (see Section 3.2.1) was performed to either establish or confirm the minimum 
inhibitory concentrations (MICs). 
The N. gonorrhoeae strains (Table 4.1) were obtained from the gonococcal collection at the 
Sexually Transmitted Bacteria Reference Unit, Public Health England, except for MS11, FA1090 
and F62 which were purchased from LGC Standards (Middlesex, UK). 
4.2.2 Detection of β-lactamase and tetracycline resistance plasmids by PCR 
The multiplex PCR developed by Fayemiwo, Muller, Gumede, and Lewis (2011) was used to detect 
and type gonococcal plasmids that encode for tetracycline and penicillin resistance (see Sections 
1.2.2 and 1.2.3). To establish the conditions for the PCR, the Asian and African gonococcal            
β-lactamase plasmids were used and obtained from strains ‘Strain 3’ and ‘WHO E’, respectively 
(Table 4.2). The Toronto/Rio plasmid was kindly provided as a purified DNA extract by Prof Jo-
Anne Dillon (University of Saskatchewan, Canada) and Prof David Lewis (National Institute for 
Communicable Diseases, South Africa). Two TRNG strains, ‘6418’ and ‘WHO G’ were used as a 
source of the American and Dutch tetracycline resistance plasmids, respectively (Table 4.2). 
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DNA lysates were prepared from the plasmid donors as previously described (see Section 3.3.1). 
Primers JDA and JDB (Table A1, Appendix One) were used to detect DNA regions from the             
β-lactamase plasmids (African, Asian and Toronto/Rio), while primers UF, AR and DR were used 
for the detection of the tetracycline resistance plasmids (American and Dutch) (Table A1, 
Appendix One). The primers were added at a concentration of 10 μM to a total volume of 50 μl, 
along with 2.5 units of Taq polymerase (Qiagen), 10x PCR buffer with MgCl2 (final concentration of 
1.5 mM) (Qiagen), 2 mM dNTPs (Life technologies), and 5 μl of DNA template. The PCR 
amplification was performed on a DNA Engine Tetrad thermocycler for the following cycling 
conditions: 94oC for 3 min, then 30 cycles of 94oC for 20 s, 58oC for 1 min and 72oC for 5 min. A 
final elongation of 72oC for 5 min was performed. PCR products were run on 0.8% E-gels as 
previously described (see Section 3.3.2). The Asian, African and Toronto/Rio plasmids produced 
4.9, 3.1 and 2.6 kb sized amplicons, respectively. The American and Dutch type plasmids produced 
amplicons of 778 and 443 bp, respectively. This is just some text to help the line become justified 
properly. I hope it is.
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Table 4.1 N. gonorrhoeae strains initially selected for further characterisation of antimicrobial susceptibility and plasmid profiles. 
Strain Reason for selection Source and reference/s Isolation 
Genome sequence 
GenBank accession 
number 
WHO F A fully susceptible strain 
WHO 2008 reference strain 
(Unemo et al., 2009) 
Canada, 1991 Not available 
WHO G 
Contains the Dutch tetracycline resistance 
plasmid 
WHO 2008 reference strain 
(Unemo et al., 2009) 
Thailand, 1997 Not available 
WHO M Contains the African β-lactamase plasmid 
WHO 2008 reference strain 
(Unemo et al., 2009) 
Philippines, 1992 Not available 
WHO N 
Contains the Dutch tetracycline resistance 
plasmid and the Asian β-lactamase plasmid 
WHO 2008 reference strain 
(Unemo et al., 2009) 
Australia, 2001 Not available 
WHO O Contains the African β-lactamase plasmid 
WHO 2008 reference strain 
(Unemo et al., 2009) 
Canada, 1991 Not available 
MS11 
A fully susceptible strain that is well 
characterised and has been used extensively 
in other transformation studies 
ATCC reference strain (ATCC® BAA-
1833) (Chaussee & Hill, 1998; 
Duffin & Seifert, 2010, 2012; Rudel 
et al., 1995) 
Uncomplicated infection, 
1960's 
CP003909 
FA1090 
A fully susceptible strain that is well 
characterised and has been used extensively 
in other transformation studies 
ATCC reference strain (ATCC® 
700825) (Duffin & Seifert, 2010, 
2012) 
Male patient with 
disseminated gonococcal 
infection, 1983 
AE004969 
FA19 
A fully susceptible strain that is well 
characterised and has been used extensively 
in other transformation studies 
ATCC reference strain (ATCC® BAA-
1838) (Biswas et al., 1989a; Biswas 
et al., 1977; Biswas & Sparling, 
1981; Duffin & Seifert, 2010).  
Uncomplicated infection, 
date unknown 
NZ_AKCG00000000 
F62 
A fully susceptible strain that is well 
characterised and has been used extensively 
in other transformation studies 
ATCC reference strain (ATCC® BAA-
1837) (Biswas et al., 1977; 
Sparling, 1966)  
Uncomplicated infection, 
1960 
293399716 
WHO E Contains the African β-lactamase plasmid 
WHO reference strain (ASM 
Antimicrobial Special Interest 
Group, 2005) 
 Unknown Not available 
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Table 4.1 N. gonorrhoeae strains initially selected for further characterisation of antimicrobial susceptibility and plasmid profiles. (Continued)  
Strain Reason for selection Source and reference/s Isolation 
Genome sequence 
GenBank accession 
number 
Strain 3 Contains the Asian β-lactamase plasmid  STBRU strain collection  Thailand Not available 
WHO J Contains the Asian β-lactamase plasmid 
WHO reference strain (ASM 
Antimicrobial Special Interest 
Group, 2005) 
 Unknown Not available 
6418 
Contains the American tetracycline 
resistance plasmid 
STBRU strain collection   Unknown Not available 
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4.2.3 Gonococcal plasmid extraction 
The gonococcal tetracycline resistance and β-lactamase plasmids to be used in the 
electroporation studies (see Section 4.2.5) were extracted using the QIAprep Spin Miniprep kit 
(Qiagen). The standard protocol was adhered to: Using a cotton swab the overnight growth from 
a GCVIT agar plate was harvested and re-suspended in 1 ml of sterile distilled water. The culture 
was pelleted by centrifugation at 9,000 rpm for 3 min. The pelleted cells were re-suspended, lysed 
and the cell debris was removed by centrifugation for 10 min at 13,000 rpm. The cleared lysates 
were applied to the QIAprep spin columns so the plasmid DNA could adsorb to the silica 
membrane. The QIAprep spin columns were washed to remove any impurities and plasmid DNA 
was eluted in 50 µl of elution buffer. The DNA concentration of the plasmid extractions were then 
established using the Qubit v3.0 Fluorometer (Life Technologies).  
4.2.3.1 Determination of gonococcal strains plasmid profiles 
The plasmid profiles of the donor strains (Strain 3, WHO E, WHO G and 6418), the electroporation 
recipient strains (MS11 and WHO M), as well as a selection of transformants, were established by 
performing the plasmid extraction as above (Section 4.2.3), however, two culture plates were 
used for the plasmid extraction. The extracted plasmids were run on a 0.8% agarose gel 
incorporated with GelRed (Biotium, Hayward, USA) for 5 h at 100 V. Gels were visualised as 
previously described (see Section 3.3.2). A previously published study was used to confirm 
plasmid locations on the gels (Roberts & Falkow, 1977). 
4.2.4 Electron microscopy 
For natural transformation piliated colonies were required (Biswas et al., 1977). The                       
N. gonorrhoeae strains (Table 4.1) were grown overnight on a GCVIT agar plate and viewed under 
a dissecting microscope. Piliated N. gonorrhoeae form smaller colonies with a darker ring around 
the edge due to expressed pili causing the cells to aggregate (Figure 4.1). The non-piliated 
colonies appear flatter and larger and are ‘pancake-like’ (Figure 4.1).  Both colony types were 
selected, when present, for electron microscopy (EM) to confirm the presence or absence of pili. 
 
  
Figure 4.1 Example Illustration of a (A) pilliated and (B) non-pilliated colony. 
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One bacterial colony was added to 10 µl of sterile distilled water and 10 µl of 10% Carson’s 
fixative (4% formaldehyde) was used to fix and kill the bacteria. The fixed material was applied to 
the surface of a formvar/carbon-coated, 3 mm, 400-mesh, copper EM grid that had been ‘glow 
discharged’, i.e. grids were made by hydrophilic deposit of negatively charged ions on the carbon. 
After 60 s incubation with the grid, the bacterial sample was removed by blotting and the grid 
surface washed with water. Particulate material adhering to the surface of the grid (including 
bacteria or pili) was negatively stained with a solution of 1.5% (w/v) phosphotungstic acid (pH 
6.5), which was itself carefully blotted from the grid surface. After drying, the prepared EM grid 
was viewed in a JEOL JEM1400 transmission electron microscope (Jeol, Peabody, USA) operating 
at 120 KeV and images were acquired with an AMT XR60 digital camera (AMT, Bury St. Edmunds, 
UK). 
4.2.5 N. gonorrhoeae electroporation 
4.2.5.1 Bacterial cell washing 
Prior to electroporation, the bacterial cells must be washed to remove impurities and salts from 
the agar plate.  These impurities can inhibit the electroporation procedure by causing ‘sparking’ 
due to an incomplete electrical current. The washing procedure as described by Dillard (2011) was 
used; overnight gonococcal growth (from GCVIT agar) of strains MS11 and WHO M were collected 
using a cotton swab and suspended in 1 ml of electroporation buffer (EB) (0.3M sucrose), and the 
bacteria were washed by centrifugation at 12,000 rpm for 1 min. The supernatant was discarded 
and the cells were re-suspended in 1 ml of 0.3 M sucrose.  Centrifugation was repeated and cells 
were re-suspended in 0.5 ml or 1 ml of 0.3 M sucrose.   
For the electroporation, 50 µl of the washed cells were added to the chamber of an ice cold 1 mm 
cuvette (Bio-Rad) and electroporation was performed using a Gene-Pulser (Bio-Rad) at 1.8 kV, 200 
Ω and 25 µF for 5 ms. Viable counts were taken before and after electroporation to establish any 
loss of viability due to the electroporation procedure. 
4.2.5.2 Establishing the electroporation protocol 
Electroporation was performed according to a modified method outlined by Dillard (2011) using 
the tetracycline resistance plasmids (American and Dutch) and β-lactamase plasmids (African and 
Asian) for electroporation into strain MS11 or, for tetracycline resistance plasmids only, strain 
WHO M (Table 4.2). A number of variables were initially tested to establish the electroporation 
conditions, such as different volumes of EB (0.3 M sucrose) to re-suspend the washed cells (1 ml, 
500 µl and 100 µl); different numbers/volumes of bacterial cells to be electroporated (CFU/ml and 
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volumes of 50 µl and 100 µl), different amounts and volumes of plasmid DNA (1 µl, 5 µl and 10 µl) 
and different levels of antibiotic selection (1–2 mg/L of penicillin and 1–8 mg/L of tetracycline) 
(Figure 4.2). 
4.2.5.3 Final electroporation protocol for the electroporation of N. gonorrhoeae with 
gonococcal β-lactamase and tetracycline plasmids 
The final electroporation protocol was performed using the tetracycline resistance plasmids 
(American and Dutch) and the β-lactamase plasmids (African and Asian) into strain MS11 or, for 
tetracycline resistance plasmids only, strain WHO M. Extracted plasmids (5 µl) were added to       
50 µl of the washed N. gonorrhoeae cells, mixed gently, and left on ice for 5 min (low temperature 
increases transformation efficiencies). The mixture of N. gonorrhoeae cells and plasmid DNA was 
then added to the chamber of an ice-cold 1 mm cuvette (Bio-Rad) and electroporation was 
performed using the Gene-Pulser at 1.8 kV, 200 Ω and 25 µF for 5 ms. After electroporation,     
500 µl of GCBL medium (see Section 4.2.5.5) was immediately added to the cuvette and the 
solution was transferred to an Eppendorf tube and incubated at 35-37oC in 5% CO2 for 30 min to 
allow the gonococci to recover. After 30 min recovery time 100 µl of the electroporated bacteria 
were plated out with a hockey stick on to GCVIT agar supplemented with tetracycline (4 and          
8 mg/L) or penicillin (2 mg/L), and incubated at 35-37oC with 5% CO2 for 6 h. In addition, after the 
30 min recovery time 200 µl of the electroporated bacteria were spotted on to a GCVIT agar plate 
and incubated at 35-37oC with 5% CO2 for 6 h. At 6 h, the growth was collected in 700 µl of the 
GCBL medium and 100 µl was plated using a hockey stick on to GCVIT agar supplemented with 
tetracycline (4 and 8 mg/L) or penicillin (2 mg/L). To ensure viability after electroporation the 
bacteria were also plated on to GCVIT agar. As a control, recipient cells that had not undergone 
electroporation with the plasmid DNA were also plated out onto selective media to ensure 
viability after the washing procedure. All plates were incubated for at least 24 h to a maximum of 
96 h at 35-37oC with 5% CO2 (Figure 4.2).  
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Figure 4.2 Schematic to illustrate the electroporation procedure. All incubations at 35-37oC in 5% 
CO2. Dashed lines represent omitted steps in the final electroporation procedure (Section 4.2.5.3). 
 
Transformants were confirmed to have acquired the plasmids by the completion of some or all of 
the following steps; 
1. Transformants were confirmed to be Gram-negative cocci and oxidase positive.  
2. Nitrocefin was used to confirm the acquisition of the β-lactamase plasmids (see Section 
3.2.3).  
3. Transformants were picked and sub-cultured on to the appropriate selective agar.  
4. Transformants were confirmed to have acquired the β-lactamase or tetracycline 
resistance plasmids by the PCR (see Section 4.2.2).  
5. E-tests or agar dilution susceptibility testing was performed (see section 3.2) to establish 
the MICs of the tetracycline resistance plasmid transformants. 
  
100 µl plated on to 
selective agar 
supplemented with 
tetracycline for a 
maximum 
incubation time of  
96 h
Transforming 
plasmid DNA
Recipient gonococcal 
strains
African & Asian 
β-lactamase plasmids
American & Dutch 
tetracycline plasmids
MS11
200 µl placed on to 
non-selective agar 
(GCVIT) for a 
6 h incubation
WHO MMS11
Immediately after electroporation- 30 min incubation
100 µl plated on to 
selective agar 
supplemented with 
penicillin for a 
maximum 
incubation time of  
96 h
200 µl placed on to 
non-selective agar 
(GCVIT) for a
6 h incubation
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4.2.5.4 Transformation frequency and transformation efficiency 
To establish the transformation frequency viable counts were performed after electroporation. 
The number of transformants from the selective plates seeded directly after electroporation 
were determined (transformation frequency counts cannot be established after the 6 h 
incubation on GCVIT as cell division occurs). 
Transformation frequency calculation 
a. Establish number of colony forming units (CFU) per ml after electroporation, e.g.  7 x 108 
b. Count the number of transformants in 1 ml of electroporated cells directly seeded on to 
selective agar, e.g.  8.64 x 104 
c. Divide the number of transformants by the number of CFU/ml after electroporation:  
8.64 x 104 / 7 x 108 = 1.2 x 10-4 
Transformation efficiency calculation  
To establish the transformation efficiency (CFU/µg of plasmid DNA) the amount of DNA (µg) was 
determined along with the number of transformants from the selective plates seeded directly 
after electroporation. As with the transformation frequency, the transformation efficiency cannot 
be established after the 6 h incubation on GCVIT as cell division occurs; 
No. of transformants/µg of DNA/dilution factor of the DNA before plating 
a. Establish the amount of plasmid DNA transformed (5 µl of DNA = 0.1 µg)  
b. Calculate the total dilution of the DNA before plating e.g. 500 µl of GCBL broth was added 
and 100 µl of electroporated cells was plated on to selective agar (100/550 = 0.18).  
c. Count the number of transformants after incubation (800);  
800/0.1/0.18 = 4.4 x 104 CFU/µg 
4.2.5.5 GCBL medium 
GCBL medium was prepared by dissolving 15 g proteose peptone #3 (Oxoid), 4 g K2HPO4 (Sigma-
Aldrich, Gillingham, UK), 1 g KH2PO4 (Sigma-Aldrich), 1 g NaCl (Sigma-Aldrich) in 1 L of sterile 
distilled water. The pH was adjusted to 7.2 with HCl (Sigma-Aldrich). The medium was autoclaved 
at 121oC for 10 min and stored at room temperature. 
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Table 4.2 Antimicrobial susceptibility profiles and plasmid profiles of N. gonorrhoeae strains. 
 MIC (mg/L) Penicillin 
plasmid 
Tetracycline 
plasmid   Ceftriaxone Cefixime Cefotaxime Spectinomycin Azithromycin Gentamicin Ciprofloxacin Penicillin Tetracycline 
Susceptible 
WHO F ≤ 0.002 ≤ 0.016 < 0.002 32 0.125 4 0.004 0.032 0.25    
MS11 ≤ 0.002 ≤ 0.016 0.004 6 0.032 2 ≤ 0.002 0.125 0.25    
FA1090 0.004 ≤ 0.016 0.008 8 0.064 4 0.004 0.064 0.064    
FA19 ≤ 0.002 ≤ 0.016 0.002 12 0.064 4 0.004 0.016 0.25    
F62 0.002 ≤ 0.016 0.004 12 0.064 4 0.004 0.016 0.125    
Penicillinase-producing N. gonorrhoeae (PPNG) 
WHO M 0.016 ≤ 0.016 0.032 16 0.25 4 2 8 1 African  
WHO O 0.032 0.016 0.064 > 1024 0.25 4 0.008 > 32 1 African  
WHO E 0.008 0.016 0.008 8 0.064 4 0.004 > 32 0.5 African  
Strain 3 0.008 ≤ 0.016 0.008 8 0.064 4 0.002 > 32 0.25 Asian  
WHO J 0.032 0.016 0.032 3 0.125 4 > 32 > 32 2 Asian  
High-level plasmid-mediated tetracycline resistant N. gonorrhoeae (TRNG) 
6418 0.008 0.016 0.016 8 0.25 2 0.004 0.25 16  American 
WHO G 0.008 ≤ 0.016 0.032 16 0.25 4 0.125 0.5 32  Dutch 
TRNG & PPNG 
WHO N 0.004 ≤ 0.016 0.032 16 0.125 4 4 8 16 Asian  Dutch 
Azithromycin resistant 
WHO P 0.004 ≤ 0.016   16 2 4 0.004 0.25  0.5 
 
  
Cefixime resistant 
WHO K 0.064 0.25   16 0.25 2 > 32 2 2    
G11-1052 
(ST1407) 0.03 0.125 0.5 16 0.5 8 > 16 1 2   
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 Results and discussion  4.3
4.3.1 Antimicrobial susceptibility and plasmid profiles of a selection of Neisseria 
gonorrhoeae strains 
The antimicrobial and plasmid profiles of the gonococcal isolates were collated as described in 
Section 4.2.1 (Table 4.2). 
4.3.2 Electron microscopy results  
To verify that piliated gonococcal colonies were correctly selected under the dissecting 
microscope, transmission electron microscopy was used to confirm the presence of pili. Strain F62 
was first viewed under the dissecting microscope and no piliated colonies could be detected by 
eye. This was confirmed by the transmission electron micrograph as no structures resembling pili 
could be visualised (Figure 4.3; i and ii), even when the cell wall was further magnified (Figure 4.3; 
iii). The amount of bacteria selected for electron microscopy was deemed to be suitable as 
displayed by the amount of dispersion of the bacterial cells (Figure 4.3; i).  The presence of the 
gonococcal diplococci within the transmission electron micrograph was confirmed by the size of 
the gonococci. For example, measurements of 630 nm x 1079 nm, and 741 nm x 890 nm were 
established for two cocci (Figure 4.3; ii), and this corresponds to published measurements of    
600 nm to 1000 nm in diameter (Todar, 2012). 
‘Pancake like’ (‘B’ example in Figure 4.1) colonies of WHO F and WHO K were also selected for 
electron microscopy as no piliated colonies could be visualised under the dissecting microscope. 
The absence of pili was confirmed in the electron micrographs (Figure 4.3; iv and v), and again the 
level of bacterial cell dispersal was judged to be appropriate (Figure 4.3; vi). 
The remaining gonococcal isolates (Table 4.2) were viewed under the dissecting microscope and 
all again looked ‘pancake’ like, other than WHO M which looked as though it had aggregated 
colonies due to the expression of pili.  It was confirmed by electron microscopy that WHO M was 
in fact piliated (Figure 4.4; i-iii) due to the appearance of hair-like long filaments on the bacterial 
cell surface. The size of the pili in the transmission electron micrographs as well as in the 
transmission electron micrograph of just pili (Figure 4.4; iv) are within the dimensions of pili 
length of 0.5–4.0 µm determined from a previous study (Swanson, Kraus, & Gotschlich, 1971).  
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Figure 4.3 i) Transmission electron micrograph of strain F62, ii) Transmission electron micrograph of strain F62 with sizing, iii) Magnified transmission 
electron micrograph of strain F62, iv) Transmission electron micrograph of strain WHO F, v) Transmission electron micrograph of strain WHO K,  
vi) Transmission electron micrograph of strain WHO K with dispersal.
i 
ii 
iii 
iv 
v 
vi 
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Figure 4.4 i-iii) Transmission electron micrograph of pilliated strain WHO M, iv) Transmission 
electron micrograph of pili from strain WHO M. 
Compared with the transmission electron micrographs of piliated N. gonorrhoeae in other 
published studies (Long et al., 2001; Long, Madraswala, & Seifert, 1998; Wolfgang et al., 1998)  
the appearance of the WHO M strain is similar to that in literature as well as in the electron 
micrograph shown in Figure 4.5. 
 
Figure 4.5 Transmission electron micrograph of piliated N. gonorrhoeae. Figure reproduced from 
the American Society for Microbiology (2014). 
i 
ii 
iii 
iv 
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4.3.3 Detection of β-lactamase and tetracycline resistance plasmids by PCR 
The conditions for the PCR to detect the presence of the gonococcal β-lactamase and tetracycline 
resistance plasmids was successfully established using plasmid DNA extracted by the QIAprep Spin 
Miniprep kit method from the four donor strains (Strain 3, WHO E, 6418 and WHO G) (Figure 4.6).  
In addition the correct PCR product size was identified from the Johannesburg plasmid extract, 
and the PCR was successful when two clinical nitrocefin positive isolates were tested (Figure 4.6).  
 
Figure 4.6 Gel of the PCR products from the β-lactamase and tetracycline resistance plasmid 
detection PCR. Lane 1 = E-gel low range ladder, Lane 2 = American tetracycline resistance plasmid 
from 6418 (778 bp), Lane 3 = Dutch tetracycline resistance plasmid from WHO G (443 bp), Lane 4 
= No template control (NTC), Lane 5 = Asian β-lactamase plasmid from Strain 3 (4.6 kb), Lane 6 = 
African β-lactamase plasmid from WHO E (3.1 kb), Lane 7 = NTC, Lane 8 = Johannesburg β-
lactamase plasmid (2.6 kb), Lane 9 = Strain G12-112, Lane 10 = Strain G12-115, Lane 11 = 1 kb 
ladder. 
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4.3.4 N. gonorrhoeae strain selection 
Eight strains were selected for further electroporation, natural transformation and conjugation 
experiments (Table 4.3).   
Table 4.3 N. gonorrhoeae strains selected electroporation, natural transformation and 
conjugation experiments. 
Strain Reason for selection 
MS11 A fully susceptible strain that is well characterised and has been used 
extensively in other transformation studies (Chaussee & Hill, 1998; 
Duffin & Seifert, 2010, 2012; Rudel et al., 1995) 
WHO M  Contains the African β-lactamase plasmid and is pilliated 
WHO E  Contains the African β-lactamase plasmid 
Strain 3  Contains the Asian β-lactamase plasmid 
WHO G  Contains the Dutch tetracycline resistance plasmid 
6418  Contains the American tetracycline resistance plasmid 
ST1407 (G11-1052)  A clinical isolate that has elevated ceftriaxone and cefixime MICs of 
0.03 mg/L and 0.125 mg/L, respectively 
WHO P  Azithromycin-resistant and ciprofloxacin-susceptible isolate – to be 
used in conjugation studies with WHO M (see Chapter 6) 
 
4.3.5 Plasmid extraction results 
It is recommended that at least 10 ng/µl of plasmid preps are used (Dillard 2011) in 
electroporations (Dillard, 2011) so the concentrations achieved by this plasmid extraction method 
are appropriate (Table 4.4).  
Table 4.4 DNA concentration (ng/µl) and amount of DNA (in 5µl) obtained from the plasmid 
extractions. 
Plasmid (originating strain) 
DNA concentration 
(ng/µl) 
Amount of DNA in     
5 µl (µg) 
African β-lactamase plasmid (WHO E) 19 0.095 
Asian β-lactamase plasmid (Strain 3) 11.4 0.057 
Dutch tetracycline resistance plasmid 
(WHO G)  
16.4 0.082 
American tetracycline resistance 
plasmid (6418) - 1 x plate / 2 x plates* 
11 / 39.8 0.055 / 0.199 
*Two plates of growth were used for the extraction of the American tetracycline resistance 
plasmid from strain 6418 due to some initial unsuccessful electroporations. 
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4.3.6 Electroporation results 
4.3.6.1 Establishment of washing procedure 
In general there was one log loss of bacteria due to the electroporation procedure (Table 4.5). 
Even though the percentage survival was only between 15.9–17.7% there were still many viable 
bacteria after the electroporation procedure.  
Table 4.5 Viable counts of N. gonorrhoeae strains before and after electroporation. 
 
Average CFU/ml (SD) 
Average % 
survival 
Strain 
(no. of biological 
repeats) 
Before electroporation After electroporation  
MS11 
(n = 10)* 
1.3 x 109 (0.7–1.9 x 109) 
2.3 x 108 
(9.9 x 107 – 4.7 x 108) 
17.7 
WHO M 
(n = 3) 
3.2 x 109 (3.0–3.3 x 109) 5.1 x 108 (3.0-7.3 x 108) 15.9 
SD – Standard deviation 
*More viable counts obtained as MS11 was initially used to establish the washing procedure, and 
was the recipient of both the β-lactamase and tetracycline plasmids. 
 
4.3.6.2 Establishing the electroporation protocol 
A number of variables were initially tested to establish the electroporation procedure (Table 4.6 & 
Table 4.7), including; 
1. Amount (µg) of plasmid DNA. 
2. Number of bacteria (CFU/ml) and different volumes (1 ml, 0.5 ml and 0.1 ml) of the EB for 
the final re-suspension of the washed bacterial cells.  
3. Ratio of volume of bacterial cells (50 µl from 1ml and 0.5 ml of washed cells, and all of the 
100 µl final re-suspension volume) to volume and amount of DNA. 
4. Different levels of antibiotic selection (1-2 mg/L of penicillin and 1–2 mg/L of 
tetracycline).  
 
Electroporated cells were plated out on to selective media after the 30 min incubation in the 
GCBL broth after electroporation. 
Electroporations which resulted in a lawn of growth (Table 4.6) showed that the selection plate 
concentration (mg/L) was not high enough to inhibit growth of recipient cells i.e. WHO M 
tetracycline MIC is 1 mg/L so the selection plate needs to be at a higher concentration to both 
inhibit growth of un-transformed WHO M and to select for the transformants.  
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Successful transformations were achieved most often using 5 µl of DNA added to 50 µl of washed 
bacterial cells from the re-suspension in 500 µl of EB (Table 4.6 and Table 4.7). Therefore the 50 µl 
volume of washed cells was chosen for the final electroporation protocol.   
For the β-lactamase plasmid electroporations using 1 mg/L penicillin for selection, there was 
often a mixture of small colonies which were non- β-lactamase producing and larger β-lactamase 
producing colonies (Table 4.6). It seems as though the larger colonies are producing β-lactamase 
into the surrounding agar and offering some protection from the penicillin in the plates to those 
bacteria nearby that did not successfully uptake the plasmids. This shows the importance of a 
more appropriate higher concentration of penicillin for selection (i.e. 2 mg/L) and the need to use 
nitrocefin to correctly detect the transformants. 
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Table 4.6 Different electroporation variables in respect to MS11 and final volumes of  wash buffer, different volume/number of bacterial cells to be 
electroporated, varying volumes/amounts of plasmid  DNA  and different levels of penicillin and tetracycline selection (where growth is recorded = GNDC, oxidase 
positive).  
Strains 
Final volume of 
washed cells 
[CFU/ml] 
Volume of washed  cells : 
Plasmid DNA volume (µl) 
[No. of bacteria : amount of 
DNA] 
Plasmid 
Antimicrobial 
selection 
No. of colonies Further investigations performed  
MS11 1 ml  [1.4  x 109] 50:5 [7 x 107 : 0.055 µg] American 1 mg/L tetracycline 200 E-test = 1mg/L 
MS11 100 µl [2.02  x 109] 100:1 [2.02 x 108 : 0.011 µg] American 1 mg/L tetracycline Lawn of growth E-test 1 = mg/L  
MS11 1 ml [1.52  x 109] 50:5 [7.6  x 107 : 0.055 µg] American 2 mg/L tetracycline 0   
MS11 100 µl [1.65  x 109] 100:1 [1.65  x 108 : 0.011 µg] American 2 mg/L tetracycline 100 E-test = 1mg/L 
MS11 500 µl [1.46  x 109] 50:5 [7.3  x 107 : 0.082 µg] Dutch 1 mg/L tetracycline 250 E-test = 1mg/L 
MS11 500 µl [1.46  x 109] 50:5 [7.3  x 107 : 0.082 µg] Dutch 2 mg/L tetracycline 2 E-test = 8 mg/L, Dutch plasmid PCR positive 
MS11 1 ml [1.4  x 109] 50:5 [7 x 107 : 0.057 µg] Asian 1 mg/L penicillin 7 All nitrocephin positive 
MS11 100 µl [2.02  x 109] 100:1 [2.02  x 106 : 0.011 µg] Asian 1 mg/L penicillin 108 All nitrocephin negative 
MS11 500 µl [1.46  x 109] 50:5 [7.3 x 107 : 0.057 µg] Asian 1 mg/L penicillin 5 large, 20 small 
Large colonies nitrocephin positive; small 
colonies nitrocephin  negative 
MS11 1 ml [1.52  x 109] 50:5 [7.6  x 107 : 0.057 µg] Asian 2 mg/L penicillin 0   
MS11 100 µl [1.65  x 109] 100:1 [1.65  x 108 : 0.011 µg] Asian 2 mg/L penicillin 0   
MS11 500 µl [1.46  x 109] 50:5 [7.3  x 107 : 0.057 µg] Asian 2 mg/L penicillin 7 Nitrocephin positive, E-test =  > 32 mg/L  
MS11 500 µl [1.46  x 109] 50:5 [7.3  x 107 : 0.095 µg] African 1 mg/L penicillin 5 large, 20 small 
Large colonies nitrocephin positive, small 
colonies nitrocephin negative 
MS11 500 µl [1.46  x 109] 50:5 [7.3  x 107 : 0.095 µg] African 2 mg/L penicillin 7 
Nitrocephin positive, E-test =   > 32 mg/L, 
African plasmid PCR positive 
Note:   Highlighted cells indicate successful transformations  
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Table 4.7 Different electroporation variables in respect to WHO M and final volumes of  wash buffer, different volume/number of bacterial cells to be 
electroporated, varying volumes/amounts of plasmid  DNA  and different levels of penicillin and tetracycline selection (where growth is recorded = GNDC, oxidase 
positive).   
Strains 
Final volume of 
washed cells 
[CFU/ml] 
Volume of washed  cells : 
Plasmid DNA volume (µl) [No. 
of bacteria : amount of DNA] 
Plasmid 
Antimicrobial 
selection 
No. of colonies Further investigations performed  
WHO M 1 ml [2.5  x 109] 50:5 [1.25 x 107 : 0.055 µg] American 1 mg/L tetracycline Lawn of growth   
WHO M 100 µl [3.5  x 109] 100:1 [3.5  x 108 : 0.011 µg] American 1 mg/L tetracycline Lawn of growth   
WHO M 1 ml [2.4  x 109] 50:5 [1.25 x 107 : 0.055 µg] American 2 mg/L tetracycline Lawn of growth 
 
WHO M 100 µl [2.79  x 109] 100:1 [2.79  x 108 : 0.011 µg] American 2 mg/L tetracycline Lawn of growth   
WHO M 500 µl [2.8  x 109] 50:5 [1.4 x 107 : 0.082 µg] Dutch 1 mg/L tetracycline Lawn of growth   
WHO M 500 µl [2.8  x 109] 50:5 [1.4 x 107 : 0.082 µg] Dutch 2 mg/L tetracycline Lawn of growth E-test = 1 mg/L 
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4.3.6.3 Establishing optimum amount of plasmid DNA for electroporation 
Different volumes/amounts  of plasmid DNA were used to establish if more transformants would 
arise from using more or less than the original volume of 5 µl (Table 4.8). Electroporated cells 
were plated out onto selective media after the 30 minutes incubation in the GCBL broth after 
electroporation. 
Table 4.8 Different amounts of plasmid DNA added to 50 µl of washed cells for electroporation. 
Strains and 
amount of 
plasmid DNA 
[volume] 
Plasmid Selection 
Average 
no. of 
colonies 
Further tests 
performed 
Transformation 
efficiency* 
MS11 – 0.041 
µg [2.5 µl] 
Dutch 
2 mg/L 
tetracycline 
160 E-test = 1 mg/L  
MS11 – 0.082 
µg [5 µl] 
Dutch 
2 mg/L 
tetracycline 
130 E-test = 1 mg/L  
MS11 – 0.164 
µg [10 µl] 
Dutch 
2 mg/L 
tetracycline 
140 E-test = 1 mg/L  
MS11 – 0.048 
µg [2.5 µl] 
African 
1 mg/L 
penicillin 
8 
All nitrocefin 
negative 
 
MS11 – 0.095 
µg [5 µl] 
African 
1 mg/L 
penicillin 
13 
All nitrocefin 
positive 
7.6 x 102 
MS11 – 0.19 µg 
[10 µl] 
African 
1 mg/L 
penicillin 
35 
28 colonies 
nitrocefin positive;  
7 colonies  
nitrocefin negative 
8.2 x 102 
WHO M - 0.041 
µg [2.5 µl] 
Dutch 
4 mg/L 
tetracycline 
~800 E-test = 64 mg/L 1.1 x 105 
WHO M - 0.082 
µg [5 µl] 
Dutch 
4 mg/L 
tetracycline 
~800 E-test = 64 mg/L 5.4 x 10
4 
WHO M - 0.164 
µg [10 µl] 
Dutch 
4 mg/L 
tetracycline 
~800 E-test = 64 mg/L 2.7 x 10
4 
* Only established when colonies were counted at 0 h 
For MS11 and electroporation with the Dutch tetracycline resistance plasmid, a high number of 
colonies (130 to 160 transformants) were counted, however the E-test result of 1 mg/L revealed 
that the electroporation was unsuccessful. The MS11 tetracycline MIC of 1 mg/L is higher than the 
pre-electroporation MIC of 0.25 mg/L, but not high enough to indicate high-level plasmid-
mediated tetracycline resistance. This could be due to some selection of mutants which increase 
the tetracycline MIC due to exposure to tetracycline in the plates or the possible transfer of some 
chromosomal DNA containing tetracycline resistance determinants from the donor of the 
plasmids. The transformation was very successful with WHO M and the Dutch tetracycline 
plasmid, with approximately 800 transformants at each volume of plasmid DNA. The E-test result 
of the WHO M transformants (64 mg/L) confirmed that the higher selection plate of 4 mg/L 
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resulted in successful transformations. For MS11 and the African β-lactamase plasmid there were 
no successful transformants at 0.048 µg (2.5 µl) of DNA, however 13 and 28 transformants were 
achieved when 0.095 µg (5 µl) and 0.19 µg (10 µl) of plasmid DNA was used, respectively. With 
0.19 µg (10 µl) of plasmid DNA there were more nitrocefin-positive as well as nitrocefin-negative 
colonies present. Even though less transformants were detected using 0.095 µg (5 µl) compared 
with 0.19 µg (10 µl) of plasmid DNA, 0.095 µg (5 µl) of plasmid DNA was chosen to not waste the 
DNA and avoid the nitrocefin-negative colonies. The purpose of these experiments was not to 
achieve the most efficient transformations but rather to show that transformations using 
electroporation worked with N. gonorrhoeae. The 5 µl aliquot of plasmid DNA (see Table 4.4 for 
the amounts of DNA) was subsequently used throughout to keep the protocol standard as even 
though 0.041 µg (2.5 µl) for the tetracycline Dutch plasmid and WHO M gave a greater 
transformation efficiency the actual number of transformants were the same. 
In respect to the concentrations of the penicillin selection, these results confirm the need for a 
higher concentration of penicillin for MS11 to avoid the appearance of the nitrocefin-negative 
colonies.  
4.3.6.4 Comparison of incubation times on non-selective media after electroporation 
Experiments were performed to establish whether transformations were more likely to be 
detected when bacterial cells were plated on to antibiotic selective agar directly after 
electroporation (after the 30 min incubation at 35-37oC with 5% CO2) or after a 6 h enrichment 
incubation on non-selective GCVIT agar (Figure 4.2). Strains MS11 and WHO M were used with the 
African β-lactamase and the Dutch tetracycline plasmids. To obtain an average number of 
transformations, electroporations were performed in triplicate (biological repeats) with the MS11 
and the African β-lactamase plasmid and selection plates were seeded twice (technical 
duplicates). Only nitrocefin-positive (β-lactamase producing) colonies were counted. For MS11 
and the WHO M electroporations with the Dutch tetracycline plasmid, electroporations were 
performed once and plated out on two different tetracycline concentrations. For these 
experiments a higher level of tetracycline selection (8 mg/L) was used.  
For MS11 and the African β-lactamase plasmid there were many more transformants at 6 h (20 
colonies average) compare to 0 h (5 colonies average) (Table 4.9). No transformants were 
detected for MS11 and the Dutch tetracycline resistance plasmid at 0 h, however on average 10 
transformants were detected at 6 h (Table 4.9). The additional time presumably allowed for 
expression of the tet(M). The MICs for these transformants were 8 mg/L, which was significantly 
higher than the tetracycline MIC of untransformed MS11 (0.25 mg/L) and showed that the 
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electroporation was successful. For WHO M and the Dutch tetracycline resistance plasmid 
transformation was extremely efficient, with ≥ 800 colonies on both the 4 mg/L and the 8 mg/L 
tetracycline plates at 0 h, and an uncountable number of transformants at 6 h (Table 4.9). The 
MICs of the WHO M transformants were determined to be 64 mg/L confirming successful 
transformation of the plasmid.  
Generally there were more colonies on the 6 h plate because cell division had occurred allowing 
the transformants to become established and to express the transformed genes, thereby 
increasing the sensitivity of the procedure. However, using the 6 h non-selective enrichment step 
did not allow transformation efficiencies to be established as cell division has occurred. For all 
subsequent experiments with MS11 and the β-lactamase plasmids, as well with WHO M and the 
tetracycline resistance plasmids, electroporated cells were plated out on to selective agar 
immediately so the transformation efficiency could be established. Electroporations with MS11 
and the tetracycline resistance plasmids were given 6 h incubation on non-selective first to 
encourage the detection of more transformants, as no transformants were detected at 0 h.  
Table 4.9 Number of transformants at 0 h and 6 h incubations after electroporation. 
Strain Plasmid Selection 
Average no. of 
transformants at 
0 h (further tests 
performed) 
Average no. of 
transformants at 6 h 
(further tests 
performed) 
Transformation 
efficiency 
MS11  African 
2 mg/L 
penicillin 
5 20 2.9 x 102 
MS11 Dutch 
4 mg/L 
tetracycline 
0 11  
 MS11 Dutch 
8 mg/L 
tetracycline 
0 19  (E-test=  8 mg/L)  
WHO M Dutch 
4 mg/L 
tetracycline 
1000 (E-test = 32 
mg/L) 
Lawn of growth 6.9 x 104 
 WHO M Dutch 
8 mg/L 
tetracycline 
800 (E-test =  64 
mg/L) 
Lawn of growth, but 
some individual 
colonies identifiable 
(E-test = 64 mg/L) 
5.4 x 104 
4.3.6.5 Electroporation results with final protocol 
Using the established electroporation conditions (final volume of 500 µl after washing, 5 µl of 
plasmid DNA into 50 µl of washed cells, electroporation at 1.8 kV, 200 Ω and 25 µF for 5 ms and 
re-suspension in 500 µl of GCBL broth), the transfer of four plasmids (African and Asian β-
lactamase plasmids and the Dutch and American tetracycline plasmids) was attempted into the 
bacterial strain MS11, whilst only the tetracycline resistance plasmids for WHO M (Figure 4.2). 
After electroporation bacterial cells were plated out onto selective plates immediately for WHO M 
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and the tetracycline resistance plasmids and for MS11 and the β-lactamase plasmids. For MS11 
and the tetracycline resistance plasmids the electroporated cells were plated out both 
immediately after the 30 min incubation and after six hours onto selective plates. Confirmation of 
transformants was established by susceptibility testing for tetracycline and penicillinase 
production, NG-MAST, and the β-lactamase and tetracycline resistance gene PCR.  
Electroporation was shown to be successful for MS11 and both of the β-lactamase plasmids 
(Table 4.10). A similar result was observed for WHO M and both of the tetracycline resistance 
plasmids allowing the calculation of the transformation frequencies and efficiencies (Table 4.11). 
The transformation efficiency and frequency for WHO M and the tetracycline resistance plasmids 
was greater than that for MS11 and the β-lactamase plasmids. This could be due to the presence 
of the conjugative plasmid in WHO M and the absence of the conjugative plasmid in MS11 (Figure 
4.7), and other genetic differences between the two strains. The electroporation with MS11 and 
the American plasmid was not successful, even after another plasmid extraction was prepared 
from two starting culture plates so the amount of plasmid DNA could be increased (Table 4.4). 
The DNA concentration, from one agar plate of bacterial growth, of the American tetracycline 
resistance plasmid was lower than the Dutch tetracycline resistance plasmid, 19 ng/µl and 11 
ng/µl, respectively. This suggests that the copy number for the American tetracycline resistance 
plasmid in 6418 is lower than the Dutch tetracycline resistance plasmid in WHO G.  However the 
number of bacteria collected from the agar plates was not determined and so different numbers 
of bacteria may have been available for the plasmid extraction. This is just some text to sort out 
the justification.                               
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Table 4.10 MS11 electroporation results; African and Asian β-lactamase plasmids into MS11, and the American and Dutch tetracycline resistance 
plasmids into MS11. 
Plasmid Selection 
No. of transformants at 
0 h (further tests 
performed) 
No. of transformants at 6 h 
(further tests performed) 
Transformation 
frequency 
Transformation 
efficiency 
African 2 mg/L penicillin 
11 colonies (all 
nitrocefin positive, 
African plasmid PCR 
positive) 
Not performed 6.79 x 10-6 6.4 x 102 
Asian 2 mg/L penicillin 
25 colonies (all 
nitrocefin positive, Asian 
plasmid PCR positive) 
Not performed 1.2 x 10-5 2.4 x 103 
Dutch 4 mg/L tetracycline 0 
13 (Dutch plasmid PCR positive. 
MIC from agar dilution*; 
transformants ≥ 64 mg/L 
(MS11=4 mg/L, WHO G=64 
mg/L)) 
   
Dutch 8 mg/L tetracycline 0 
5 colonies. (Picks for confirmation 
taken from 4 mg/L plate above) 
   
American 4 mg/L tetracycline 0 0    
American 8 mg/L tetracycline 0 0    
American* 4 mg/L tetracycline 0 0    
American* 8 mg/L tetracycline 0 0    
Notes: *Tetracycline MICs are higher using the agar dilution method 
**2x culture plates used for plasmid extraction 
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Table 4.11 WHO M electroporation results; American and Dutch tetracycline resistance plasmids into WHO M.  
Plasmid Selection 
No. of transformants at 0 h 
(further tests performed) 
No. of transformants at 6 h 
(further tests performed) 
Transformation 
frequency 
Transformation 
efficiency 
Dutch 8 mg/L tetracycline 
512 (Dutch plasmid PCR 
positive, MIC from agar 
dilution*; transformants > 64 
mg/L (WHO M = 8 mg/L, 
WHO G = 64 mg/L)) 
Not performed 9.14 x 10-5 3.5 x 104 
American 8 mg/L tetracycline 
864 (American plasmid PCR 
positive, MIC from agar 
dilution*; transformants > 64 
mg/L) (WHO M = 8 mg/L, 
6418 = 64 mg/L) 
Not performed 1.23 x 10-4 8.7  x 104 
 Note: *Tetracycline MICs are higher using the agar dilution method 
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To try and increase the efficiency of the uptake of the American tetracycline resistance plasmid by 
MS11 different amounts of plasmid DNA were used, as well as an increase in the voltage of the 
electroporation. Transformants were successfully achieved with an increase in the amount of 
plasmid DNA as well as an increase in voltage (Table 4.12), indicating that the tetracycline 
resistance plasmid from strain 6418 is less transformable that the tetracycline resistance plasmid 
from WHO G.  
Throughout all the electroporations, no arcing occurred, which suggests that the plasmid isolation 
and washing procedures were suitable as all the salts were efficiently removed.  
Table 4.12 Electroporation of MS11 with the American tetracycline resistance plasmid with 
varying amounts of plasmid DNA and increased voltage. 
Amount of 
plasmid DNA 
[volume] 
Tetracycline 
selection 
No. of 
transformants 
at 0 h 
No. of 
transformants 
at 6 h 
Further investigations 
performed 
0.199 µg [5 µl] 4 mg/L  NR 0  
0.597 µg [15 µl] 4 mg/L  NR 8  
0.796 µg [20 µl] 4 mg/L NR 20 
Picked 10 colonies: 
American plasmid PCR 
positive. MIC from agar 
dilution*; transformants 64 
mg/L; (MS11 4 mg/L, 6418 
64 mg/L) 
0.199 µg [5 µl] at 
2.5kV 
4 mg/L  NR 9  
Notes: NR = No result 
*Tetracycline MICs are higher using the agar dilution method 
4.3.6.6 Confirmation of transformation by NG-MAST  
To further confirm the successful transformations, NG-MAST was performed on the plasmid 
donors and from 10 colony picks (10 technical replicates) from each of electroporation 
experiments (Tables 4.10, 4-11 and 4.12). All of the transformants maintained their original      
NG-MAST ST which confirmed that the plasmids were successfully transferred (Table 4.13).  
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Table 4.13 Confirmation of transformation by NG-MAST. 
Strain ST (porB, tpbB) Transformants* ST (porB, tpbB) 
6418 176 (140, 9) 
MS11 and Dutch tetracycline resistance 
plasmid from WHO G 
4813 (2906, 6) 
MS11 4813 (2906, 6) 
MS11 and Asian β-lactamase plasmid 
from Strain 3 
4813 (2906, 6) 
Strain 3 172 (90, 2) 
MS11 and American tetracycline 
resistance plasmid from 6418 
4813 (2906, 6) 
WHO E 1699 (144, 440) 
MS11 and African β-lactamase plasmid 
from WHO E 
4813 (2906, 6) 
WHO G 621 (90, 18) 
WHO M and American tetracycline 
resistance plasmid from 6418 
3304 (2000,4) 
WHO M 3304 (2000,4) 
WHO M and Dutch tetracycline resistance 
plasmid from WHO G 
3304 (2000,4) 
NOTE: *Performed x10 – consensus result shown and no variation 
4.3.6.7 Plasmid profiles of donors and recipients 
The plasmid profiles of the recipients (Figure 4.7) and the plasmid donors (Figure 4.8) confirm the 
absence and presence of plasmids. The plasmid profiles of the transformants also confirmed the 
successful transfer of the African and Asian β-lactamase plasmid from WHO E and Strain 3, 
respectively, into MS11 (Figure 4.8), as well as the successful transfer of the American and Dutch 
tetracycline resistance plasmids from 6418 and WHO G, respectively, into MS11 and WHO M 
(Figure 4.9). DNA ladders were run on the gels to confirm successful migration; however the DNA 
ladder bands are not indicative of the size of the plasmids as the plasmids are in circular forms. A 
previously published study was used to confirm plasmid locations on the gels (Roberts & Falkow, 
1977). 
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Figure 4.7 Gel displaying the plasmid profile of the recipients MS11 (Lane 2) and WHO M (Lane 3). 
Lane 1 = 1 kb ladder. 
 
 
OC1 = Open circular form of the African β-lactamase plasmid (3.2 MDa)
OC2= Open circular form of the cryptic plasmid (2.6 MDa)
Chromosomal DNA
African β-lactamase 
plasmid, 3.2 MDa
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Conjugative plasmid, 
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3000
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8000
1        2         3
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Figure 4.8 Gel displaying the plasmid profiles the donor strains of 6418 (American tetracycline 
plasmid donor, Lane 2), WHO G (Dutch tetracycline plasmid donor, Lane 3), Strain 3 (Asian            
β-lactamase plasmid donor, Lane 4), WHO E (African β-lactamase plasmid donor, Lane 5).         
Lane 6 = MS11 transformant with the Asian β-lactamase plasmid, Lane 7 = MS11 transformant 
with the African β-lactamase plasmid, Lane 8 = ST1407 G11-1052 transformant with Dutch 
tetracycline plasmid, Lane 8). Lane 1 = 1 kb ladder.  
 
OC = open circular form of the cryptic plasmid (2.6 MDa)
Conjugative plasmid, 
24.5 MDa or Tetracycline 
plasmid 25.2 MDa
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Cryptic plasmid, 2.6 MDa
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1           2          3           4          5         6           7           8       
10
African β-lactamase 
plasmid, 3.2 MDa
bp
Asian β-lactamase 
plasmid, 4.4 MDa
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Figure 4.9 Gel displaying the plasmid profiles the transformants.  Lane 1 = MS11 transformant 
with the Dutch tetracycline plasmid, Lane 2 = MS11 transformant with the American tetracycline 
plasmid, Lane 3 = WHO M transformant with the Dutch tetracycline plasmid, Lane 4 = WHO M 
transformant with the American tetracycline plasmid, Lane 5 = WHO M, Lane 6 = 1 kb plus ladder. 
 
 Conclusion 4.4
An electroporation protocol for gonococci was developed, evaluated and used successfully to 
transform (i) the American and Dutch tetracycline resistance plasmids into N. gonorrhoeae strains 
WHO M and MS11, and (ii) the African and Asian β-lactamase plasmids into MS11. The 
experiments demonstrated the importance of having the right level of selection for 
transformants. Too little selection either resulted in no transformants, the appearance of 
‘satellite’ colonies, which were not true transformants, or a lawn of growth if the selecting 
concentration was not high enough to inhibit growth. 
Overall the transformation efficiency was higher for WHO M in respect to the transformation of 
the tetracycline resistance plasmids, whereas MS11 required further time after electroporation 
on non-selective media for expression to allow the detection of the transformants. Genetic host 
differences, such as the presence of the conjugative plasmid in WHO M and absence of the 
plasmid in MS11, may explain the differences in these transformation efficiencies. Genetic 
differences which can influence transformation experiments have been identified in E. coli 
(Hanahan, Jessee, & Bloom, 1991) including genes mediating DNA repair (e.g. gyrA) and 
recombination (e.g. recA), and in genes involved in restriction. These genetic markers have also 
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been shown to affect the transformation efficiencies of Salmonella typhimurium strains (Hanahan 
et al., 1991). No genetic markers have been identified in N. gonorrhoeae which effect 
transformation through electroporation because electroporation has been used so infrequently 
for this species. In time, whole genome sequencing of these two strains may identify genetic 
differences responsible for the differences in plasmid transformation. It has however been 
established previously that natural plasmid transformation is less efficient that chromosomal DNA 
transformation and can result in plasmid alterations (Sox et al., 1979). The factors affecting the 
efficiency of natural plasmid transformation, such as host restriction and re-coiling of sheared 
linear DNA may also be applicable to transformation using electroporation. DNA is subjected to 
restriction modification after importation into the cell (Sox et al., 1979) and it is this gonococcal 
restriction barrier that contributes, most significantly, to the reduced efficiency of plasmid 
transformation (Stein, Gunn, Radlinska, & Piekarowicz, 1995). However it would be expected that 
like plasmids acquired via conjugation, the plasmids transformed via electroporation would not be 
subjected to any host restriction. Differences in host-restriction could be investigated further by 
the extraction of the transformed plasmid from MS11 and then subsequent electroporation into a 
native MS11 strain to see if the transformation efficiency is increased. Other host factors may 
include the presence of the conjugative plasmid, as it has been shown that natural transformation 
is more efficient when this plasmid is present (Biswas et al., 1982; Norlander, Davies, & Normark, 
1979). The presence of the conjugative plasmid in WHO M may have allowed for homologous 
recombination with the tetracycline resistance plasmids as opposed to direct plasmid transfer, as 
it has previously been shown that the presence of a homologous plasmid can increase 
transformation of linear plasmid DNA (Contente & Dubnau, 1979). It would be unlikely that the 
DNA in these electroporation experiments would have been linearized, however marker rescue, 
such as the transposition of tet(M) into the conjugative plasmid in response to the presence of 
tetracycline,  may have occurred (Biswas et al., 1982).   
In addition to the two studies describing electroporation in N. gonorrhoeae (Dillard, 2011; Genco 
et al., 1991), there is one published study describing electroporation conditions for                        
N. meningitidis (Duenas, 1998). In contrast to the work described in this chapter and the two 
gonococcal electroporation papers where the gonococci were grown overnight on solid agar, the 
N. meningitidis strain was grown in liquid broth until exponential phase. The use of cells at mid-
exponential phase was not performed in these experiments with N. gonorrhoeae as fresh 
overnight growth from agar was used as prescribed by Dillard (2011) and Genco et al. (1991). Cells 
harvested at mid-exponential phase are also used for creating competence in other bacteria such 
as E. coli and Salmonella typhimurium (Sambrook, 1989). The use of mid-exponential phase 
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growth may increase the transformation efficiency of MS11 if MS11 is more sensitive to nutrient 
depletion by the use of overnight cultures. The use of overnight cultures resulted in a large 
number of viable bacteria for washing (approximately 109 CFU/ml before electroporation) so this 
is unlikely to be a factor. The N. meningitidis study re-suspended the cells in a similar volume of 
EB (400 µl) after washing resulting in a similar starting density of cells (109 CFU/ml). Similar 
volumes of washed bacterial cells (40 µl) and plasmid DNA (1 µl) were used for electroporation. 
The following electroporation settings were investigated in the N. meningitidis study: 0.8-1.4 kV 
(per mm), 25-50 µF and 100-600 Ω (compared to our gonococcal conditions of 1.8 kV, 25 µF and 
200 Ω for 5 ms). A final volume of 1 ml of broth (compared to 0.5 ml) was added after 
electroporation followed by 3 h incubation (compared to either 30 min or 6 h (Figure 4.2)) before 
the electroporated cells were plated out onto selective media. Initially the best transformation 
efficiency was achieved at 1.0-1.25 kV/mm to give 103 transformants/µg with a 60% survival rate. 
When the voltage was increased (13-15 kV/cm) the survival decreased (30%), and a decrease in 
voltage (9-9.5 kV/cm) resulted in much higher survival (90%) but lower transformation efficiency. 
Overall the study determined that a pulse time of 8.31 ms at 1.15 kV/mm and 25 ΩF and 400 Ω, 
and 50–200 ng of DNA resulted in the best transformation efficiency of 6.5 x 104 transformants.  
Carefully prepared E. coli competent cells can result in up to 109 transformant colonies/µg of 
supercoiled plasmid DNA (Sambrook, 1989) and efficiencies greater than 1010 transformants/µg 
using pUC18 have been reported (Hanahan et al., 1991). High transformation efficiencies may be 
required for cloning of high-complexity plasmids or if there is a very limited supply of starting DNA 
(Hanahan et al., 1991). The key aim of these experiments was to determine whether these two 
strains (MS11 and WHO M) could acquire plasmids by electroporation, so high transformation 
efficiencies were not required, however many parameters could be altered if a higher 
transformation efficiency was required. Parameters that could be optimised to increase the 
transformation efficiency include increasing the electrical field strength and duration of pulse. 
Increasing both these parameters can result in loss of viability of the bacteria and the 
electroporation parameters results used already result in approximately 80% loss of bacteria, 
even though the overall numbers are still very high (108 CFU/ml), so there is little scope  for 
increasing field strength and/or pulse duration. The amount of starting plasmid DNA could be 
altered. The N. meningitidis study (Duenas, 1998) found that the most efficient DNA load was 50 
ng and the transformation efficiency started to decrease at 200 ng. However the amount of DNA 
used in this study were already within these parameters. A transformation guide from Sigma 
(http://www.sigmaaldrich.com/life-science/molecular-biology/cloning-and-expression/learning-
center/transformation-efficiency.htm) suggests that no more than 1 µl of DNA should be used in 
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electroporations due to the high level of salt, and 5 µl was used in these experiments  to ensure 
sufficient DNA was available when the Qiagen mini-prep method for plasmid DNA extraction was 
used. However no arcing was detected and experiments using different starting volumes of DNA 
showed that the number of transformants were in general either reduced or there was no 
difference. The starting density of cells used for electroporation is also a parameter that can 
affect transformation efficiency. On average the starting density of cells for electroporation was 
2.7 x 109 CFU/ml. In the literature there are some discrepancies on what the optimum density of 
E. coli cells are required for high frequency transformation; one protocol states that the for high 
frequency transformation E. coli cells should not exceed 1 x 108 CFU/ml (Sambrook, 1989), 
however, transformation efficiency was shown to increase with a higher starting density of E. coli 
of 4 x 108 CFU/ml (Tang et al., 1994), and another article describes cells at a concentration of        
5 x 1010 to 1011 CFU/ml is appropriate (Hanahan et al., 1991). It is unlikely that starting cell density 
is a factor with these gonococcal electroporations and the large number of viable cells after 
electroporation (approximately 2.7 x 109 CFU/ml) show that viable cells are not a limiting factor.  
In general, other bacteria have successfully employed electroporation with overall parameters of 
6.25-12.5 kV/cm, 5 ms and bacteria suspensions of a high density such as 5 x 1010 CFU/ml (Elkins 
et al., 1991). The electroporation conditions used in this study were the same as were used for a 
study that the electroporated pEK204 into E. coli (Dhanji, Doumith, Hope, Livermore, & 
Woodford, 2011a). Overall the transformation efficiency in this study was higher for WHO M and 
the American tetracycline resistance plasmid at 8.7 x 104 CFU/µg than the transformation 
efficiency reported in the N. meningitidis study (6.5 x 104 CFU/µg) (Duenas, 1998), which could be 
due to the higher voltage, albeit with a reduced survival rate. As the transformation efficiency was 
higher in this study the higher voltage was maintained to give the maximum opportunity for the 
transfer of pEK204 into N. gonorrhoeae (as described in Chapter 5) and to keep the 
electroporation conditions for N. gonorrhoeae and E. coli the same. 
This work showed for the first time that electroporation is an effective method for transferring 
plasmids into N. gonorrhoeae in the laboratory, and so could be used in other studies to avoid the 
requirements of piliation, the gonococcal DUS, the presence of conjugative plasmids, host-
restriction and to avoid plasmid alteration.   
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5 Transfer of ESBL genes into N. gonorrhoeae 
 Background 5.1
Extended-spectrum β-lactamases (ESBLs) are diverse plasmid-mediated enzymes with the CTX-M 
(cefotaximase-Munich) family being the leading cause of extended-spectrum cephalosporin 
resistance in E. coli globally (Canton & Coque, 2006). This is of major public health concern and 
presents great therapeutic challenges (Bonnet, 2004; Livermore et al., 2007). The widespread 
distribution of cefotaxime resistance can be attributed to selection due to the use of extended-
spectrum cephalosporins and the dissemination of CTX-M plasmids by conjugation (Bonnet, 
2004). The presence of insertion sequences such as ISEcp1 and transposons on the plasmids 
(Canton & Coque, 2006) allow the mobilisation of blaCTX-M genes to other plasmids and to the 
chromosome of the host bacterium, and has also contributed to this spread.  
Within the UK, ESBL-producing E. coli are dominated by variants of the uropathogenic ST131 
lineage and most express CTX-M-15 or, to a lesser extent, CTX-M-3 -lactamases (Dhanji et al., 
2011b; Lau et al., 2008). Infection with E. coli can cause life-threatening bacteraemia, however, 
the majority of infections are in the urinary tract and are associated with the elderly, long hospital 
stays and heavy antibiotic use (Oteo et al., 2010). There is increasing prevalence of ESBL E. coli in 
the community setting (Oteo et al., 2010; Rodriguez-Bano et al., 2010), which may provide N. 
gonorrhoeae, a naturally transformable species, further opportunities to be exposed to ESBL-
encoding genes in the uro-genital tract. Additionally rectal N. gonorrhoeae infections may be 
exposed to enteric bacteria with plasmid-encoded antimicrobial resistance determinants. 
There is no published research on the cloning of ESBL genes, or the introduction of plasmids 
encoding ESBLs into N. gonorrhoeae. Additionally there is no reported evidence that naturally-
occurring plasmids can be transferred into N. gonorrhoeae from E. coli, with the closest success 
being the transfer of a Haemophilus ducreyi plasmid (pHD131) from E. coli to N. gonorrhoeae 
(Piffaretti & Soldati, 1990).  
Electroporation was previously established for the transformation of native gonococcal                 
β-lactamase and tetracycline resistance plasmids into a selection of N. gonorrhoeae strains (see 
Chapter 4). The aim of the work presented in this chapter was to investigate whether                    
N. gonorrhoeae could acquire the IncI1 resistance plasmid pEK204 via electroporation. The 
plasmid originated from an uropathogenic E. coli strain (belonging to ST131) and harbours both 
blaCTX-M-3 and blaTEM-1b, but no other resistance genes (Figure 5.1) (Woodford et al., 2009). As there 
is no reported evidence of enteric plasmid transfer to N. gonorrhoeae, pEK204 was not expected 
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to be stably maintained in N. gonorrhoeae. However, it was hypothesized that under selective 
pressure with a cephalosporin, transient carriage of pEK204 in gonococcal cells might lead to 
‘marker rescue’ (Biswas et al., 1982) by transposition of the blaCTX-M-3 gene into the gonococcal 
genome. Alternatively, the presence of a blaTEM-1 gene in PPNG may facilitate homologous 
recombination between a native gonococcal β-lactamase plasmid and pEK204. 
The blaCTX-M-3 gene from pEK204 was amplified with and without the predicted promoter plus 
flanking sequences to ensure that any negative transformation results were not due to the 
recipient cell not recognizing the blaCTX-M-3 promoter. The gonococcal DNA uptake sequence (DUS) 
(Smith et al., 1999) was also incorporated into the PCR products using suitable primers during 
amplification. Electroporation and natural transformation was used to transform gonococci with 
the blaCTX-M-3 gene variants. Additionally blaTEM-10 was amplified with and without the gonococcal 
DUS to investigate whether the gonococci could be transformed naturally or by electroporation 
with a TEM-ESBL (Figure 5.2).  
 
Figure 5.1 Schematic to illustrate the resistance region of pEK204 and how pEK204 arose through 
acquisition of Tn3 transposon and ISEcp1-blaCTX-M-3 by a pCOL1b-like plasmid. The tnpA gene 
(encoding the Tn3 transposase, shown in yellow) is disrupted by ISEcp1-blaCTX-M-3 (shown in 
orange).  The TATTG repeats are consistent with ISEcp1-mediated transposition. The remainder of 
the Tn3 gene is shown in blue; tnpR (encoding the resolvase of Tn3), blaTEM-1b and the flanking      
5-bp Tn3 left inverted repeats (IRL) and right inverted repeats (IRR) (TTTTC).  Figure taken from 
Woodford et al. (2009). 
ISEcp1 blaCTX-M-3 tnpA 
pCOL1b-like  
backbone 
tnpR blaTEM-1b 
IRL IRR 
TTTTC TTTTC 
TATTG TATTG 
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Note: *Cefotaxime only for WHO M, PP = predicted promoter GC-DUS = gonococcal DNA update sequence  
Figure 5.2 Schematic to illustrate the different transforming DNA, recipient strains and antimicrobial selection used in the electroporation and natural 
transformation experiments. ST1407 = Strain G11-1052.  
Electroporation Natural transformationTransformation 
technique
Transforming 
DNA
Recipient 
strains
Antimicrobial 
Selection
pEK204
blaCTX-M-3
blaCTX-M-3 with PP
penA from F89 (control)
blaTEM-10
blaTEM-10 with GC-DUS
penA from F89 (control)
(above also by 
electroporation)
blaCTX-M-3
blaCTX-M-3 with GC-DUS
blaCTX-M-3 with PP
blaCTX-M-3 with PP and GC-DUS
penA from F89 (control)
E. coli α-Select (control) N. gonorrhoeae strains; MS11, ST1407, WHO M
N. gonorrhoeae strains;
G12-1283, Strain 3 and 
WHO M
Ampicillin and cefotaxime* Ceftazidime and ceftriaxone 
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 Methods 5.2
5.2.1 E. coli and N. gonorrhoeae electroporation with pEK204 
5.2.1.1 Alkaline lysis plasmid extraction  
Plasmid pEK204 was extracted from E. coli ‘Strain C’ (Woodford et al., 2009) using the alkaline 
lysis plasmid extraction method. Using a cotton swab the overnight growth of Strain C from a 
GCVIT agar plate was harvested and re-suspended in 2 ml TE buffer (50 mM Tris pH 8, 10 mM 
EDTA) and the culture was pelleted by centrifugation at 8,000 rpm for 5 min. The supernatant was 
discarded and the cells were resuspended in 0.5 ml TE buffer and were centrifuged at 8000 rpm 
for 2 min. The supernatant was discarded and the pellet re-suspended in 40 µl of TE buffer. The 
cells were lysed by the addition of 600 µl of freshly prepared lysis buffer (0.05 M Tris, 0.01 M 
EDTA, 4% w/v SDS, pH adjusted to 12.45). The mixture was gently mixed and lysis was completed 
by incubating at 55oC for 40 min. For neutralization 50 µl of 2 M Tris (pH 7.0) was added and 
mixed gently. To precipitate the chromosomal DNA and protein, 240 µl of 5 M NaCl was added 
and the mixture was incubated on ice for 20 min. The suspension was centrifuged at 4oC at 13,000 
rpm for 60 min. The upper layer (about 800 µl) of the supernatant was removed and added to an 
Eppendorf tube with 800 µl of 100% ice-cold ethanol and mixed gently. The chromosome strands 
were visible at this point. The mixture was centrifuged at 4oC at 13,000 rpm for 30 min. As much 
ethanol as possible was gently removed by pouring at the opposite side to the pellet. One 
millilitre of 70% ice-cold ethanol was then added to the Eppendorf tube and a final centrifugation 
at 4oC at 13,000 rpm for 20 min was performed. All of the ethanol was gently removed and the 
pellet was air dried at room temperature. The pellet was re-suspended in 50 µl of elution buffer 
(Qiagen). The solution was left at 4oC overnight so the extracted plasmid re-suspended into the 
solution and the solution was then placed at -20oC for long-term storage. 
5.2.1.2 Electroporation of pEK204 into E. coli 
Electroporation was performed as previously described for N. gonorrhoeae (see Section 4.2.5.3) 
with the following modifications; 1 µl of the extracted pEK204 was added to 25 µl of α-Select 
electrocompetent E. coli cells (Bioline). After electroporation, 500 µl of SOC medium (Bioline) was 
added to the cells. The mixture was transferred to a Falcon tube and rotated at 200 rpm for 45 
min at 35-37oC. Transformants were selected by plating 100 µl on GCVIT plates supplemented 
with 100 mg/L ampicillin along with a 30 µg cefotaxime disc (Oxoid) placed on the agar plate. 
Plates were incubated overnight at 35-37oC. 
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5.2.1.3 N. gonorrhoeae electroporation with pEK204 
Electroporation of pEK204 into gonococcal strains MS11, G11-1052 (ST1407) and WHO M was 
performed as previously described (see Section 4.2.5.3), but with different selective plates. For 
selection, the cefotaxime concentrations were selected by performing a sub-culture of the 
gonococcal strains on to GCVIT plates supplemented with a concentration range of cefotaxime 
starting at two- fold higher concentration than the recipients MIC; the lowest concentration 
where growth was first inhibited was selected as well as the concentration two fold higher. 
Concentrations of cefotaxime selected were 0.064 mg/L and 0.125 mg/L for MS11, 0.125 mg/L 
and 0.25 mg/L for WHO M and 1 mg/L and 2 mg/L for G11-1052. Additionally G11-1052 and MS11 
were plated out on GCVIT supplemented with ampicillin (150 mg/L for G11-1052 and 10 mg/L for 
MS11) as well as a cefotaxime disc. This was to allow for selection of the blaTEM-1 from pEK204 to 
determine if pEK204 was transferred to N. gonorrhoeae and the blaCTX-M-3 gene was not expressed. 
All electroporations were performed on three different occasions (biological repeats) and 
electroporation of α-Select electrocompetent E. coli with pEK204 was performed at each 
electroporation session as a control.  
5.2.1.4 Electroporation of gonococcal resistance plasmids into strain G11-1052 (ST1407)  
Strain G11-1052 of ST1407 was not originally selected to establish the electroporation procedure 
(see Section 4.2.5.3) therefore to confirm G11-1052 could acquire and express gonococcal 
plasmids the strain was electroporated with the Dutch tetracycline resistance plasmid (as 
described in Section 4.2.5.3) and with the African β-lactamase plasmid from WHO M (as described 
in Section 6.2.4). 
5.2.1.5 CTX-M group 1 PCR 
To confirm the transformation of pEK204 into the α-Select cells, a PCR was performed which 
amplifies a conserved region of blaCTX-M group 1 alleles (Woodford, Fagan, & Ellington, 2006). 
Three to four half colonies growing closest to the cefotaxime disc were selected. Half a colony was 
added to 100 µl of sterile distilled water, boiled for 5 min and centrifuged at 13,000 rpm for 5 
min. The supernatant was then used as the template in the PCR. In 20 µl reactions, 10 µM of each 
primer (CTX-M-gp1-F and CTX-M-gp1-R; Table A1, Appendix One) was added to 2x MyTaq Red Mix 
(Bioline) with 2 µl of template. PCR amplification was performed on a DNA Engine Tetrad 
thermocycler (MJ Research) for the following cycling conditions: 95oC for 2 min, then 35 cycles of 
95oC for 15 s, 60oC for 15 s and 72oC for 15 s. PCR products were visualised under UV after 
separation on 2% E-gels (Invitrogen) (see Section 3.3.2). 
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5.2.2 N. gonorrhoeae transformation with blaCTX-M-3 
5.2.2.1 Amplification of blaCTX-M-3 and penA for electroporation and natural transformation 
experiments  
The blaCTX-M-3 gene from pEK204 was amplified from E. coli Strain C using primers CTX3_geneF and 
CTX3_geneR (Table A1, Appendix One) and the PCR conditions previously described (see Section 
5.2.1.5), but in larger 200 µl reactions. To ensure that any negative transformation results were 
not due to the inability of the strains to use internal promoters to transcribe blaCTX-M-3, primers 
CTX-M-gp1-PPF and CTX-M-gp1-PPR (Table A1, Appendix One. PP = predicted promoter) were 
designed that included the blaCTX-M-3 predicted promoter. For natural transformation to be 
efficient in N. gonorrhoeae, the transforming DNA should contain the gonococcal DUS (Ambur et 
al., 2007). The gonococcal DUS was incorporated into the amplified blaCTX-M-3 with and without the 
predicted promoter, by the addition of the 12-mer sequence (5’ ATGCCGTCTGAA 3’) on to the 5’ 
end of the forward and reverse CTX3_gene and CTX-M-gp1-PP primers (CTX-M-gp1-PPGCF, CTX-
M-gp1-PPGCR, CTX3_gene_GC_F and CTX3_gene_GC_R; Table A1, Appendix One). PCR products 
were then purified (see Section 5.2.2.2). 
DNA sequencing was performed to confirm that the gonococcal DUS was incorporated into the 
PCR products.  Primer pairs CTX3_gene_GC and CTX-M-gp1-PP-GC, as well as internal sequencing 
primers (CTX3_seqF and CTX3_seqR, Table A1, Appendix One) were used for the sequencing 
reaction. The DNA sequencing was performed as described in Section 3.3.3, however, the BigDye® 
Terminator v1.1 Cycle Sequencing (Life Technologies) technology was used that allows for optimal 
base-calling adjacent to the primer. 
The penA gene from N. gonorrhoeae strain F89 that confers high-level ceftriaxone resistance 
(Unemo et al., 2011b) was amplified and purified to be used as an experimental control in natural 
transformation and electroporation experiments. A DNA lysate from strain F89 was prepared as 
previously described (see Section 3.3.1). The penA PCR was performed as previously described 
(Ohnishi et al., 2010b) with some modifications; in 200 µl reactions, 10 µM of each primer 
(penA_F and penA_R; Table A1, Appendix One) was added to 2x MyTaq Red Mix (Bioline) with 20 
µl of template. PCR amplification was performed on a DNA Engine Tetrad thermocycler (MJ 
Research) for the following cycling conditions: 96oC for 2 min, then 30 cycles of 96oC for 10 s, 65oC 
for 10 s and 72oC for 2 min. PCR products were purified (see Section 5.2.2.2) and were visualised 
under UV after separation on E-gels (Invitrogen) (see Section 3.3.2).  
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5.2.2.2 Purification of PCR products  
The PCR products for transformation were purified using the MultiScreen PCR96 filtration system 
(Millipore, Watford, UK). The PCR products were transferred into a MultiScreen PCR96 plate and 
any unused wells were covered with plate sealing tape. The plate was placed on to the Millipore 
vacuum manifold without the plate lid and a vacuum pressure of 20 inches Hg for 10 min was 
applied. During the vacuum filtration the size-exclusion membrane captured the PCR products 
while dNTPS, salts and primers passed through the membrane. Nuclease free water (50 µl) was 
added to each well to re-suspend the PCR products and the plate placed on a plate shaker for     
20 min. The purified PCR products were removed, the DNA concentrations were established by 
the Qubit v3.0 Fluorometer (Life Technologies) and the PCR products were stored at -20oC until 
required. 
5.2.2.3 N. gonorrhoeae electroporation with blaCTX-M-3 
Electroporation was performed as previously described (see Section 4.2.5.3), however, 0.3 µg 
(equivalent to 1 to 2 µl) of the purified blaCTX-M-3 PCR products (with and without the predicted 
promoter, but not including the gonococcal DUS) were used as the transforming DNA (Figure 5.2). 
The same selective plates were used as with the pEK204 electroporation (see Section 5.2.1.3). As 
a control, the purified penA PCR product (0.3 µg) was electroporated into WHO M and a GCVIT 
plate supplemented with 2 mg/L cefotaxime was used for selection. The electroporation 
experiments were performed on three different occasions (biological repeats). To confirm that 
MS11 and G11-1052 could also transform chromosomal DNA via electroporation penA was 
transformed into MS11 and G11-1052. Selection was performed (4-16 fold above the recipients 
MIC) using GCVIT plates supplemented with 0.06 mg/L and 0.12 mg/L of cefotaxime for MS11 and 
2 mg/L of cefotaxime for G11-1052. The ceftriaxone and cefotaxime MICs for the transformants 
were established by E-test as previously described (see Section 3.2.1). 
5.2.2.4 N. gonorrhoeae natural transformation with blaCTX-M-3  
Transformation experiments were performed as previously described (Ohnishi et al., 2011). 
Gonococcal strains MS11, G11-1052 and WHO M were sub-cultured from a piliated colony (see 
Section 4.2.4) and incubated at 35-37oC with 5% CO2 for 18-24 h. A 1 ml suspension equivalent to 
0.5 MacFarlands of each of the gonococcal strains were made in GC broth.  The PCR products 
from the amplification and purification of blaCTX-M-3 with and without the predicted promoters, 
and with and without the gonococcal DUS (see Section 5.2.2.1) were added at a concentration of 
30 µg/ml (Figure 5.2). The suspension was incubated for 6 h at 35-37oC in 5% CO2 and then 100 µl 
of the transformation suspension was plated out on to GCVIT plates supplemented with 
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cefotaxime for selection (see Section 5.2.1.3). Plates were incubated for up to 72 h. As a 
transformation control, WHO M was transformed with penA and selection was performed on 
GCVIT plates supplemented with 2 mg/L of cefotaxime. Transformation experiments were 
performed on three separate occasions (biological repeats). In addition transformations using 
penA was also performed with MS11 and G11-1052 using 0.06 and 0.125 mg/L selection for MS11 
and 2 mg/L selection for G11-1052, which were cefotaxime concentrations 4-16 fold above the 
recipients MIC. The ceftriaxone and cefotaxime MICs for the transformants were established by  
E-test as previously described (see Section 3.2.1). 
5.2.3 N. gonorrhoeae transformation with blaTEM-10 
Electroporation and natural transformation was also attempted using blaTEM-10 amplified from a 
DNA lysate (see Section 3.3.1) obtained from E. coli strain NCTC 13352. PCR amplification, PCR 
products purification, electroporation and natural transformation were identical as previously 
described for blaCTX-M-3, with the following differences; blaTEM-10 was amplified with and without 
the gonococcal DUS using primers TEM10_F and TEM10_R, and TEM10_GC_F and TEM10_GC_R, 
respectively (Table A1, Appendix One). Transformations were performed only on isolates already 
expressing TEM-1 or TEM-135 (as confirmed by the Nitrocefin test, see Section 3.2.3) to optimize 
the likelihood of recombination of blaTEM-10 with blaTEM-1/135; G12-1283 (TEM-135 harboured on a 
Toronto β-lactamase plasmid); Strain 3 (TEM-1 harboured on an Asian β-lactamase plasmid) and 
WHO M (TEM-1 harboured on an African β-lactamase plasmid) (Figure 5.2). Selection was 
performed (3-4 fold above the recipients MIC) using 0.06 and 0.125 mg/L of ceftriaxone for all 
three strains and 0.5 mg/L and 1 mg/L of ceftazidime for G12-1283 and WHO M, and 0.125 mg/L 
and 0.25 mg/L of ceftazidime for Strain 3. Transformations were performed on three separate 
occasions (biological repeats). Transformation of strain WHO M with penA was performed as a 
control using 0.25 mg/L of ceftriaxone for selection. It was also confirmed that 1 mg/L of 
ceftazidime was suitable for selection of transformation of penA. The blaTEM genes were 
sequenced from all transformants as previously described (see Section 3.3.3) using BlaF and BlaR 
primers (Table A1, Appendix One) (Ohnishi et al., 2010a). The ceftazidime and ceftriaxone MICs 
for the recipients and transformants were established by E-test as previously described (see 
Section 3.2.1). 
5.2.4 PCR-based replicon typing of plasmids 
A commercially-available kit, PCR based replicon typing (PBRT) (Diatheva, Italy), was used to 
confirm that the recipient strains (MS11, G11-1052 and WHO M) did not contain any plasmids of 
the same incompatibility (Inc) group as pEK204 (IncI1) (Woodford et al., 2009). Plasmids of the 
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same incompatibility group cannot propagate in the same bacterial cell (Carattoli et al., 2005). 
The M1 PCR mix from the PBRT kit is a multiplex PCR for the amplification of amplicons from 
plasmids with IncHI1, IncHI2 and IncI1. Plasmid pEK204 was extracted from E. coli Strain C using 
the alkaline lysis plasmid extraction method as previously described (see Section 5.2.1.1). Plasmid 
extractions were performed on the gonococcal strains as previously described (see Section 4.2.3). 
The PCR was performed according to the manufacturer’s instructions. Each PCR reaction 
contained 23.8 µl of M1 PCR mix, 0.2 µl of DNA polymerase and 1 µl of extracted plasmid DNA. 
PCR amplification was performed on a DNA Engine Tetrad thermocycler (MJ Research) for the 
following cycling conditions: 95oC for 10 min, then 25 cycles of 96oC for 60 s, 60oC for 30 s and 
72oC for 60 s, with a final cycle of 72oC for 5 min. PCR products and a 100 bp ladder (Qiagen) were 
visualised under UV after separation on 2% E-gels (Invitrogen) (see Section 3.3.2). 
 Results 5.3
5.3.1 E. coli and N. gonorrhoeae electroporation with pEK204 
Plasmid pEK204 was successfully electroporated into α-Select electrocompetent E. coli during 
each electroporation. Approximately 1000 colonies were counted on the selection plates          
(100 mg/L ampicillin) with many transformants identified by growth near (within 4 mm) the 
cefotaxime disc. The presence of the plasmid was confirmed by subsequent sub-culture of four 
transformants on to a GCVIT plate supplemented with 2 mg/L cefotaxime. The presence of    
blaCTX-M-3 was confirmed by the CTX-M group 1 PCR (Figure 5.3). The cefotaxime MIC for the         
α-Select electrocompetent E. coli was 0.032 mg/L, while that for the transformants increased to 
>32 mg/L. 
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Figure 5.3 CTX-M group 1 PCR gel from electroporation of α-Select electrocompetent E. coli with 
pEK204. Lane 1 = Transformant 1, Lane 2 = Transformant 2, Lane 3 = Transformant 3,                 
Lane 4 = Transformant 4, Lane 5 = pEK204 positive control, Lane 6 = No template control (NTC), 
Lane 7 = 100 bp ladder. 
 
By contract, acquisition of pEK204 was not demonstrated for any of the gonococcal strains used 
(MS11, G11-1052 and WHO M). Even though electroporation of E. coli with pEK204 was 
performed at each electroporation session, and all the gonococcal strains were still viable after 
electroporation and had previously been shown to be electro-competent (see Section 4.3.6), it is 
not possible to say that the gonococcal strains remained electro-competent throughout the 
experiments as no positive controls were used for each of the three strains. In the instances 
where colonies were present on the selective plates (Table 5.1), all the colonies were confirmed 
to be Gram-negative and oxidase-positive cocci, and were successfully sub-cultured on to GCVIT 
plates with the same cefotaxime concentration, however, these colonies were all β-lactamase-
negative and no products were amplified with the CTX-M-group 1 PCR. Growth was most 
probably due to insufficient cefotaxime in the selective plates or the development of mutations to 
enable growth. To investigate this further, suspensions of the strains (MS11, G11-1052 and    
WHO M) were prepared in GC broth at a similar density to the growth taken at 6 h after 
electroporation and 100 µl was plated out GCVIT plates supplemented with 1 mg/L of cefotaxime 
for G11-1052, 0.125 mg/L for WHO M and O.064 mg/L for MS11. After 48 h incubation at 35-37oC 
with 5% CO2, two Gram-negative cocci and oxidase-positive colonies were present on each plate 
showing that the cefotaxime concentrations were not quite high enough for these electroporation 
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experiments. When selective agar with a higher concentration of cefotaxime was used there were 
no transformants or no break-through colonies.   
5.3.2 Electroporation of gonococcal resistance plasmids into strain G11-1052 (ST1407)  
Electroporation of strain G11-1052 of ST1407 with the Dutch tetracycline resistance plasmid 
extracted from WHO G resulted in three transformants. The tetracycline MIC of the transformants 
was 32 mg/L. The presence of the plasmid was confirmed by the PCR which was Dutch plasmid 
PCR positive and the plasmid profile of a transformant revealed the presence of the 25.2 MDa 
tetracycline resistance plasmid (Figure 4.8). G11-1052 was also confirmed to be able to acquire 
and express a gonococcal β-lactamase plasmid and the results are described in detail in Section 
6.3.4. 
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Table 5.1 Number of colonies counted after electroporation of MS11, G11-1052 and WHO M with pEK204 (all results from 6 h). 
Strain (replicate 
number) 
Ampicillin concentration with cefotaxime disc  
(30 µg) Cefotaxime concentration 
150 mg/L 10 mg/L 0.064 mg/L 0.125 mg/L 0.25 mg/L 1 mg/L 2 mg/L 
G11-1052 (1) NG 
    
5 colonies NG 
G11-1052 (2) NG 4 colonies NG 
G11-1052 (3) NG 
    
50 colonies NG 
WHO M (1) 
   
1 colony NG 
  WHO M (2)   1 colony NG 
WHO M (3)   
  
3 colonies NG 
  MS11 (1)   NG NG NG 
   MS11 (2)   NG 50 colonies NG 
   MS11 (3)   NG 1 colony NG 
   Note: NG = No growth. Shaded areas indicate that selection was not performed at this concentration.
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5.3.3 N. gonorrhoeae electroporation and natural transformation with blaCTX-M-3  
Amplification of blaCTX-M-3 with and without the predicted promoters, and with and without the 
gonococcal DUS was successful (Figure 5.4), and the presence of the gonococcal DUS was 
confirmed by DNA sequencing. The penA from strain F89 was successfully amplified (Figure 5.5). 
 
Figure 5.4. CTX-M-gp1-PP and CTX3_gene PCR, with and without the gonococcal DUS. Lane 1 = 
100 bp ladder, Lane 2 = CTX-M-gp1-PP PCR (1194 bp), Lane 3 = CTX-M-gp1-PP with the gonococcal 
DUS PCR (1218 bp), Lane 4 = CTX3_gene with the gonococcal DUS PCR (917 bp), Lane 5 = 
CTX3_gene PCR (893 bp), Lanes 6-9 = NTC for each PCR. 
 
 
Figure 5.5 Gel of the penA PCR. Lane 1 = F89 PCR positive penA, Lane 2 = NTC, Lane 3 = 100 bp 
ladder. 
 
No transformants were detected for both the natural transformation and electroporation of the 
blaCTX-M-3 PCR products with and without the predicted promoter, and with and without the 
gonococcal DUS.  However, strain WHO M successfully acquired penA in each experiment 
performed, with 160–180 transformants at 0 h demonstrating that the experimental procedures 
were sound (Table 5.2). In addition, both natural transformation and electroporation were used 
2000
800
400
1      2      3        4       5      6       7       8       9      
bp
penA
(2038 bp)
2000
800
400
1   2      3
bp
91 
 
successfully to transform penA into G11-1052, although only electroporation was successful for 
strain MS11 (Table 5.2). The MICs of ceftriaxone and cefotaxime for transformants all increased at 
least 16-fold (16-256 fold increases) compared with the MICs of the respective parental strain 
(Table 5.3) confirming successful acquisition of penA. Three attempts of natural transformation of 
MS11 with penA were unsuccessful, most probably due to the lack of piliated colonies. 
Table 5.2 Number of transformants from electroporation and natural transformation using penA. 
 
Strain (replicate number) 
Cefotaxime concentration 
0.064 mg/L 0.125 mg/L 2 mg/L 
N
at
u
ra
l t
ra
n
sf
o
rm
at
io
n
  
WHO M (1) 
  
912 
WHO M (2) 
  
800 
WHO M (3) 
  
768 
MS11 (1) NG NG 
 MS11 (2) NG NG 
 MS11 (3) NG NG 
 G11-1052   11 
El
ec
tr
o
p
o
ra
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o
n
   
   
(0
 h
 r
es
u
lt
s)
 
WHO M (1)   184 
WHO M (2) 
  
180 
WHO M (3) 
  
160 
G11-1052 
  
2048 
MS11 720 
  Note: NG = No growth. Shaded areas indicate that selection was not performed at that cefotaxime 
concentration. 
 
Table 5.3 Ceftriaxone and cefotaxime MICs for MS11, WHO M and G11-1052 pre and post 
transformation. 
Strain Ceftriaxone (mg/L) Cefotaxime (mg/L) 
Pre 
transformation 
Post 
transformation 
Pre 
transformation 
Post 
transformation 
MS11 ≤ 0.002 0.125 0.004 1 
WHO M  0.016 1 0.032 2 
G11-1052 0.032 1 0.25 4 
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5.3.4 N. gonorrhoeae electroporation and natural transformation with blaTEM-10  
The blaTEM-10 with and without the gonococcal DUS was successfully amplified from E. coli NCTC 
13352 (Figure 5.6).  
 
Figure 5.6 Amplified blaTEM-10 with and without the gonococcal DUS PCR results. Lane 1 = 100 bp 
ladder, Lane 2 = blaTEM-10 PCR (755 bp), Lane 3 = blaTEM-10 PCR NTC, Lane 4 = blaTEM-10 with the 
gonococcal DUS (779 bp), Lane 5 = blaTEM-10 with the gonococcal DUS NTC. 
 
There was only one successful transformant from the electroporation experiments; Strain 3 from 
the 0.25 mg/L ceftazidime plate. The MIC results showed a fourfold increase in the ceftriaxone 
and ceftazidime MICs for the Strain 3 transformant (Table 5.4). The WHO M and penA 
electroporation controls produced 700–800 transformants on 0.25 mg/L of ceftriaxone and 576-
700 transformants on 1 mg/L of ceftazidime at 0 h. 
There were a total of four transformants from the natural transformation of WHO M with blaTEM-10  
with the gonococcal DUS from the ceftazidime 0.5 mg/L plate; WHO-M1, WHO-M2, WHO-M3 and 
WHO-M4. All other transformations were unsuccessful. The MIC results show a four to eight fold 
increase in the ceftriaxone and ceftazidime MICs for the transformants (Table 5.4). The WHO M 
and penA natural transformation controls produced 960–1824 transformants on 0.25 mg/L of 
ceftriaxone and 1920–2000 transformants on 1 mg/L of ceftazidime at 0 h. 
Table 5.4 Ceftriaxone and ceftazidime MICs for WHO M, G12-1283, and Strain 3 pre- and post- 
transformation with blaTEM-10. 
Strain Ceftriaxone (mg/L) Ceftazidime (mg/L) 
Pre 
transformation 
Post transformation 
(transformant 
number) 
Pre 
transformation 
Post transformation 
(transformant 
number) 
WHO M 0.016 0.064 (M1/2), 0.125 
(M3/4) 
0.064 0.5 (all) 
G12-
1283  
0.008 N/A 0.064 N/A 
Strain 3 0.008 0.032 0.032 0.125 
2000
800
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DNA sequencing of the transformants’ blaTEM region revealed that the blaTEM gene from the    
WHO-M2 transformant was identical to blaTEM-10. There was one base-pair difference at different 
positions between blaTEM-10 and the blaTEM gene from the WHO-M3, WHO-M1 and Strain 3 
transformants, and three base-pair differences were identified between the blaTEM gene from the 
WHO-M4 transformant and blaTEM-10. Translation of the DNA sequences (Figure 5.7), using the 
standard numbering scheme for β-lactamases (Ambler et al., 1991), revealed that both the TEM 
enzyme from Strain 3 and the WHO-M2 transformants had the same amino acid sequence as the 
TEM-10 enzyme. The remaining three WHO-M transformants all expressed TEM enzymes with 
one amino acid difference compared with TEM-10; WHO-M1 (E28G), WHO-M3 (I173V) and   
WHO-M4 (M182T), none of which correspond to known naturally-occurring TEM variants.  
94 
 
                          10        20        30        40        50        60        70        80        90       100                   
                 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TEM 10 E.coli    --MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQN  
WHO M1 TEM-10    --MSIQHFRVALIPFFAAFCLPVFAHPGTLVKVKDAEDQLGARVGYIELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQN  
WHO M2 TEM-10    --MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQN  
WHO M3 TEM-10    --MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQN  
WHO M4 TEM-10    --MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQN  
Strain 3 TEM-10  --MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQN  
Strain 3 TEM-1   --MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQN  
WHO M TEM-1      --MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQN  
 
                         110       120       130       140       150       160       170       180       190       200          
                 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TEM 10 E.coli    DLVEYSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDSWEPELNEAIPNDERDTTMPAAMATTLRKLLTGELLT  
WHO M1 TEM-10    DLVEYSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDSWEPELNEAIPNDERDTTMPAAMATTLRKLLTGELLT  
WHO M2 TEM-10    DLVEYSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDSWEPELNEAIPNDERDTTMPAAMATTLRKLLTGELLT  
WHO M3 TEM-10    DLVEYSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDSWEPELNEAVPNDERDTTMPAAMATTLRKLLTGELLT  
WHO M4 TEM-10    DLVEYSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDSWEPELNEAIPNDERDTTTPAAMATTLRKLLTGELLT  
Strain 3 TEM-10  DLVEYSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDSWEPELNEAIPNDERDTTMPAAMATTLRKLLTGELLT  
Strain 3 TEM-1   DLVEYSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRWEPELNEAIPNDERDTTMPAAMATTLRKLLTGELLT  
WHO M TEM-1      DLVEYSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRWEPELNEAIPNDERDTTMPAAMATTLRKLLTGELLT  
 
                         210       220       230       240       250       260       270       280       290               
                 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TEM 10 E.coli    LASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAG.KRGSRGIIAALGP.DGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW  
WHO M1 TEM-10    LASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAG.KRGSRGIIAALGP.DGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW  
WHO M2 TEM-10    LASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAG.KRGSRGIIAALGP.DGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW  
WHO M3 TEM-10    LASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAG.KRGSRGIIAALGP.DGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW  
WHO M4 TEM-10    LASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAG.KRGSRGIIAALGP.DGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW  
Strain 3 TEM-10  LASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAG.KRGSRGIIAALGP.DGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW  
Strain 3 TEM-1   LASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAG.ERGSRGIIAALGP.DGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW  
WHO M TEM-1      LASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAG.ERGSRGIIAALGP.DGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW  
Figure 5.7 Amino acid alignment of TEM-10 ESBL, TEM-1 penicillinase, and the TEM variants from transformants of strain 3 (n = 1) and WHO M (n = 4). 
Amino acid differences compared with TEM-10 are highlighted and underlined. Amino acid sequences aligned using the standard numbering scheme for 
β-lactamases (Ambler et al., 1991). 
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5.3.5 PCR-based replicon typing  
The PCR based replicon typing demonstrated that none of the gonococcal strains (MS11. WHO M 
and G11-1052) used in the electroporation experiments with pEK204 harboured plasmids of the 
same incompatibility group as pEK204, IncI1 (Figure 5.8). 
 
Figure 5.8 PCR-based replicon typing gel. Lane 1 = 100 bp ladder, Lane 2 = WHO M, Lane 3 = 
MS11, Lane 4 = G11-1052, Lane 5 = pEK204, Lane 6 = M1 positive control. 
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 Discussion  5.4
No gonococcal transformants were identified from the electroporation experiments with pEK204. 
Electroporation was not a limiting factor because the α-Select E. coli successfully acquired 
pEK204, and electroporation of native gonococcal plasmids into N. gonorrhoeae was previously 
successful (see Chapter 4). Positive controls were not used for each of the gonococcal recipients 
so it is not possible to say that the strains remained electro-competent throughout and is a 
limitation of the study. The negative results were not due to plasmid incompatibility issues as 
none of the gonococcal strains harboured any plasmids with the same incompatibility group of 
pEK204, IncI1. It was possible that pEK204 could have been acquired transiently, but that blaCTX-M-3 
was not expressed, however, there was also no expression of blaTEM-1b from pEK204 in MS11 and 
G11-1052 when ampicillin was used for selection. Plasmid pEK204 may be too large (94 kb) to be 
acquired by N. gonorrhoeae; the largest known gonococcal plasmids, encoding tetracycline 
resistance, are only 42 kb. Homologous recombination of blaTEM-1b on pEK204 with the blaTEM-1 on 
the gonococcal β-lactamase plasmid in WHO M, and then subsequent transposition of blaCTX-M-3 
was not detected.  
Plasmid pEK204 is thought to have arisen through acquisition of Tn3 and ISEcp1-blaCTX-M-3 by a 
pCOL1b-like plasmid, which resulted in a disrupted tnpA gene (Figure 5.1) (Woodford et al., 2009). 
It has been demonstrated that the ISEcp1 element on pEK204 can mediate transposition of  
blaCTX-M-3 alone and blaCTX-M-3-blaTEM1b to other plasmids co-resident in a host E. coli strain (Dhanji 
et al., 2011a). These transposition events seemingly did not occur during the electroporation 
experiments with N. gonorrhoeae.  
Additionally no transformants were identified from the electroporation and natural 
transformation experiments with all the blaCTX-M-3 gene variants; with and without the predicted 
promoter and/or the gonococcal DUS. The experimental control of WHO M as a recipient for penA 
worked successfully, but was not used for the other gonococcal strains as a positive control and 
so is a study limitation. A lack of recombination site in the gonococcal genome for recombination 
for blaCTX-M-3 is the most probable reason for no incorporation of blaCTX-M-3. There was also no 
recombination of blaCTX-M-3 with blaTEM-1 in WHO M. As the amino acid sequences of CTX-M-3 and 
TEM-1 are only 39% identical (using blastp), and there was no significant nucleotide similarity 
(using blastn), the nucleotide sequence difference of the two genes are most probably too great 
for homologous recombination. 
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The size of pEK204 and the lack of recombination site for blaCTX-M-3 offer some explanation for the 
unsuccessful transformation. There is no published research on the successful transfer of enteric 
plasmids into N. gonorrhoeae suggesting protective mechanisms are in place to restrict this 
transfer. However, there is some evidence of direct laboratory plasmid transfer between              
N. gonorrhoeae and different bacterial genera (Brunton et al., 1986; McNicol, Albritton, & Ronald, 
1986), as well as evidence of plasmid transfer between N. gonorrhoeae and other Neisseria 
species (Genco et al., 1984; Ison, Gill, & Woodford, 1990; Roberts & Falkow, 1977; van Passel, van 
der, & Bart, 2006). Gonococcal tetracycline resistance plasmids have been detected in                   
N. meningitidis, Eikenella corrodens and Kingella denitrificans and it was suggested they were 
acquired from N. gonorrhoeae via cross-species conjugative transfer (Knapp et al., 1988). In 
addition, E. corrodens and K. denitrificans have been shown to be donors of the tetracycline 
resistance plasmids to commensal Neisseria species and N. meningitidis (Roberts & Knapp, 
1988a). The conjugal transfer of a gonococcal β-lactamase plasmid from N. gonorrhoeae to other 
Neisseria species as well as conjugal transfer from a N. cinerea transconjugant into                         
N. gonorrhoeae has also been demonstrated (Genco et al., 1984). The gonococcal conjugative 
plasmid has been shown to mobilise the gonococcal β-lactamase plasmids in intergeneric 
conjugations to H. influenzae and E. coli (Flett et al., 1981).  However, the plasmids were not 
successfully transferred back to N. gonorrhoeae from H. influenzae and E. coli, which was most 
probably due to a restriction barrier (Flett et al., 1981). The Haemophilus ducreyi plasmid, 
pHD131, was successfully transferred and maintained from E. coli to N. gonorrhoeae by 
transformation (Piffaretti & Soldati, 1990) demonstrating the  transfer of non-gonococcal 
plasmids into N. gonorrhoeae is possible, albeit rare. It is perhaps unlikely that N. gonorrhoeae 
would obtain an ESBL-encoding plasmid directly from an enteric host. The most likely route might 
be via an intermediate host. The gonococcal β-lactamase plasmids are examples of this indirect 
route; they are thought to have originated in Haemophilus species (Brunton et al., 1986; Chen & 
Clowes, 1987; Roberts et al., 1977) with a prior link to enterobacteria due to the presence of the 
TnA (Fayet et al., 1982), Insertion Sequence 5 (IS5) (Pagotto et al., 2000a), and the ability of the 
plasmids to be transferred and replicated in E. coli and other genera (Dillon & Yeung, 1989).   
The gonococcus harbours plasmids and resistance genes that are not gonococcal in origin - most 
often blaTEM and tet(M) - so it is not unreasonable to speculate that an ESBL gene could be 
acquired. Examples include a self-mobile rRNA methylase gene, erm(F), which was detected in 
three N. gonorrhoeae strains with erythromycin and azithromycin resistance (Roberts et al., 
1999). The gene was located in the chromosome and was found to be 99% similar to genes from 
colonic Bacteroides spp with a G+C content of 15% less than the average gonococcal 
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chromosomal G+C contents (50%). This suggests that erm(F) is non-gonococcal in origin (Roberts 
et al., 1999) and erm genes have been detected in other urogenital bacteria (Chung, Werckenthin, 
Schwarz, & Roberts, 1999). The isolates were able to transfer the erythromycin resistance by 
conjugation to other N. gonorrhoeae, as well as to N. meningitidis and E. faecalis recipients 
revealing that the erm(F) is, or is associated with, a self-mobilising element such as a integrative 
and conjugative element (ICE), which was previously referred to as a complete conjugative 
transposon. This was the first time an ICE had been identified in N. gonorrhoeae as the blaTEM 
(Pagotto et al., 2000a) and tet(M) (Swartley et al., 1993) are located on incomplete transposons. 
The tet(M) determinant was acquired from different species, most probably in response to 
tetracycline usage for the treatment of gonorrhoea as different levels of sequence homology with 
Tn1545, Tn916 and Ureaplasma urealyticum tet(M) genes have been demonstrated (88). As 
erm(F) was detected in the gonococcal chromosome and tet(M) has been found in the 
chromosome in some Neisseria species (Knapp et al., 1988) any acquisition of an ESBL gene by    
N. gonorrhoeae may not necessarily be plasmid mediated.  
Future work to further investigate whether blaCTX-M-3 could be expressed in N. gonorrhoeae 
includes incorporating blaCTX-M-3 into other plasmids that have successfully mobilised into              
N. gonorrhoeae such pHD131 (Piffaretti & Soldati, 1990), as well as modified gonococcal plasmids, 
such as the shuttle cloning vector pLES2 developed from a chimeric β-lactamase plasmid pFT180 
that can replicate in both N. gonorrhoeae and E. coli (Stein et al., 1983a). Other cosmid cloning 
vectors and plasmids that have been used to transfer genes from E. coli into N. gonorrhoeae could 
be utilised (Dillard & Seifert, 2001; Goodman & Scocca, 1988; Johnston & Cannon, 1999; Koomey 
& Falkow, 1987; Koomey et al., 1982; Pagotto et al., 2000b; Power et al., 1992; Sandlin et al., 
1993; Stein, 1991; Stein et al., 1992; Zhou & Apicella, 1996). We were, however, hesitant to 
perform such recombinant work as it is not likely to represent the natural environment and would 
be for academic interest only. Conjugations between E. coli harbouring pEK204 and                        
N. gonorrhoeae were not attempted as this is unlikely to occur naturally. However, if work was to 
be performed in this area then the use of the broad host-range conjugative plasmid pUB307, 
which is a derivative of IncP RP1 plasmid, to promote the transfer of gonococcal resistance 
plasmids and pLES2 from E. coli to N. gonorrhoeae (Piffaretti et al., 1988) via conjugation could be 
used.  
To investigate whether the unsuccessful blaCTX-M-3 transformations were due to a lack of 
recombination site, work was performed using the TEM-derived ESBL, TEM-10, which has two 
amino acid differences from TEM-1. In total five transformants were obtained; one with Strain 3 
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via electroporation and four from WHO M via natural transformation with a blaTEM-10 amplicon 
that contained the gonococcal DUS. Only one transformant had the exact same DNA sequence as 
blaTEM-10 (WHO M2), although the Strain 3 transformant harboured a gene with one silent 
nucleotide difference resulting in the TEM-10 amino acid sequence. These results showed that    
N. gonorrhoeae can acquire and express an ESBL and that this was associated with four to eight 
fold increases in MICs of ceftriaxone and ceftazidime. The final ceftazidime MICs for the 
transformants were all 0.5 mg/L, so more transformants with WHO M may have been acquired if 
a lower concentration of 0.5 mg/L ceftazidime was used for selection. Again, a limitation of the 
study was the lack of positive control strains for all gonococcal blaTEM-10 recipients; other than the 
use of penA to transform WHO M as an experimental control. 
It should be noted that the transformants’ amino acid sequences where closest to TEM-10 (just 
one amino acid difference) so they were most probably due to transformation and subsequent 
mutations, or partial gene recombination. However, it should be noted that the change in the 
TEM-1 sequences could have arose due to selection because of the presence of ceftazidime in the 
agar plates. Future work to investigate whether TEM-1 mutants can be selected using ceftazidime 
should be performed.  
Transformation of the blaTEM-10 gene into N. gonorrhoeae was not demonstrated when ceftriaxone 
was used for selection. This might suggest that using ceftriaxone, as recommended for effective 
gonorrhoea treatment, might reduce the probability of an ESBL gene with a high degree of 
similarity to blaTEM-1, transforming into N. gonorrhoeae in the natural environment. The risk of 
using sub-optimum cephalosporins has been demonstrated by a group who showed that penA 
mutants were easily selected using cefpodoxime, which is an oral third-generation cephalosporin, 
but were more difficult to select using cefixime and ceftriaxone. The cefixime and ceftriaxone 
MICs also increased from mutants achieved through cefpodoxime selection. The use of sub-
optimal oral cephalosporins in the Western Pacific (Lo et al., 2008) may have contributed to the 
initial development of decreased susceptibility to the oral cephalosporins in Japan in 2001 (Ito et 
al., 2004). Other examples of the use of sub-optimum treatments for gonorrhoea relate to 
treatment failure such as the use of ceftibuten as a single 400 mg oral dose in Hong Kong since 
1997  (Lo et al., 2008). This regime resulted in 45 possible treatment failures from October 2006 
to August 2007, and 8.2% of isolates in 2011 harboured a mosaic penicillin-binding protein 2 
mainly with amino acid sequence pattern X or closely related, which was associated with 
treatment failure (Lo, Ho, & Lo, 2012).  Another example is a treatment failure with the non-
recommended injectable third-generation cephalosporin, cefotaxime, given at a 1 g dose (van 
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Dam et al., 2014). The treatment failure was attributed to a decreased duration of the serum 
concentration of cefotaxime (1.35 h half-life) (Harvengt, Wauters, & Meunier, 1981) when 
compared with the more active ceftriaxone, which has a 7 h half-life (Patel, Weinfeld, Konikoff, & 
Parsonnet, 1982).  
It is encouraging that N. gonorrhoeae was not able either to acquire or express the CTX-M-3 ESBL, 
however, it is concerning that TEM-10 ESBL was expressed, resulting in increased MICs of 
cephsalosporins. Vigilance to detect the acquisition or emergence of an ESBL in N. gonorrhoeae is 
essential and this work highlights the need to use the recommended and highly effective 
ceftriaxone, in combination with azithromycin (Bignell & Fitzgerald, 2011), to treat gonorrhoea.   
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6 Transfer of gonococcal β-lactamase plasmids into                     
N. gonorrhoeae (ST1407) and investigating the genetic 
diversity of PPNG and non-PPNG isolates 
 Background 6.1
The majority (77%) of isolates with decreased susceptibility or resistance to cefixime in England from 
2007 to 2011 belonged to multi-antigen sequence typing (NG-MAST) sequence type (ST) 1407, 
which was  associated with infections in men who have sex with men (MSM) (Ison et al., 2013b). 
This ST1407 clone and closely related isolates (i.e. genogroup 1407 (G1407) which consists of 
isolates the same ST or ≥ 99% similar) have been detected globally (Cheng, Li, Su, Li, & Yen, 2014; 
Chisholm et al., 2013; Martin et al., 2013; Nguyen et al., 2014; Shimuta et al., 2013) with the 
proportion of this ST ranging from 5.3% (Cheng et al., 2014; Shimuta et al., 2013) to 23% 
(Chisholm et al., 2013). ST1407 isolates are also multidrug-resistant, with decreased susceptibility 
or resistance to azithromycin, ceftriaxone and ciprofloxacin and are also responsible for many 
cefixime and ceftriaxone treatment failures (Chisholm et al., 2013; Ison et al., 2011; Unemo et al., 
2011a; Unemo et al., 2011b; Unemo et al., 2012; Unemo et al., 2011c; Unemo et al., 2010).  
It is not yet understood why ST1407 isolates, even in such great numbers globally, do not harbour 
the β-lactamase plasmids that confer high-level penicillin resistance. This successful clone may 
harbour mechanisms to avoid plasmid acquisition, as harbouring a plasmid that confers no 
selective advantage (i.e. penicillin is no longer used for the treatment of gonorrhoea) may impose 
a biological fitness cost. It should however be noted that some N. gonorrhoeae strains harbour 
the conjugative and cryptic plasmids even in the absence of selective pressure.   
Acquisition of a gonococcal β-lactamase plasmid by N. gonorrhoeae of ST1407 during natural 
infection would confer high-level penicillin resistance to this already multidrug-resistant clone. 
Due to the successful global distribution of ST1407, the subsequent spread of a β-lactamase 
plasmid throughout the sexually active population could ensue. Increases in proportions of 
penicillinase-producing N. gonorrhoeae (PPNG) may also increase the chance of native gonococcal 
blaTEM-1 or blaTEM-135 recombining with genes encoding extended-spectrum -lactamases (ESBLs) 
from other bacteria, such as E. coli causing urinary tract infections (UTIs). In addition selection 
pressure from the use of extended-spectrum cephalosporins (ESCs) to treat gonorrhoea could 
result in the emergence of additional amino acid mutations in the TEM-1 or TEM-135 enzymes in 
N. gonorrhoeae leading to an ESBL. 
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The aim of the work presented in this chapter was to establish whether a selection of clinical 
strains of N. gonorrhoeae of the NG-MAST ST1407 lineage could acquire and express a gonococcal 
β-lactamase plasmid using conjugation and electroporation techniques. In addition, the NG-MAST 
STs of the PPNG isolates and non-PPNG isolates from the UK in 2012-2013 were compared to 
establish the level of genetic relatedness between these two isolate groups.  
 Methods 6.2
6.2.1 Selection of ST1407 isolates  
A selection of N. gonorrhoeae isolates of NG-MAST ST1407 were identified from the Gonococcal 
Resistance to Antimicrobial Surveillance Programme (GRASP) 2010-2012 database (Table 6.1). The 
selection included isolates from different patient groups (heterosexual and men who have sex 
with men), geographical location and ethnicity. The minimum inhibitory concentrations (MICs) 
and plasmid profiles of the strains were determined as previously described (see Sections 3.2.1 
and 4.2.3.1). 
6.2.2 Establishing the N. gonorrhoeae conjugation procedure 
To establish the conjugation procedure, control strain WHO M with an azithromycin MIC of 0.25 
mg/L was selected as the donor of the β-lactamase plasmid. Control strain WHO P, which does 
not harbour any β-lactamase plasmids (penicillin MIC 0.25 mg/L) but has a high azithromycin MIC 
(2 mg/L), was selected as the recipient (Table 4.2). GCVIT plates with both penicillin and 
azithromycin at 2 mg/L were used for selection.   
Conjugation experiments were performed using a filter-mating procedure previously described by 
Ison et al. (1990) with some modifications. Bacterial suspensions were prepared in proteose 
peptone to an equivalent McFarland’s standard of 1 to a final volume of 900 µl. The donor 
suspension was diluted 1:10 using proteose peptone to a final volume of 900 µl. DNase I 
(AppliChem) at a concentration of 1 mg/L was prepared in 0.15 M NaCl, and 100 µl of the DNase I 
was added to each of the donor and recipient suspensions to give a final concentration of           
0.1 mg/L.  A 25 mm circle of 0.45 µm cellulose-acetate filter paper (Millipore) was laid on to a 
GCVIT plate and 100 µl of the donor and recipient suspensions were placed on the filter paper, 
along with 100 µl of DNase I (1 mg/ml).  The GCVIT plate was then carefully laid on a flat surface in 
a 35-37oC incubator with 5% CO2 for 2 h, after which an extra 100 µl of DNase I (1 mg/ml) was 
added. The plate was re-incubated for 2 h. To disrupt conjugation the filter paper was removed 
from the agar surface and placed in 1 ml of saline and vortexed vigorously. To detect 
transconjugants, 100 µl of the donor:recipient suspensions were plated on to selective agar, and 
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the suspension was additionally streaked on to a non-selective control to ensure the viability of 
the organisms. Selection plates were incubated for up to 72 h at 35-37oC in 5% CO2. Viable counts 
of the recipient strain were performed by serial dilutions in PBS and 100 µl of each of the donor 
and recipient suspensions were plated out onto the selective and non-selective plates as controls. 
Controls on non-selective media and viable counts were incubated for 24 h, and the controls on 
the selective plates were incubated for 72 h.   
The conjugation frequency was calculated as the number of transconjugants obtained per 
recipient cell exposed to donor cells. For example, the total number of recipient cells was           
1.1 x 108 CFU/ml and 944 transconjugants were counted from 100 µl plated on to a selective plate 
resulting in 9.4 x 103 transconjugants/ml.  The conjugation frequency was established to be        
9.4 x 103 / 1.1 x 108 = 8.6 x 10-5. 
Transconjugants were confirmed to be Gram-negative cocci and oxidase-positive. Nitrocefin was 
used to confirm the acquisition of the β-lactamase plasmids (see Section 3.2.3). Ten colonies were 
picked and sub-cultured on to the appropriate selective agar and NG-MAST was performed (see 
Section 3.3.4). The plasmid profile of a transconjugant was determined to additionally confirm the 
acquisition of the β-lactamase plasmid (see Section 4.2.3.1). 
6.2.3 ST1407 conjugations with WHO M as β-lactamase plasmid donor 
Control strain WHO K (penicillin MIC 2 mg/L, ciprofloxacin MIC > 32mg/L) was selected as the 
conjugation control recipient as the MICs of WHO K were similar to the ST1407 isolates (Table 
4.2). Conjugations were initially performed three times (biological repeats) between the WHO M 
donor (PPNG, ciprofloxacin MIC 2 mg/L) and the WHO K recipient to ensure suitability as controls 
and to obtain a conjugation frequency mean.  GCVIT plates with both penicillin (8 mg/L) and 
ciprofloxacin (16 mg/L) were used for selection. Transconjugants were confirmed to be Gram-
negative cocci and oxidase-positive, and nitrocefin was used to confirm the acquisition of the      
β-lactamase plasmids (see Section 3.2.3). The plasmid profiles of the transconjugants were 
determined to additionally confirm the acquisition of the β-lactamase plasmid (see Section 
4.2.3.1). 
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For the ST1407 conjugations with WHO M, as the β-lactamase plasmid donor, a range of penicillin 
and ciprofloxacin concentrations were used to establish optimal selection; 
 8 mg/L penicillin and 16 mg/L ciprofloxacin   
 8 mg/L penicillin and 8 mg/L ciprofloxacin  
 4 mg/L penicillin and 4 mg/L ciprofloxacin  
6.2.4 Electroporation with the WHO M African β-lactamase plasmid and the ST1407 
isolates 
The African β-lactamase plasmid was extracted from strain WHO M as described in Section 4.2.3.  
To confirm the African plasmid could be used successfully in electroporation experiments, strain 
MS11 was initially used as a recipient and electroporation was performed as previously described 
(see Section 4.2.5.3), using penicillin at 4 mg/L and 8 mg/L for selection.  Electroporation, again 
using the same methodology, was performed on the panel of ST1407 isolates with the African     
β-lactamase plasmid from WHO M. Control strain WHO K was used as an electroporation control. 
Six hours after electroporation and incubation on GCVIT at 35-37oC in 5%, selection was 
performed on plates with 8 mg/L of penicillin.  Selection plates were incubated for up to 72 h at 
35-37oC in 5% CO2. Transformants were confirmed to be Gram-negative cocci and oxidase-
positive, and nitrocefin was used to confirm the acquisition of the β-lactamase plasmids (see 
Section 3.2.3). The plasmid profiles of the transformants were determined to additionally confirm 
the acquisition of the β-lactamase plasmid (see Section 4.2.3.1). Transformation efficiencies and 
frequencies were not calculated for the ST1407 electroporation experiments as only a 6 h time 
point was used to enable the most likelihood of achieving a positive result.  
6.2.5 Comparison of NG-MAST STs of PPNG and non-PPNG isolates  
NG-MAST data from previously typed isolates from the GRASP 2012 and 2013 collection were 
collated. The similarity of the NG-MAST concatenated tbpB and porB alleles was evaluated in 
BioNumerics v6.1 (Applied Maths, Sint-Martens-Latem, Belgium) by neighbour-joining multiple 
alignment. The similarity of the NG-MAST STs from PPNG verses non-PPNG was assessed. 
Additional phylogram visualisation was performed in FigTree version 1.4.2 (A. Rambaut, University 
of Edinburgh, UK).   
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Table 6.1 N. gonorrhoeae strains selected for conjugational transfer of β-lactamase plasmids. 
Strain no. Year Age Gender Sexual orientation Ethnicity Clinic location 
MIC (mg/L) 
Penicillin Ciprofloxacin Cefixime Ceftriaxone 
G10-1836 2010 37 Male MSM White British London 2 > 32 0.125 0.03 
G11-1015 2011 30 Female Heterosexual White British London 1 > 32 0.125 0.015 
G11-1052 2011 28 Male Heterosexual Black African Brighton 2 > 32 0.125 0.03 
G12-0410 2012 48 Male Heterosexual Black Caribbean London 2 > 32 0.25 0.03 
G12-1225 2012 40 Male MSM White British London 2 > 32 0.125 0.03 
G12-1360 2012 39 Female Heterosexual Bangladeshi Newcastle 2 > 32 0.25 0.03 
G12-1682 2012 20 Male Heterosexual White British Newcastle 1 > 32 0.125 0.03 
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 Results 6.3
6.3.1 Antimicrobial susceptibilities and plasmid profiles of a selection of                       
N. gonorrhoeae ST1407 isolates 
The antimicrobial and plasmid profiles of the ST1407 gonococcal isolates were collated (Table 6.1, 
Figure 6.1). All the ST1407 isolates harboured only the 2.6 kb cryptic plasmid (Figure 6.1). 
 
Figure 6.1 Gel displaying the plasmid profiles of the ST1407 isolates. Lane 1 = 1 Kb ladder,        
Lane 2 = MS11 plasmid profile, Lane 3 = WHO M plasmid profile, Lane 4 = ST1407 G11-1052 
plasmid profile, Lane 5 = ST1407 G10-1836 plasmid profile, Lane 6 = ST1407 G11-1015 plasmid 
profile, Lane 7 = ST1407 G12-0410 plasmid profile, Lane 8 = ST1407 G12-1225 plasmid profile, 
Lane 9 = ST1407 G12-1360 plasmid profile, Lane 10 = ST1407 G12-1682 plasmid profile. 
6.3.2 Establishment of conjugation procedure 
Conjugation between the donor WHO M and the recipient WHO P was successful, with 944 
colonies resulting in a frequency of conjugation of 8.6 x 10-5. Ten colony picks were all Gram-
negative, oxidase-positive and nitrocefin-positive. The NG-MAST STs of the ten colony picks were 
all ST3305, which was the same ST as WHO P. The NG-MAST ST of WHO M was ST3304. The 
plasmid profile of the WHO P transconjugant (Figure 6.2) revealed that the β-lactamase plasmid 
was successfully transferred from WHO M (plasmid profile in Figure 6.1) to WHO P (Figure 6.2). In 
addition WHO P also acquired the conjugative plasmid from the conjugation with WHO M    
(Figure 6.2). The MIC of penicillin for the WHO P transconjugant was > 32 mg/L which is at least 
128-fold higher than the original WHO P penicillin MIC of 0.25 mg/L. 
OC = open circular form of the cryptic plasmid (2.6 MDa)
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Figure 6.2 Gel displaying the plasmid profiles WHO P, WHO P transconjugant (from conjugation 
with WHO M) and the ST1407 transformants (from electroporation with the WHO M β-lactamase 
plasmid). Lane 1 = 1 Kb ladder, Lane 2 = WHO P plasmid profile, Lane 3 = WHO P transconjugant 
plasmid profile, Lane 4 = ST1407 G11-1052 transformant plasmid profile, Lane 5 = ST1407 G10-
1836 transformant plasmid profile, Lane 6 = ST1407 G11-1015 transformant plasmid profile, Lane 
7 = ST1407 G12-0410 transformant plasmid profile, Lane 8 = ST1407 G12-1225 transformant 
plasmid profile, Lane 9 = ST1407 G12-1360 transformant plasmid profile, Lane 10 = ST1407 G12-
1682 transformant plasmid profile. 
6.3.3 ST1407 conjugations with WHO M as donor 
The conjugation between the donor WHO M and the recipient WHO K was successful with the 
colony picks confirmed as Gram-negative, oxidase-positive and nitrocefin-positive. The mean 
frequency of conjugation was 7.3 x 10-7. 
Conjugations between the donor WHO M and the recipient ST1407 isolates were successful, with 
the optimum combination of selection at 8 mg/L or 4 mg/L for both penicillin and ciprofloxacin 
(Table 6.2). All transconjugants were confirmed to have the same NG-MAST types of the 
recipients, which were all ST1407.  
The plasmid profiles of the WHO K and ST1407 transconjugants (Figure 6.3) revealed that the      
β-lactamase plasmid was successfully transferred from WHO M (plasmid profile in Figure 6.1) to 
all the recipients (Figure 6.3). In addition all of the recipients, other than G12-1682, also acquired 
the conjugative plasmid from the conjugations with WHO M (Figure 6.3). The MICs of penicillin for 
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the WHO K and the ST1407 transconjugants were all > 32 mg/L which is at least 16-fold higher 
than the original penicillin MICs of 1 to 2 mg/L.  
Table 6.2 Number of ST1407 transconjugants and conjugation frequency. 
Strain no. 
No. of transconjugants (conjugation frequency) at varying levels of 
antimicrobial selection 
Penicillin 8 mg/L & 
ciprofloxacin 16 mg/L 
Penicillin 8 mg/L & 
ciprofloxacin 8 mg/L 
Penicillin 4 mg/L & 
ciprofloxacin 4 mg/L 
G10-1836 0 34      (6.3 x 10
-7) 38      (7.0 x 10-7) 
G11-1015 0 5        (2.2 x 10
-7) 6        (2.6 x 10-7) 
G11-1052 0 116    (2.4 x 10
-6) 170    (3.5 x 10-6) 
G12-0410 0 100    (2.0 x 10
-6) 100    (2.0 x 10-6) 
G12-1225 0 25      (6.0 x 10
-7) 30      (7.1 x 10-7) 
G12-1360 1 30      (6.5 x 10
-7) 38      (8.3 x 10-7) 
G12-1682 0 20      (3.7 x 10
-7) 24      (4.4 x 10-7) 
    
       
 
Figure 6.3 Gel displaying the plasmid profiles WHO K, WHO K transconjugant and the ST1407 
transconjugants (from conjugation with WHO M). Lane 1 = 1 Kb ladder, Lane 2 = WHO K plasmid 
profile, Lane 3 = WHO K transconjugant plasmid profile, Lane 4 = ST1407 G11-1052 transconjugant 
plasmid profile, Lane 5 = ST1407 G10-1836 transconjugant plasmid profile, Lane 6 = ST1407 G11-
1015 transconjugant plasmid profile,  Lane 7 = ST1407 G12-0410 transconjugant plasmid profile, 
Lane 8 = ST1407 G12-1225 transconjugant plasmid profile, Lane 9 = ST1407 G12-1360 
transconjugant plasmid profile, Lane 10 = ST1407 G12-1682 transconjugant plasmid profile. 
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6.3.4 Electroporation with the WHO M African β-lactamase plasmid and the ST1407 
isolates 
The African β-lactamase plasmid (32 ng/µl) extracted from WHO M was successfully 
electroporated into strain MS11 (Table 6.3) with an average transformation frequency and 
efficiency of 2.4 x 10-7 and 1.7 x 102, respectively. 
Table 6.3 Number of MS11 transformants at 0 h and 6 h incubations after electroporation with 
the WHO M African β-lactamase plasmid.  
MS11 
replicate 
no.  
Penicillin 
selection 
No. of 
transformants 
at 0 h 
No. of 
transformants 
at  6 h 
Transformation 
frequency 
Transformation 
efficiency 
MS11-1 2 mg/L 5 88 1.4 x 10-7 1.7 x 102 
  4 mg/L 4 80 1.1 x 10-7 1.4 x 102 
MS11-2 2 mg/L 0 184   
  4 mg/L 3 136 1.9 x 10-7 1 x 102 
MS11-3 2 mg/L 4 132 3 x 10-7 1.4 x 102 
  4 mg/L 9 160 6.7 x 10-7 3.1 x 102 
 
The African β-lactamase plasmid was also successfully electroporated into the selection of ST1407 
isolates (Table 6.4). Transformation frequencies and efficiencies were not calculated as no results 
were available from 0 h. The plasmid profiles of the ST1407 transformants revealed that the        
β-lactamase plasmid was successfully transformed into all the recipients (Figure 6.2). 
Table 6.4 Number of ST1407 transformants at 6 h incubation after electroporation with the WHO 
M African β-lactamase plasmid. 
Strain No. of transformants at 6 h 
G10-1836 344 
G11-1015 296 
G11-1052 284 
G12-0410 244 
G12-1225 160 
G12-1360 464 
G12-1682 220 
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6.3.5 NG-MAST ST analysis of PPNG and non-PPNG isolates from GRASP 2012-2013 
In total, 460 isolates from GRASP in 2012-2013 were previously typed using NG-MAST; 89 were 
PPNG and 371 were non-PPNG. The 89 PPNG isolates were composed of 42 different NG-MAST 
STs, of which 33 isolates had a unique ST, 25 isolates were  in nine smaller clusters of between 
two to seven members, and there were three larger clusters of 10 (n = 2) and 11 isolates. From 
the 371 non-PPNG isolates a total of 106 different STs were identified, of which 62 isolates had a 
unique ST, 167 isolates were in smaller clusters of between two and nine members and there 
were five large clusters composed of 15, 16, 18, 24 and 69 isolates. The phylogram of the           
NG-MAST concatenated porB and tbpb sequences in polar tree layout displays the similarity of the 
NG-MAST STs of these PPNG and non-PPNG isolates (Figure 6.4). The PPNG and non-PPNG isolates 
mainly cluster separately from each other; however, in some regions of the phylogram 
interspersing of the two phenotypes is apparent, as well as instances of a high degree of            
NG-MAST ST similarity between the PPNG and the non-PPNG isolates (Regions A-D, Figure 6.4). Of 
the non-PPNG STs the ST1407 was the largest cluster with 69 isolates (Region E, Figure 6.4). 
However an additional 31 STs had ≥ 99% sequence similarity (concatenated tbpB and porB alleles) 
with ST1407 resulting in the largest cluster of 160 isolates (43%), G1407 (Region E, Figure 6.4). 
Overall the STs were either exclusively PPNG or non-PPNG other than ST1780 (PPNG = 7,          
non-PPNG = 5) and ST4995 (PPNG = 11, non-PPNG = 8), which consisted of both phenotypes.  
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Figure 6.4 Phylogram of concatenated porB and tbpB alleles (880 bp) from PPNG and non-PPNG 
from GRASP 2012-13. Branch colours: Red = PPNG, Black = Non-PPNG, Blue = PPNG/Non-
PPNG.Node labels: NG-MAST ST.  
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 Discussion 6.4
The acquisition and expression of a gonococcal β-lactamase plasmid by a selection of                      
N. gonorrhoeae isolates with NG-MAST ST1407 was successful via both conjugation and 
electroporation. This suggests that ST1407 strains could acquire gonococcal β-lactamase plasmids 
in natural mixed gonococcal infections. The ST1407 isolates would be unable to transfer the 
plasmid onwards to other N. gonorrhoeae due to the lack of a conjugative plasmid in these 
isolates; however acquisition of the conjugative plasmid, as was achieved by six of the seven 
ST1407 isolates in the conjugation study, could also happen in a mixed infection.  It has been 
previously demonstrated that some N. gonorrhoeae do not acquire β-lactamase plasmids, such as 
strains that  do not carry the cryptic plasmid (Dillon & Pauze, 1981) and those that do not utilise 
ornithine and require proline, arginine and uracil (PAOU-requiring) (Ison et al., 1990). However 
the ST1407 isolates readily acquired the β-lactamase plasmids in this study so have no 
mechanisms in place to avoid plasmid acquisition.  
As ST1407 gonococci can acquire resistance plasmids, the apparent absence of naturally-occurring 
ST1407 PPNG strains to date is most probably due to a lack of exposure to other gonococci that 
harbour β-lactamase plasmids.  Within the UK the ST1407 clone has been generally associated 
with MSM (Ison et al., 2013b). Even though PPNG are detected in MSM, PPNG have traditionally 
been associated with heterosexuals;  in London in 1983 few PPNG isolates were obtained from 
MSM (Easmon et al., 1984) and just 2.6% of PPNG were from MSM in Amsterdam, where the 
spread was in part attributed to commercial sex workers from Asia (Ansink-Schipper et al., 1984). 
More recently, PPNG were significantly associated with heterosexuals in Europe from 2011-2013 
(European Centre for Disease Prevention and Control, 2013, 2014, 2015), and the GRASP study 
identified a significant difference (P = 0.004) in the proportion of PPNG from heterosexual men 
(7.8%) compared with MSM (1.9%) in 2011 (Health Protection Agency, 2012). Male heterosexual 
sex abroad in South-East Asia, where PPNG rates have been as high as 100% (Bala et al., 2013), 
could be a reason why PPNG was first detected in this sexual network. So rather than biology, a 
lack of bridging from heterosexual networks to MSM, such as those infected with ST1407,  could 
be why PPNG has never been detected in this NG-MAST ST. 
Variation in the conjugation frequencies was noted for the ST1407 isolates and the frequencies 
were at a similar magnitude that was found in a study investigating the conjugal movement of 
plasmids between gonococci (Ison et al., 1990). The study revealed strain variation in the ability to 
acquire β-lactamase plasmids with three strains of three different serovars not acquiring a 
plasmid, as well as observations of conjugation frequency variation that were not influenced by 
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the serovar; the factors responsible for these conjugation variations were not identified (Ison et 
al., 1990). Electroporation and conjugation experiments were only performed once due to the 
rapid acquisition of the β-lactamase plasmid by these isolates and the confirmation that the 
ST1407 can acquire and express the plasmids. Therefore further experiments are required to 
establish if there is any variation between experiments in the transformation and conjugation 
frequencies of the ST1407 isolates. Whole genome sequencing of these isolates should elucidate 
how different these ST1407 isolates are at the genetic level. 
It was interesting that even though the ciprofloxacin MIC of the ST1407 isolates was > 32 mg/L 
and the transconjugants were successfully sub-cultured on a plate containing 16 mg/L of 
ciprofloxacin, the 16 mg/L of ciprofloxacin used for selection in the conjugation experiments 
resulted in just one transconjugant from all of the ST1407 isolates tested. This scenario was also 
experienced in two other conjugation studies (Biswas, Blackman, & Sparling, 1980; Ison et al., 
1990); lower conjugation frequencies where established when concentrations of the 
antimicrobials used for selection were increased. This highlights the need for appropriate levels of 
antibiotic selection to be used in conjugation experiments, as was demonstrated in the 
electroporation experiments described in Chapter 4 (Section 4.4). 
It was first suggested that there was a clonal distribution of the PPNG from phenotypic analysis of 
PPNG strains in the 1980’s (Ansink-Schipper et al., 1984; Easmon et al., 1984). The investigations 
of NG-MAST sequence similarity in this study using recent PPNG and non-PPNG isolates from 
GRASP revealed the PPNG isolates and the non-PPNG isolates mainly cluster separately suggesting 
that the strains have evolved independently. A large level of diversity, with respect to NG-MAST, 
was identified in the PPNG; 42 different NG-MAST STs, although three large clusters of 10 to 11 
isolates were identified so the association with some STs is apparent. It is likely that in the 1980’s 
the PPNG were more clonal but mixing and diversity has occurred. The instances where the same 
STs contained PPNG and non-PPNG (ST1780 and ST4995), and where there was a high degree of 
similarity between NG-MAST STs of PPNG and non-PPNG isolates could be due to the strains 
losing or gaining the β-lactamase plasmids, which is not surprising considering that the                  
β-lactamase plasmids are easily transferrable in some N. gonorrhoeae strains via conjugation 
(Biswas et al., 1989b; Ison et al., 1990). The 2012 and 2013 NG-MAST data from GRASP also 
revealed that ST1407 (and G1407) continues to predominate in this gonococcal population. 
Molecular typing of isolates from GRASP combined with antimicrobial susceptibility and 
epidemiological data enabled this study to focus on a subset of isolates from the successful multi-
drug resistant ST1407 clone. This study established that ST1407 isolates can acquire and express a 
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gonococcal β-lactamase plasmid, and also that the most likely reason that the ST1407 isolates 
distributed globally do not harbour β-lactamase plasmids is based on epidemiology and is not 
related to the inherent biology of the ST1407 isolates. Antimicrobial susceptibility surveillance, 
molecular typing and the collection of epidemiological and behavioural data is essential to 
provide detailed information on N. gonorrhoeae strains currently circulating, to identify at risk 
patient groups and to inform treatment guidelines.   
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7 Genetic diversity of blaTEM alleles, antimicrobial susceptibility 
and molecular epidemiological characteristics of penicillinase-
producing Neisseria gonorrhoeae  
 Background 7.1
Since 1987 penicillin has not been used for the treatment of gonorrhoea (Ropp et al., 2002; 
Unemo & Shafer, 2014), however, penicillinase-producing N. gonorrhoeae (PPNG) are still 
circulating globally (Bala et al., 2013; European Centre for Disease Prevention and Control, 2015; 
Kirkcaldy et al., 2013). In 2012 and 2013, the total penicillin resistance (chromosomal mosaicism 
of penicillin-binding protein (PBP) genes and plasmid-mediated resistance) in gonococci in 
England and Wales was 14.6% and 18.4%, respectively, and PPNG prevalence was 4.6% and 6.7%, 
respectively (Public Health England, 2013, 2014a).  This PPNG level is low compared with some 
countries in South-East Asia, where PPNG rates may be as high as 100% (Bala et al., 2013).  
PPNG strains usually produce TEM-1 β-lactamase, however, the TEM-135 enzyme has been 
sporadically detected in N. gonorrhoeae (Chen et al., 2013; Endimiani et al., 2014; Gianecini et al., 
2014; Muhammad et al., 2014; Nakayama et al., 2012; Ohnishi et al., 2010a; Srifeungfung et al., 
2009; Whiley et al., 2014) since it was first reported in this species in Thailand in 2009 
(Srifeungfung et al., 2009). A recent retrospective study revealed that the TEM-135 enzyme was 
present in the Toronto/Rio plasmid in N. gonorrhoeae since at least 1984 (Muhammad et al., 
2014). Both TEM-1 and TEM-135 enzymes hydrolyse penicillins, but are not active against the 
extended-spectrum cephalosporins (ESCs) cefixime and ceftriaxone, which are currently used for 
the treatment of gonorrhoea (Bignell & Fitzgerald, 2011). The TEM-135 enzyme differs from   
TEM-1 by one amino acid substitution (M182T), and only one additional amino acid change at one 
of several crucial amino acid positions is required for the enzyme to gain ability to hydrolyse ESCs. 
Extended-spectrum β-lactamases (ESBLs) are prevalent worldwide in the Enterobacteriaceae and 
the increasing prevalence of ESBL-producing Escherichia coli in the community setting provides 
further opportunities for the naturally transformable N. gonorrhoeae, to be exposed to ESBL-
encoding genes in the urogenital tract. 
The genetic diversity of blaTEM alleles among PPNG strains collected in England and Wales was 
investigated to identify the proportion of TEM-1 and TEM-135 and to seek any further circulating 
blaTEM alleles, which may have emerged due to the use of ESCs to treat gonorrhoea. Additionally, 
the antimicrobial susceptibilities and molecular epidemiological characteristics, using                    
N. gonorrhoeae multi-antigen sequence typing (NG-MAST) (Martin et al., 2004), of the PPNG 
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isolates were established. The NG-MAST sequence types (STs) of TEM-135 isolates detected in this 
study were compared with those of TEM-135 isolates from previously published studies to 
investigate any global dissemination or common evolutionary origins of PPNG isolates with     
TEM-135.  
 Methods 7.2
7.2.1 Gonococcal isolates and antimicrobial susceptibility testing 
Gonococcal isolates submitted to the 2012 Gonococcal Resistance to Antimicrobial Surveillance 
Programme (GRASP) (Public Health England, 2014a) were retrieved from storage at -80oC as 
described in Section 3.1. 
The MICs of azithromycin, cefixime ceftriaxone ciprofloxacin, penicillin, spectinomycin and 
tetracycline were determined using the GRASP agar dilution methodology (Chisholm et al., 2011), 
as previously described (see Section 3.2.2).  The nitrocefin test was used to detect β-lactamase 
production (see Section 3.2.3). 
7.2.2 Molecular analyses of the PPNG isolates 
DNA lysates were made from the PPNG isolates as previously described (see Section 3.3.1). The  
β-lactamase plasmid profiles were determined by PCR (Fayemiwo et al., 2011) as described in 
Section 4.2.2. The blaTEM genes were amplified using 0.5 µl each of primers BlaF and BlaR (Ohnishi 
et al., 2010a) (Table A1, Appendix One) at a concentration of 100 μM, along with 10x MyTaq 
RedMix and 5 μl of DNA template to a total volume of 50 μl. PCR amplification was performed on 
a DNA Engine Tetrad thermocycler for the following cycling conditions: 96oC for 2 min, then 30 
cycles of 96oC for 10 s, 60oC for 10 s and 72oC for 1 min. PCR products were visualised by running 
the PCR products on an E-gel (see Section 3.3.2).  
The amplified blaTEM genes were sequenced using the BlaF and BlaR primers (Table A1, Appendix 
One) as described previously (see Section 3.3.3).  NG-MAST was performed on the DNA lysates as 
previously described (Section 3.3.4). All sequence analysis was performed using Bionumerics 
version 6.1 (Applied Maths, Sint-Martens-Latem, Belgium). The similarity of concatenated tbpB 
and porB alleles was evaluated in BioNumerics v6.1 by neighbour-joining multiple alignment. 
Additional phylogram visualisation was performed in FigTree version 1.4.2 (A. Rambaut, University 
of Edinburgh, UK). To confirm any discordant results, the plasmid profiles and blaTEM allele 
sequencing were repeated. Consensus results were used if more than two repeats were 
performed. 
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7.2.3 Statistical analysis 
The patient gender and age distributions were established for the following isolate groups: all 
isolates; all PPNG isolates; PPNG isolates with TEM-135; PPNG isolates with TEM-1 and non-PPNG 
isolates. The Fisher’s exact test was used to test whether the ratios of men:women were 
significantly different between any of the isolate groups. A P-value of < 0.05 indicated 
significance. 
Geometric means of the MICs were calculated for three N. gonorrhoeae categories (non-PPNG, 
PPNG isolates with TEM-1, and PPNG isolates with TEM-135). Any MICs with ‘less than’ or ‘greater 
than’ values were converted to ‘equal to’ values. For example, all ceftriaxone MICs ≤ 0.002 were 
categorised as 0.002 and all ciprofloxacin MICs > 32 were categorised as 32. Linear regression was 
used to study the relationship between the MICs and the three different groups, as well as the 
relationship between TEM-1 and TEM-135 isolates when the median MICs of the isolate groups 
differed by ≥ 2 dilutions.  
7.2.4 Collection of NG-MAST data from other studies  
NG-MAST data from TEM-135 isolates from other published studies (Chen et al., 2013; Gianecini 
et al., 2014; Nakayama et al., 2012; Ohnishi et al., 2010a) was collated and the tbpB and porB 
alleles were concatenated and analysed as in Section 7.2.2. 
 Results 7.3
7.3.1 GRASP 2012 PPNG isolates 
Seventy-five PPNG isolates were identified through GRASP in 2012. Two duplicate isolates from 
two patients were removed resulting in 73 different episodes of infection (4.6%, 73/1603). The 
gender and age distributions were similar for all groups (all isolates, all PPNG isolates, TEM-135 
isolates, TEM-1 isolates and non-PPNG isolates) other than for patients with TEM-135 isolates 
who had a higher proportion of males (90%) and an older median age (31.5 years) (Table 7.1). 
However the standard deviation of the mean did overlap with each isolate group (Table 7.1). The 
TEM-1 PPNG isolates were isolated from the lowest proportion of male patients (75.5%)        
(Table 7.1). All gender differences were not significant using Fisher’s exact test. 
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Table 7.1 Patient characteristics (age and gender) of all 2012 GRASP isolates, all PPNG, TEM-1 
PPNG, TEM-135 PPNG and non-PPNG. 
 All isolates     
(n = 1,603; gender 
= 1,596*) 
All PPNG  
(n = 73) 
TEM-1 PPNG         
(n = 53) 
TEM-135 
PPNG 
(n = 20) 
Non-PPNG  
(n = 1,530; 
gender  = 1523*) 
Men 81.1% (1294) 79.5% (58) 75.5% (40) 90% (18) 81.2% (1236) 
Women 18.9% (302) 20.5% (15) 24.5% (13) 10% (2) 18.8% (287) 
Median age 28 28 27 31.5 28 
Mean age   
(± 1 SD) 
29.7  
(20.1-39.3) 
32.2  
(20.8-43.6) 
31.8  
(20.1-43.6) 
32.9  
(22.2-43.6) 
29.6  
(20.1-39.1) 
Age range 13-78 18-70 18-70 19-58 13-78 
*Number of isolates with linked gender information 
SD = Standard deviation 
 
 
Three different blaTEM alleles were identified encoding two mature penicillinases (Figure 7.1). Fifty-
three (73%) isolates produced TEM-1 enzyme, 39 (53%) with the classical allele and 14 (19%) with 
a variant that differed from TEM-1 by one amino acid, in the signal peptide region, at position 14 
(blaTEM-P14S) (Ambler et al., 1991). Twenty PPNG (27%) produced TEM-135 (Figure 7.1).  
7.3.2 Plasmid profiles and NG-MAST STs 
The blaTEM-135 allele was harboured on African, Asian and Toronto/Rio plasmids (Figure 7.1). Four 
different NG-MAST STs were identified in each of the TEM-135 PPNG groups with the Asian and 
the Toronto/Rio plasmids, and an NG-MAST ST was successfully identified for the single PPNG 
with TEM-135 on an African plasmid (Figure 7.1).  Other than an Asian plasmid found in one 
isolate, the TEM-1-encoding plasmids were all African, in gonococci belonging to 27 different     
NG-MAST STs (Figure 7.1). For the TEM-1 isolates the most common STs were 8997 (n = 8), 1780 
(n = 7), 10678 (n = 2) and 10684 (n = 2). The other NG-MAST STs (n = 19) were each identified 
once (586, 1528, 1612, 4849, 5793, 6974, 8512, 8671, 8996, 10679, 10683, 10685, 10687-93).  For 
all isolates, fifteen STs were newly assigned (STs 10678–10693) via the NG-MAST website.  
The population structure in respect to the genetic relatedness of the NG-MAST STs of the PPNG 
isolates was established. A phylogram created from concatenated porB and tbpB alleles displayed 
two main clades; the smaller clade represented isolates of the PorB1a (WI) serogroup, while the 
larger clade represented isolates of the PorB1b (WII/III) serogroup (Figure 7.2). Some tight 
clustering of isolates with TEM-1 enzymes harboured on the African-type plasmids was evident, 
particularly at the bottom part of the bigger clade, with STs 10679-10691 showing a high degree 
of similarity (> 99%, only 3 bp differences between the four NG-MAST STs). Interspersed between 
the isolates with TEM-1 on the African plasmid were NG-MAST STs with TEM-135 enzyme on 
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either Toronto/Rio, African or Asian plasmid-types. The single isolate with TEM-1-P14S on the 
Asian plasmid was positioned within the PorB1a (WI) serogroup clade (ST2025). The four           
NG-MAST STs which consisted of isolates with TEM-1-P14S on African plasmids were all in the 
PorB1b (WII/III) serogroup clade, of which three NG-MAST STs (ST8669, ST5268 and ST26) were 
positioned next to each other and included the TEM-1-P14S cluster (n = 10, ST5268). The isolate 
with NG-MAST ST4644 was closely related (1-bp difference) to an isolate with NG-MAST ST4849 
which harboured TEM-1 on an African plasmid. The phylogram additionally revealed that each 
individual NG-MAST ST from the TEM-135 isolates (Figure 7.2) was at least 14 bp (1.6%) different 
from its nearest ‘neighbours’ (Figure 7.2). According to a previously used definition of NG-MAST 
genogroups (one of the two alleles identical and the other ≥ 99% similar)(Chisholm et al., 2013), 
this suggests that many of the TEM-135 isolates were not closely related. No overlap was seen 
among NG-MAST STs of isolates with TEM-1 or TEM-135 penicillinases (Figure 7.1 and Figure 7.2). 
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Figure 7.1 Pie chart - TEM enzyme distribution. Bar chart - β-lactamase plasmid–type and NG-MAST ST of penicillinase-producing N. gonorrhoeae isolates 
from England and Wales (2012) with TEM-135. NT = not type-able. NG-MAST STs of the TEM-1 isolates; 586, 1582, 1612, 1780 (n = 7), 4849, 5793, 6974, 
8512, 8671, 8996, 8997 (n = 8), 10678 (n = 2), 10679, 10683, 10684 (n = 2), 10685, 10687, 10688, 10689, 10690, 10691, 10692, 10693, NT=1. Figure 
reproduced and amended from Cole et al. (2015b).
ST217 (n=1)
ST4995 (n=7), ST5785 (n=2), 
ST10680 (n=1), ST10686 (n=1) 
NT=1
ST10681 (n=2), ST5624 
(n=2), ST10682 (n=1), 
ST661 (n=1), NT=1
NG-MAST STs of TEM-135
ST5268 (n=10) 
ST26 (n=1) 
ST8669 (n=1)
ST4644 (n=1)
ST2025 (n=1, 
Asian)
23 different  NG-
MAST STs
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Figure 7.2 Phylogram of concatenated porB and tbpB alleles (880 bp) from penicillinase-producing N. gonorrhoeae isolates from England and Wales 
(2012). Node labels: NG-MAST ST_TEM enzyme_single ST or Cluster (≥ 2 isolates)_plasmid type. Figure reproduced and amended from Cole et al. 
(2015b).
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7.3.3 MICs for the PPNG isolates 
MICs of penicillin for all the PPNG ranged from 1 to > 4 mg/L and were significantly higher than 
the non-PPNG isolates (P < 0.001) (Table 7.2). The ciprofloxacin and the tetracycline MICs for the 
TEM-135 isolates were significantly higher (P < 0.001) than those for TEM-1 isolates and the non-
PPNG isolates (Table 7.2). For the remaining antimicrobials the median and modal MICs for the 
TEM-135 isolates were either the same or one dilution higher than for isolates with TEM-1 (Table 
7.2). 
7.3.4 GRASP 2012 TEM-135 isolates compared to other studies 
The phylogram displaying the similarity of the NG-MAST STs of the GRASP 2012 TEM-135 isolates 
compared with other TEM-135 isolates with published NG-MAST STs (Chen et al., 2013; Gianecini 
et al., 2014; Nakayama et al., 2012; Ohnishi et al., 2010a) (Figure 7.3) also  revealed two main 
clades, which again represented isolates of the PorB1a (WI; small clade) and the PorB1b (WII/III; 
large clade) serogroups, respectively (Figure 7.3).  Even though there was some tight clustering of 
the TEM-135 isolates from individual countries (China STs 8793, 8762 and 2288, and Argentina STs 
10981 and 10977), overall there was large genetic diversity in respect to the concatenated porB 
and tbpb sequences. There were only two instances where there was a high degree of relatedness 
(> 99%) in respect to NG-MAST between countries; ST1053 and ST4745 from China and ST10686 
from the UK (Figure 7.3, Branches A), as well as ST8801 and ST641 from China and ST4013 from 
Japan (Figure 7.3, Branches B). The phylogram did not reveal a single common ancestor of PPNG 
with TEM-135.  
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Table 7.2 Minimum, maximum, modal, median and geometric mean MICs of non-penicillinase-producing N. gonorrhoeae (PPNG) and PPNG with        
TEM-135 and TEM-1 in England and Wales, 2012. Figure reproduced and amended from Cole et al. (2015b). 
 
Parameter Non-PPNG TEM-1 TEM-135 Non-PPNG TEM-1 TEM-135 Non-PPNG TEM-1 TEM-135 Non-PPNG TEM-1 TEM-135
Min ≤ 0.06 1 4 ≤ 0.002 ≤ 0.002 ≤ 0.002 ≤ 0.002 ≤ 0.002 0.004 ≤ 0.03 ≤ 0.03 4
Max 2 > 4 > 4 0.125 0.03 0.015 0.25 0.03 0.125 >16 16 >16
Mode 0.25 > 4 > 4 0.004 ≤ 0.002 0.004 0.008 0.004 0.004 ≤ 0.03 < 0.03 8
Median 0.25 > 4 > 4 0.004 ≤ 0.002 0.004 0.008 0.008 0.008 ≤ 0.03 < 0.03 8
Geomean* 0.218 3.331 4 0.005 0.003 0.005 0.011 0.007 0.009 0.128 0.219 8.574
P value (Non-PPNG 
as reference) - < 0.001 < 0.001 - 0.134 < 0.001
P value (TEM-1 as 
reference) - < 0.001
Parameter Non-PPNG TEM-1 TEM-135 Non-PPNG TEM-1 TEM-135 Non-PPNG TEM-1 TEM-135
Min ≤ 0.03 ≤ 0.03 ≤ 0.03 ≤ 8 ≤ 8 16 ≤ 0.5 1 4
Max > 256 0.25 0.5 64 32 32 > 16 > 16 > 16
Mode 0.125 0.06 0.125 16 16 32 4 > 16 > 16
Median 0.125 0.06 0.125 16 16 32 4 4 > 16
Geomean* 0.106 0.078 0.128 19.54 19.804 26.909 3.052 5.334 12.553
P value (Non-PPNG 
as reference) - < 0.001 < 0.001
P value (TEM-1 as 
reference) - < 0.001
No. of observations; Non-PPNG (1530), TEM-1 (53), TEM-135 (20)
Bold values - significant <0.05
Penicillin Ceftriaxone Cefixime Ciprofloxacin
Azithromycin Spectinomycin Tetracycline
124 
 
Figure 7.3 Phylogram of concatenated porB and tbpB alleles (880 bp) from TEM-135 isolates from previously published studies. Branch colours:              
Red = China, Blue = Thailand, Green = UK, Orange = Argentina, Black = Japan. Node labels: NG-MAST ST_TEM enzyme_single ST or Cluster                               
(≥ 2 isolates)_plasmid type_country.
Branches B
Branches A
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 Discussion 7.4
The sequence analysis of the blaTEM alleles among PPNG isolates collected in England and Wales 
revealed TEM-1 penicillinase to be the most common (found in 73% of PPNG), with the blaTEM-135 
allele also identified in some gonococcal lineages (27% of PPNG). The proportion of isolates with 
the TEM-135 enzyme in this study (27%) is similar to the median value of the eight other studies 
which investigated the proportion of blaTEM-135 alleles; 25.6% (range of 9.3 to 57.9%) (Chen et al., 
2013; Endimiani et al., 2014; Gianecini et al., 2014; Muhammad et al., 2014; Nakayama et al., 
2012; Ohnishi et al., 2010a; Srifeungfung et al., 2009; Whiley et al., 2014). This is the first time 
that TEM-135 has been reported in PPNG from the UK. 
The blaTEM-135 allele was present on three plasmid-types, with the Asian plasmid-type 
predominating (Asian = 12, Toronto/Rio = 7, African = 1). These data differ from studies 
performed in Thailand (Nakayama et al., 2012), Argentina (Gianecini et al., 2014), Australia 
(Whiley et al., 2014) and a global study (Muhammad et al., 2014), which all showed the 
Toronto/Rio plasmid to be the most prevalent carrier of blaTEM-135, and it is in this plasmid-type 
where the blaTEM-135 allele was first proposed to have evolved (Muhammad et al., 2014). The 
association with the TEM-135 enzyme and the Asian plasmid was validated from repeat testing 
and the demonstration of two NG-MAST ST clusters (≥ 2 isolates with the same ST; ST4995 n = 7 
and ST5785 n = 2) with this genotype (Asian plasmid with TEM-135).  In common with other 
studies; TEM-1 was predominantly encoded by the African plasmid (Gianecini et al., 2014; 
Muhammad et al., 2014; Nakayama et al., 2012; Whiley et al., 2014), the Toronto/Rio plasmid did 
not harbour the blaTEM-1 allele in all but one (Nakayama et al., 2012) of the aforementioned 
studies, and there was an association between NG-MAST STs, the TEM enzyme and plasmid-type 
(Chen et al., 2013; Gianecini et al., 2014; Nakayama et al., 2012; Ohnishi et al., 2010a). Only one 
study has identified both blaTEM-1 and blaTEM-135 alleles in the same NG-MAST ST (Chen et al., 2013).   
Sequence analysis of NG-MAST sequences along with the TEM enzymes and plasmid-types 
revealed no common linkage to the TEM-135 alleles in the 2012 GRASP PPNG isolate collection as 
they were highly interspersed with TEM-1-producing isolates. Even though there was some tight 
clustering of the NG-MAST STs with TEM-1 enzymes on the African plasmid-types and NG-MAST 
clusters, which show transmission of the isolates with the same or highly related NG-MAST STs, 
there is generally a high-level of genetic variability in respect to the PPNG NG-MAST STs. This is 
also reflected by the large number of STs. The phylogram indicates that the plasmids have been 
introduced into multiple lineages over time. 
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Compared with the TEM-1 and non-PPNG isolates, the TEM-135 isolates were all resistant to 
ciprofloxacin and tetracycline, whereas other studies have not reported any significant difference 
between the MICs of the antimicrobials tested of the TEM-1 and TEM-135 isolates (Gianecini et 
al., 2014; Muhammad et al., 2014; Ohnishi et al., 2010a). These TEM-135 isolates possessed three 
different plasmids and belonged to dissimilar NG-MAST STs, so the association with ciprofloxacin 
and tetracycline resistance is interesting. It should be noted that the number of TEM-135 isolates 
was quite small (n = 20) so it is difficult to establish any reasons for this antimicrobial resistance 
association. Future work could involve extending this work to future GRASP collections to 
establish if this association remains with greater numbers. In addition, whole-genome sequencing 
of the TEM-135 isolates to help establish any genetic relatedness between the TEM-135 isolates 
that cannot be distinguished from NG-MAST and plasmid typing would be of interest.  Historical 
typing of TEM-135 isolates could help establish if this tetracycline and ciprofloxacin resistance 
with TEM-135 are separate evolutionary events. 
The NG-MAST STs of the TEM-135 isolates from GRASP 2012 combined with TEM-135 isolate    
NG-MAST STs from previously published studies show a similar population structure as the GRASP 
2012 PPNG isolates. The two examples of clustering between different countries (China/UK and 
China/Japan) may be due to inter-country strain transmission. None of the NG-MAST STs from the 
GRASP 2012 PPNG isolates were identified in the previously published studies (Chen et al., 2013; 
Gianecini et al., 2014; Nakayama et al., 2012; Ohnishi et al., 2010a). The global TEM-135 NG-MAST 
sequence data show some evidence of multiple independent acquisition/evolution events, which 
is confirmed by the fact the blaTEM135 alleles have been detected on the Asian, African and 
Toronto/Rio type plasmids in this study and other studies. However, there are some strains with 
very similar NG-MAST sequences showing global and/or clonal dissemination spread of these 
TEM-135 isolates. It is not clear from these data if there is a common ancestor of TEM-135, so 
more sequencing of TEM-135 isolates is required to help establish this or to establish if TEM-135 
has occurred through multiple independent origins. Further sequencing of historical isolates 
would help elucidate how TEM-135 evolved in N. gonorrhoeae. TEM-135 may have evolved in     
N. gonorrhoeae from; i) multiple separate mutation events of the blaTEM-1 parent allele in different 
lineages and plasmid types, ii) a plasmid with blaTEM-135 could have been introduced once and then 
transferred horizontally between gonococcal strains with subsequent transposition on to different 
plasmid types, or iii) blaTEM-135 could have been repeatedly acquired from an unknown source.  
It was originally proposed that M182T is always a secondary ‘stabilising’ mutation or a 
‘suppressor’ of substitutions that decreases enzyme stability or disrupts folding (Huang & Palzkill, 
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1997; Orencia et al., 2001; Sideraki, Huang, Palzkill, & Gilbert, 2001), because until TEM-135 was 
first described (Pasquali et al., 2005), the M182T substitution was only found in combination with 
other amino acid substitutions. Amino acid substitutions near the active site of TEM can increase 
the activity of the enzyme by enlarging the active site and thereby increasing the ability of the 
enzyme to hydrolyse ESCs which have larger oxyimino side-chains. These substitutions can come 
at a cost of de-stabilising the enzyme and lowering the penicillinase activity (Huang & Palzkill, 
1997; Wang, Minasov, & Shoichet, 2002), hence the advantage of a secondary ‘stabilising’ 
mutation like the M182T substitution. A recently published study describing some global PPNG 
isolates (Muhammad et al., 2014) revealed that the degradation of ampicillin by TEM-1 and    
TEM-135 was indistinguishable using a hydrolysis assay, revealing no disadvantage of the M182T 
substitution. Additionally, other studies that have created M182T mutants have revealed either 
slightly lower ampicillin resistance and specific activity of the TEM enzyme with the M182T 
mutation (Huang & Palzkill, 1997; Sideraki et al., 2001) or no difference in the activity of the   
TEM-M182T enzyme (Wang et al., 2002). The presence of the M182T mutation in the TEM 
enzyme, in addition to substitutions at single and multiple positions, results in restored activity 
and increased stability of the TEM enzyme  (Hall, 2002; Huang & Palzkill, 1997; Sideraki et al., 
2001; Wang et al., 2002). 
Why this functionally non-advantageous enzyme is present in the gonococcal population, since at 
least 1984 (Muhammad et al., 2014), and why TEM-135 has been detected sporadically in animals 
(Jones-Dias et al., 2013), including the first isolation from Salmonella enterica subsp. enterica 
serovar Typhimurium from a rabbit in Italy (Pasquali et al., 2005), as well as in a patient with a 
lower respiratory tract infection in China (An et al., 2012), is interesting. M182T may simply be a 
natural polymorphism which confers no disadvantage and so is maintained within the gonococcal 
population as an efficient penicillin resistance mechanism as TEM-135 in gonococci predated the 
increased use of cephalosporins for gonorrhoea treatment (Muhammad et al., 2014). Additionally 
the increased stability conferred by M182T far from the active site, in the hinge region between 
the two β-lactamase domains (Orencia et al., 2001), may have allowed this variant to become 
fixed in the population. This single-year study does not indicate when TEM-135 emerged in the 
gonococcal population in England and Wales. Therefore further sequencing of plasmids with  
TEM-135 and genomes from older isolates may help in answering how and why the M182T 
substitution is circulating. Sequencing of more historical isolates to determine if TEM-135 has 
spread throughout the different β-lactamase plasmids by horizontal transfer or has occurred in 
situ through single nucleotide polymorphisms (SNPs) in TEM-1 would also be of interest.  
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It is encouraging that no further blaTEM alleles have been detected in this gonococcal population 
other than blaTEM-135, and blaTEM-1-P14S, which has been detected elsewhere (Muhammad et al., 
2014). A non-ESBL β-lactamase, TEM-220, with both the M182T and an A185T substitution has 
recently been identified in a N. gonorrhoeae strain isolated in Argentina (Gianecini et al., 2014). 
This could have evolved from an isolate with TEM-135 isolate already harbouring the M182T 
substitution, and even though the enzyme is non-ESBL with the additional A185T substitution, it 
shows the ability of the TEM-135 enzyme in N. gonorrhoeae to maintain additional substitutions. 
Even though extended-spectrum cephalosporin use may not have selected for TEM-135 in           
N. gonorrhoeae the fact remains that just a single specific mutation near the β-lactamase active 
site in this already stable enzyme could result in TEM-135 evolving into an ESBL. Currently there 
are three ESBLs that differ from TEM-135 by one amino acid substitution (TEM-20, TEM-106 and 
TEM-126) (Lahey Clinic, 2015). In fact M182T is a common amino acid substitution in the TEM 
enzymes, as it is present in a total of 23 enzymes (TEM-20, 32, 43, 52, 63, 72, 87, 88, 91 – 94, 106 -
7, 113, 124, 126, 131, 149, 153, 159, 161, 165 177, 184, 205 and 211) (Lahey Clinic, 2015).  Even 
though resistance and decreased susceptibility to ESCs in gonococci has, to date, been 
chromosomally-mediated (Unemo & Shafer, 2014), it is not unreasonable to foresee the 
emergence of further mutations in the TEM-1 or TEM-135 enzymes in N. gonorrhoeae, selected 
by increasing cephalosporin dosages. It is also possible that N. gonorrhoeae may acquire a 
complete ESBL or TEM-ESBL, as TEM enzymes are associated with transposable elements and are 
very prevalent in Gram-negative bacteria (Liu, Gur, Hall, & Livermore, 1992). In N. gonorrhoeae 
blaTEM-1 is encoded by a TnA (ampicillin)-like transposon, Tn2 (Chen & Clowes, 1987; Pagotto et al., 
2000a). The regions flanking blaTEM-1 in N. gonorrhoeae include about 40% of the Tn2 sequence 
(Elwell et al., 1977; Fayet et al., 1982; Roberts et al., 1977) making it non-transposable (Fayet et 
al., 1982), however other transposon regions in N. gonorrhoeae do exist. The potential emergence 
of an ESBL in the UK TEM-135 gonococcal population is of additional concern as all isolates 
already display high-level ciprofloxacin and tetracycline resistance which would make effective 
administration of therapy challenging. Therefore, monitoring genetic changes in blaTEM alleles 
which may result in blaTEM-1 or blaTEM-135 developing into an ESBL in N. gonorrhoeae is important to 
enable patients with gonorrhoea to be treated appropriately. 
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8 Conclusions and future work 
The work presented in this thesis showed for the first time that electroporation is an effective 
method for transferring gonococcal resistance plasmids into N. gonorrhoeae. Electroporation is 
advantageous over natural transformation for plasmid transfer because it does not require 
piliated strains (Biswas et al., 1977) or the gonococcal DNA uptake sequence (DUS) on the plasmid 
(Ambur et al., 2007) and host-restriction is not a factor (Stein et al., 1988). Electroporation also 
alleviates the requirement for donor strains to harbour the conjugative plasmids when plasmid 
transfer is performed using conjugation (Sox et al., 1978).  
When electroporation was used to transfer the E. coli plasmid pEK204, which harbours both 
blaCTX-M-3 and blaTEM-1b, no gonococcal transformants were identified either by plasmid transfer or 
by transposition of blaCTX-M-3. The large size of pEK204 (94 kb) is a possible factor in the 
unsuccessful plasmid transfer. No transformants were identified from the electroporation and 
natural transformation experiments with the blaCTX-M-3 gene variants; with and without the 
predicted promoter and/or the gonococcal DUS. A lack of recombination site in the gonococcal 
genome for recombination for blaCTX-M-3 is the most plausible reason for no incorporation of   
blaCTX-M-3. Additionally no recombination of blaCTX-M-3 with the gonococcal blaTEM-1 was most 
probably because the differences between the two genes were too great for homologous 
recombination. 
In total five transformants were obtained using the TEM-derived extended-spectrum -lactamase 
(ESBL), TEM-10. These results showed that N. gonorrhoeae can acquire and express an ESBL and 
that this was associated with four- to eight- fold increases in MICs of ceftriaxone and ceftazidime. 
This work is the first report of ESBL activity in the species, although achieved under laboratory 
conditions. Transformation of the blaTEM-10 gene into N. gonorrhoeae was not demonstrated when 
ceftriaxone was used for selection. This may indicate that using ceftriaxone, as recommended for 
effective gonorrhoea treatment (Bignell & Fitzgerald, 2011), might reduce the probability of an 
ESBL gene with a high degree of similarity to blaTEM-1, transforming into N. gonorrhoeae in the 
natural environment. 
The sequence analysis of the blaTEM alleles among PPNG isolates collected in England and Wales 
revealed TEM-1 penicillinase still to be the most common (found in 73% of PPNG), with the  
blaTEM-135 allele also identified in some gonococcal lineages (27% of PPNG). This is the first time 
that TEM-135 has been reported in PPNG from the UK and just a single specific mutation near the 
β-lactamase active site in this stable enzyme could result in TEM-135 evolving into an ESBL. This is 
130 
 
concerning because the TEM-135 isolates were associated with high-level ciprofloxacin and 
tetracycline resistance. Sequence analysis of NG-MAST sequences along with the TEM enzymes 
and plasmid-types revealed no common linkage to the blaTEM-135 alleles in the 2012 GRASP PPNG 
isolate collection. The global TEM-135 NG-MAST sequence data showed some evidence of 
multiple independent acquisition/evolution events. The investigations of NG-MAST sequence 
similarity using recent PPNG and non-PPNG isolates from GRASP revealed a large level of diversity 
and the PPNG isolates and the non-PPNG isolates mainly cluster separately suggesting that the 
strains have evolved independently.  
The acquisition and expression of a gonococcal β-lactamase plasmid by a selection of                     
N. gonorrhoeae isolates with NG-MAST ST1407 was successful, suggesting that this already 
multidrug-resistant strain could acquire gonococcal β-lactamase plasmids in natural mixed 
gonococcal infections. The apparent absence of naturally-occurring ST1407 PPNG strains to date is 
most probably based on epidemiology and is not related to the inherent biology of the ST1407 
isolates.  
It is encouraging that N. gonorrhoeae was not able to acquire or express the CTX-M-3 ESBL, 
however it is concerning that the TEM-10 ESBL was expressed, resulting in increased MICs of 
cephalosporins. The data presented in this thesis suggests that N. gonorrhoeae is unlikely to 
acquire an ESBL-encoding plasmid directly from an enteric host; however acquisition might occur 
via an intermediate host. An ESBL may arise due to further mutations in the TEM-1 or TEM-135 
enzymes in PPNG, or might be acquired by transposition of an ESBL gene after entry into               
N. gonorrhoeae. Both events are more likely if sub-optimal cephalosporins are used for 
gonorrhoea treatment. However, high-level ceftriaxone resistance is most likely to arise, as at 
present, through chromosomal mutations in penicillin-binding protein 2 (PBP 2).  
These data highlight the need to use the recommended and highly effective ceftriaxone, in 
combination with azithromycin, to treat gonorrhoea (Bignell & Fitzgerald, 2011). It is essential to 
continue antimicrobial susceptibility surveillance via phenotypic methods and to develop 
molecular surveillance to detect rapidly the emergence of any ESBLs in N. gonorrhoeae. ESBL-
producing N. gonorrhoeae would render the last remaining option for monotherapy, ceftriaxone, 
useless and would be a public health emergency as there are currently no other long-term 
treatment options available (Unemo, 2015).  
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Future work 
The progression of much of the work presented in this thesis involves whole genome sequencing 
to help elucidate the following; 
1. Genetic differences responsible for the differences in plasmid transformation 
efficiencies. 
2. The level of genetic differences between the ST1407 isolates used in the conjugation 
studies. 
3. Genetic relatedness between the TEM-135 isolates that cannot be distinguished from 
NG-MAST and plasmid typing.   
4. Whether there is a common ancestor of TEM-135 in N. gonorrhoeae or whether 
acquisition or evolution of TEM-135 has occurred through multiple independent 
events. 
Further work in respect to the blaTEM-135 study includes the typing of historical TEM-135 isolates to 
help establish if the tetracycline and ciprofloxacin resistance with TEM-135 are separate 
evolutionary events. In addition further typing would help elucidate how and why TEM-135 
evolved in N. gonorrhoeae and whether TEM-135 has spread throughout the different                   
β-lactamase plasmids by horizontal transfer or has occurred in situ through single nucleotide 
polymorphisms in TEM-1. 
Future work to further investigate whether blaCTX-M-3 could be expressed in N. gonorrhoeae 
includes incorporating blaCTX-M-3 into other plasmids that have successfully mobilised into              
N. gonorrhoeae, and investigations into whether TEM-1 mutants can be selected using a sub-
optimal cephalosporin such as ceftazidime are of interest. 
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9 Changes to professional practice 
 Background 9.1
The genetic diversity of blaTEM alleles of penicillinase-producing Neisseria gonorrhoeae described 
in Chapter 6 revealed the value of performing molecular surveillance; genetic changes in genes 
such as blaTEM can be detected before any rise in the minimum inhibitory concentrations (MICs) 
become apparent, and these changes may be precursors to extended-spectrum β-lactamases. The 
methods used in this thesis were based on Sanger DNA sequencing (see Section 3.3.3), however 
whole genome sequencing (WGS) could be implemented not only to detect changes in blaTEM 
alleles but also, potentially, to predict susceptibility or resistance to antibiotics, to replace 
conventional diagnostics, to assist in the development of diagnostic tests and to enable enhanced 
molecular typing. WGS could also be developed to be used directly on clinical specimens. 
 
There are only a few published articles that describe the use of WGS for N. gonorrhoeae in 
relation to antimicrobial susceptibility profile. WGS was performed on one isolate with decreased-
susceptibility to cefixime from the USA in 2012 (Hess et al., 2012), and on another isolate from 
Italy in 2013 (Anselmo et al., 2015). Larger studies have been performed to investigate the 
emergence and spread of cefixime decreased-susceptibility and the relatedness of the isolates in 
the USA (Grad et al., 2014) and Canada (Demczuk et al., 2015). An international study investigated 
the population structure of 76 isolates and the known antibiotic resistance determinants in the 
strains (Ezewudo et al., 2015). 
 
 WGS and the Gonococcal Resistance to Antimicrobial Surveillance 9.2
Programme (GRASP) 
The Sexually Transmitted Bacteria Reference Unit (STBRU) at Public Health England (PHE) is 
currently collaborating with other groups to perform some large WGS studies. The expertise and 
data obtained from these projects, along with the bioinformatics pipelines, can subsequently be 
applied to the Gonococcal Resistance to Antimicrobial Surveillance Programme (GRASP) so WGS 
can be used for antimicrobial susceptibility molecular surveillance. The current GRASP model 
utilises agar dilution of susceptibility testing of seven antimicrobials of approximately 2200 
isolates per year (Public Health England, 2014a) so this current programme could be modified to 
reap the benefits of WGS as subsequently described. 
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1. Establish relationships between genetic markers of resistance mechanisms and MICs   
For some antimicrobials WGS would enable antimicrobial susceptibility to be predicted from the 
sequence data and would enable less phenotypic susceptibility testing to be performed. It is 
predicted that WGS should be reliable for predicting susceptibility to some antimicrobials, 
particularly for those not currently used for the treatment of gonorrhoea, such as ciprofloxacin 
and spectinomycin (Unemo, 2015), as the resistance mechanisms are well defined. Using WGS 
susceptibility and resistance can be indicated for azithromycin (Unemo, 2015), especially if it is 
high-level resistance, but WGS is less reliable for the β-lactam antibiotics as there are usually a 
number of different genes involved in resistance (see Section 1.2.2 and 1.2.6) and extended-
spectrum cephalosporin resistance is currently emerging due to the real-time selection pressure 
from current usage. The acquisition of WGS data alongside phenotypic antimicrobial susceptibility 
testing would allow the identification of new and emerging mechanisms of resistance. WGS could 
also be used to sequence gonococcal DNA present in clinical specimens; approximately 50% of 
gonorrhoea diagnoses do not have a gonococcal culture available for susceptibility testing 
(Mohammed et al., 2015) so directly sequencing clinical specimens would enable resistance 
determinants information to be gathered on currently circulating strains. This in turn will provide 
a more representative dataset to inform prescribing policy. 
 
2. Molecular identification  
Once validated, the identification of N. gonorrhoeae could be established using the WGS data. 
WGS could replace current phenotype and genetic identification tests used in routine and 
reference  diagnostic service such as the Phadebact Monoclonal GC test (Launch Diagnostics, 
Longfield, UK), the API NH Test (BioMérieux), MALDI-TOF (Bruker, Coventry, UK) and a variety of 
molecular diagnostics (Toby et al., 2015). The WGS data could also provide a database for 
development and subsequent monitoring of current DNA targets used in molecular diagnostics 
such as to identify single nucleotide polymorphisms or gene replacements which could result in 
false-negative results. An example of which is the replacement of the gonococcal porA 
pseudogene with the meningococcal porA in some N. gonorrhoeae isolates (Ison, Golparian, 
Saunders, Chisholm, & Unemo, 2013a). The data could be used for the development of point-of-
care (POC) tests which could not only be used for the diagnostics of N. gonorrhoeae, but also 
direct patient management as antimicrobial susceptibility could be detected in parallel (Sadiq, 
Dave, & Butcher, 2010).   
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3. Enhanced molecular typing 
Sequence types (STs), such as those derived from the N. gonorrhoeae multi-antigen sequence 
typing (NG-MAST) method (Martin et al., 2004) could be established from the WGS data which 
would enable the monitoring of the different STs in the GRASP gonococcal population. This ST 
data could in turn be used to compare the GRASP STs with other studies from the UK and 
internationally, as well as providing a base-line of circulating STs so potential outbreaks can be 
verified. WGS would enable greater discrimination than currently provided by the two sequenced 
alleles in NG-MAST and would allow for the relatedness of strains to be explored further, such as 
in the analysis of transmission in sexual networks and the evolution of resistance. The enhanced 
discrimination may also allow for WGS data to be used in medico-legal cases where patient 
linkage could be demonstrated. However, the rate of genetic change between contacts needs to 
be established first. 
 Stakeholders benefits 9.3
The following encompasses those who would benefit from the use of WGS in GRASP; 
 Patients – The patient pathway at the clinic visit would not alter, however, the enhanced 
information obtained by WGS with the cultures obtained from the patients would assist in 
the development of POC tests and other diagnostic tests and this would eventually impact 
favourably on patient management. 
 
 Referring laboratories - The isolates for GRASP and the routine diagnostic service are sent 
to STBRU from primary diagnostic laboratories. These laboratories in turn would receive 
reports confirming the diagnosis of gonorrhoea, enhanced data on the isolates such as 
NG-MAST ST, and WGS has the potential to improve turnaround times of the surveillance 
data. 
 
 British Association of Sexual Health and HIV (BASHH) – National guidelines concerning 
patient management for the treatment of gonorrhoea is in part based on the 
antimicrobial susceptibility surveillance data generated by GRASP (Bignell & Fitzgerald, 
2011).  The use of WGS to provide information on circulating resistance markers in clinical 
specimens when culture is not available could also provide a more representative dataset 
to inform patient management. 
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 Governmental and commercial laboratories – The WGS data can be used to develop and 
monitor molecular tests for the identification of N. gonorrhoeae as well as for the 
prediction of antimicrobial susceptibility. 
 
 Costs 9.4
WGS is currently still quite expensive (£30 per isolate using the research four week turnaround 
price) and it could not directly replace all phenotypic susceptibility testing. However, susceptibility 
testing could be performed on only the clinically relevant antimicrobials; ceftriaxone, cefixime and 
azithromycin (Bignell & Fitzgerald, 2011), and susceptibility and resistance predictions for the 
previously used antimicrobials could be obtained from the sequence data. NG-MAST is currently 
performed on approximately 500 isolates per year from GRASP (Ison et al., 2013b) so this 
information could be obtained from the WGS data as opposed to performing Sanger sequencing. 
The strain identification could also be determined by WGS as opposed to the current methods. 
 
To perform WGS on all the GRASP isolates would cost an additional £52,210 (Table 9.1). This is not 
viable in the current economic climate. Therefore, WGS could be performed on a subset of 
isolates, or the total number of isolates submitted to GRASP could be reduced if the 
representativeness of GRASP was shown to not be affected. A reduction in the number of isolates 
tested in GRASP would also reduce staff costs. Even though WGS would represent an additional 
cost, the extra information obtained as previously described and the subsequent Public Health 
benefits are clear. 
 
 Implementation 9.5
To implement WGS in the GRASP the concept first needs to be presented to the GRASP steering 
group. Logistical and financial support for the development of WGS in GRASP needs to be 
provided by Public Health England. Initially a pilot could be performed to establish the feasibility 
of performing WGS in real-time.  
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Table 9.1 Current laboratory GRASP cost, cost of WGS and the combined cost of GRASP with WGS 
Current GRASP costs (for 2200 isolates) Cost (£) 
Isolate retrieval, identification and archiving of isolates 10,260 
MIC testing  9,948 
NG-MAST costs (~500 isolates/year currently typed) 17,150 
Total 37,358 
    
WGS costs for 2200 isolates   
DNA extraction and quantification 15,884 
WGS 66,000 
Total 81,884 
    
Revised GRASP costs with WGS (2200 isolates)   
Retrieval only 3,420 
MIC of ceftriaxone, cefixime and azithromycin only 4,263 
WGS cost 81,884 
Total 89,567 
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10 Personal and professional reflection 
Reflection has been defined by Johns (1995) as “…the method to access, make sense of and learn 
through experience” (p. 25). Johns additionally states that in the professional workplace setting, 
one should use reflective practice “…to access, make senses of and learn through work 
experience, to achieve more desirable, effective and satisfying work” (1995, p. 23-24). Reflection 
enables us to learn from our experience and then initiate change to avoid repeating the same 
negative experiences (Moon, 1999, p. 27). To assist with my own critical reflection on my learning 
and professional development in relation to the work described in this thesis, Gibbs’ Reflective 
Cycle was used as a reflection tool (Gibbs, 1988, Section 4.3.5) (Figure 10.1). 
 
Figure 10.1 Gibbs Reflective cycle (Gibbs, 1988, Section 4.3.5)  
  
2. What were your 
reactions and feelings? 
3. What was good and 
bad about the 
experience? 
6. From what you have 
learnt, what will you do 
differently next time? 
Description 
Feelings 
Evaluation 
Action 
plan
4. What sense can you 
make of the situation? 
Analysis 
5. What can be 
concluded from this 
experience? 
Conclusion 
1. What happened? 
138 
 
1. Description 
This thesis forms part of the work submitted to achieve a Professional Doctorate degree in 
Biomedical Science. To achieve completion of this thesis I aimed to develop competencies in four 
areas which are also invaluable to my future career as a scientist: 
 To develop into an effective scientific writer  
 To obtain a high knowledge base in my specialist subject area 
 To develop laboratory skills in molecular biology techniques 
 Become more focused and develop concentration 
The project work contained in the thesis was originally described in the project proposal. The 
proposal was in general adhered to, with some minor modifications with some extra work added, 
such as the work described in Chapter 7.  
2. Feelings 
In respect to the writing of the thesis I was very apprehensive; I find writing difficult and I was 
concerned that it would not be good enough and not at the right level.  I also felt scared that I 
would never complete it, and it was a bit depressing at times that I could not fully engage in the 
more fun aspects of life as the doctorate work had to take priority at times.  
3. Evaluation 
The time spent studying for this Professional Doctorate has unfortunately coincided with some 
major personal and professional challenges over the past few years. The professional challenges 
were mainly down to severe staff shortages, which have meant that for many years I have had to 
do the work of two roles. I lost my main supervisor at Public Health England for her own personal 
reasons, and the Unit also lost its Director, and subsequently many years of experience. There was 
no-one left in the Unit that I could turn to for advice in respect to the doctoral work, but I was 
very fortunate that my other PHE supervisor, in a different Unit, was very supportive and always 
offered me his time, along with some members of his team. In the absence of any direct support I 
was very appreciative of the support from my supervisor and the course leader at the University 
of Portsmouth. It has been very hard but I have shown that if you keep at it you can make it in the 
end.  
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For many years I always put my day job first and therefore it was very difficult to find the time and 
space to perform the doctoral work.  However, it became clear that the only way was I was ever 
going to finish my doctorate was if I prioritised it over everything else. Of course not to the 
complete exclusion of everything else as I still needed my job and friends when the writing was 
finished! So for the last five months or so completing the thesis has been my priority. I did this 
with the blessing of my work place; as long as my work deliverables were met I could say no to 
other work. I only really started making real progress with my thesis when I learnt a valuable 
lesson; if you want to achieve something big, it has to be your main focus. 
I feel that I have achieved my main four objectives which will be invaluable for my future career. 
Even though I feel am not a natural at scientific writing, I do feel that I have improved a great deal 
and I am no longer apprehensive about writing work for peer-review. I am aware that I still need 
to do more work to improve my writing skills, but this will come with time as I do more scientific 
writing. I am now confident that I have a high knowledge base in my specialist subject area. In 
particular my literature searching skills have improved tremendously and I keep up to date with 
current published literature and I continue to attend scientific conferences and seminars. My 
laboratory skills in molecular biology techniques have developed well, and I now have the 
confidence to try new techniques independently. The whole Professional Doctorate process has 
meant that I have had to improve my time management skills and become more focused. I have 
found that meditation, mindfulness and exercise assist greatly in helping with my concentration.  
4. Analysis and conclusion 
Scientists must write and publish and now I feel I can do this with confidence. Publishing work 
provides evidence to your funders and workplace that work has been performed well. It is also 
important that the work is appropriately disseminated to the right audience in a timely manner. I 
have improved my presentation skills on this doctoral journey and gained more contacts in the 
Biomedical Science field. I can now see that self-sufficiency is an extremely valuable life skill, in 
and out of the work place, and if you have a good knowledge base it opens more doors for you in 
the future. The most important thing I have learnt is that I can achieve something big when also 
faced with other challenges. 
5. Action plan 
My action plan for the future is to keep on writing, to publish more work, to develop some ideas 
that that spun out of both my doctoral work and from the field of N. gonorrhoeae antimicrobial 
resistance in general, and to move onto bigger and exciting new challenges.  
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12 Appendix One – Primer sequences 
Table A1 Primer sequences. 
Primer name 5’ to 3’ sequence 
PorB-F CAAGAAGACCTCGGCAA 
PorB-R CCGACAACCACTTGGT 
TbpB-F CGTTGTCGGCAGCGCGAAAAC 
TbpB-R TTCATCGGTGCGCTCGCCTTG 
BlaF CGCTCATGAGACAATAACCCTGG 
BlaR GGGTCTGACGCTCAGTGGAACG 
JDA  TACTCAATCGGTAATTGGCTTC 
JDB CCATATCACCGTCGGTACTG 
UF CTCGAACAAGAGGAAAGC 
AR  GCATTCCACTTCCCAAC 
DR TGCAGCAGAGGGAGG 
CTX-M-gp1-F AAAAATCACTGCGCCAGTTC 
CTX-M-gp1-R AGCTTATTCATCGCCACGTT 
CTX3_geneF  TAAGGAATCCCATGGTTA 
CTX3_geneR        CCGCTATTACAAACCGTC    
CTX-M-gp1-PPF    TGCTCTGTGGATAACTTGC 
CTX-M-gp1-PPR  CCGTTTCCGCTATTACAAAC 
CTX3_gene_GC_F  ATGCCGTCTGAATAAGGAATCCCATGGTTA 
CTX3_gene_GC_R       ATGCCGTCTGAACCGCTATTACAAACCGTC 
CTX-M-gp1-PPGCF   ATGCCGTCTGAATGCTCTGTGGATAACTTGC 
CTX-M-gp1-PPGCR  ATGCCGTCTGAACCGTTTCCGCTATTACAAAC 
CTX3_seqF TTAGGAAGTGTGCCGCTGTA 
CTX3_seqR TCACTTTTCTTCAGCACCGC 
TEM10_F CATTTTCGTGTCGCCCTTAT 
TEM10_R ATACGGGAGGGCTTACCATC 
TEM10_GC_F ATGCCGTCTGAACATTTTCGTGTCGCCCTTAT 
TEM10_GC_R ATGCCGTCTGAAATACGGGAGGGCTTACCATC 
penA_F CGGGCAATACCTTTATGGTGGAAC 
penA_R ACAACGGCGGCGGGGATATAAC 
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13 Appendix Two – Ethics 
This section contains information relating to the ethical considerations of the work presented in 
this thesis; 
1. A letter from the Health Protection Agency (now Public Health England) R&D Office 
stating that ethical approval was not required for the proposed work.  
2. A letter from the BioSciences Research Ethics Committee, University of Portsmouth, 
stating that the proposed work was given a favourable opinion.  
3. A completed research ethics review checklist for the University of Portsmouth (form 
UPR16).  
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Health Protection Agency 
HPA R&D Office 
R&D Division 
Centre for 
Emergency 
Preparedness and 
Response 
Porton Down 
Salisbury 
Wiltshire 
SP4 0JG 
 
T: 01980 619916 
F: 01980 612216 
 
 
Dear Michelle,  
It is the opinion of the HPA R&D Office that, from the information supplied by you, you do not 
need to seek ethical approval for the above named project as it meets the criterion below set 
out in NHS National Research Ethics Service guidance “Does my project require review by a 
Research Ethics Committee?”:  
 
3. Research involving acellular material  
Research limited to acellular material (e.g. plasma, serum, DNA) extracted from tissue 
previously collected in the course of normal care is generally excluded from REC review, 
provided that the patients or service users are not identifiable to the research team in 
carrying out the research. 
 
The HPA R&D Office is content that the proposed project can be started once your line manager 
has confirmed that they are willing for you to spend time on the project and that there are 
sufficient resources to support the study. 
 
Yours sincerely, 
 
Professor Paul Boseley 
Deputy Director of R&D 
Deputy Chair of RSRSG 
Health Protection Agency 
paul.boseley@hpa.org.uk 
 
Encl: National Research Ethics Service guidance document: “Does my project require review 
by a Research Ethics Committee?” 
 
Michelle Cole 
Health Protection Agency 
Sexual Transmitted Bacterial Reference Laboratory 
61 Colindale Avenue 
London  
NW9 5EQ 
04 April 2012 
Re: Title of Doctorate Project:   Extended spectrum -lactamases and Neisseria 
gonorrhoeae: pre-empting a mechanism that could abolish cephalosporins for the 
treatment of gonorrhoea 
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Dr. Jeremy Mills 
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School of Pharmacy and Biomedical 
Sciences  
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T: 023 9284 2652 
F: 024 9284 3656 
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ETHICAL REVIEW – BSREC 12/066   
 
Protocol Title: Extended spectrum -lactamases and Neisseria gonorrhoeae: pre-
empting a mechanism that could abolish cephalosporins for the treatment of 
gonorrhoea 
 
 
Date Submitted: 2nd May 2012 
 
Thank you for submitting your protocol for ‘light touch’ ethical review. The protocol 
has been reviewed by the undersigned in accordance with current procedures1 on 
behalf of the BioSciences Research Ethics Committee. 
 
On behalf of the Committee I am happy to give a favourable opinion of your 
application under Approval Code BSREC 12/066. 
 
 
 
 
 
 
 
 
Dr Jeremy Mills 
Co-chair of the BioSciences Research Ethics Committee 
                                                 
1
 The Schedule of Approved Procedures (Annex C to Procedures for Ethical Review). Biosciences 
Research Ethics Committee, University of Portsmouth, December 2009).  
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14 Appendix Three – Dissemination evidence 
The presentation details from the work presented at the 29th IUSTI European Conference on 
Sexually Transmitted Infections, Sitges (Spain), 24-26 September is shown in Figure A1, and the 
accepted abstract is shown below; 
Can Neisseria gonorrhoeae acquire, maintain and express an extended-spectrum β-
lactamase gene?  
Michelle Cole, Catherine Ison & Neil Woodford 
Background 
Ceftriaxone is the last option for empiric monotherapy for the treatment of gonorrhoea. 
In recent years chromosomally-mediated resistance to ceftriaxone has emerged in 
Neisseria gonorrhoeae. Therefore increasing doses of ceftriaxone, administered with 
azithromycin, are now recommended for effective treatment. Fortunately, extended-
spectrum β-lactamases (ESBLs), which would render the last treatment option for 
monotherapy (ceftriaxone) unusable, have not been detected in N. gonorrhoeae.  
Objectives 
Can an ESBL gene be transferred into, maintained and expressed by N. gonorrhoeae? 
Methods 
Electroporation was used to transfer pEK204 (harbouring blaCTX-M-3 and blaTEM-1, 95 kp) 
extracted from an uropathogenic E. coli strain (ST-131) into various gonococcal strains. 
The blaCTX-M-3 gene from pEK204 was amplified with and without the open-reading frame, 
and also with and without the gonococcal DNA uptake sequence incorporated into the 
PCR products. Electroporation and natural transformation was used to transform 
gonococci with the blaCTX-M-3 gene variants. All experiments were performed in triplicate 
with varying levels of cefotaxime selection. 
Results 
None of the electroporation and natural transformation experiments resulted in any 
transformants. All the controls, DH5-α E. coli as a recipient for pEK204 and the gonococcal 
penA for the blaCTX-M-3 experiments worked successfully.  
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Discussion 
Previous electroporation of native gonococcal plasmids into N. gonorrhoeae was 
successful so electroporation was not a limiting factor. pEK204 is probably too large to be 
acquired by N. gonorrhoeae. Future work using TEM-ESBLs are required to establish if the 
unsuccessful blaCTX-M-3 transformations were due to a lack of recombination site. It is 
encouraging that N. gonorrhoeae was not able acquire and express this ESBL. Vigilance to 
detect the acquisition or emergence of an ESBL in N. gonorrhoeae is however essential.   
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Figure A1 Presentation details taken from the 29th IUSTI European Conference on Sexually Transmitted Infections programme (Presentation O-14).
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The poster details from the work presented at the Public Health England Annual Conference 2014, 
16-17 September 2014, are shown in Figure A1. The presented poster and the subsequent 
publication in the Journal of Antimicrobial Chemotherapy is included at the end of this thesis. 
 
Figure A2 Poster details taken from the Public Health England Annual Conference 2014 
programme (poster 146).
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molecular epidemiological characteristics of penicillinase-producing
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Objectives: The objective of this study was to investigate the genetic diversity of blaTEM alleles, antimicrobial sus-
ceptibility andmolecular epidemiological characteristics of penicillinase-producing Neisseria gonorrhoeae (PPNG)
isolates collected in 2012 from England and Wales.
Methods: PPNG isolates were from the 2012 Gonococcal Resistance to Antimicrobial Surveillance Programme
(GRASP). Their susceptibility to seven antimicrobials was determined using agar dilution methodology.
b-Lactamase production was detected using a nitrocefin test. b-Lactamase plasmid types were determined
and blaTEM genes were sequenced. Isolates were also typed by N. gonorrhoeae multi-antigen sequence typing
(NG-MAST).
Results: Seventy-three PPNG isolates were identified in the 2012 GRASP collection (4.6%, 73/1603). Three differ-
ent blaTEM alleles were identified, encoding three TEM amino acid sequences: TEM-1 (53%), TEM-1 with a P14S
substitution (19%) and TEM-135 (27%). The blaTEM-135 allele was present in nine different NG-MAST types and
was found mostly on Asian (60%) and Toronto/Rio (35%) plasmids. By contrast, most TEM-1-encoding plasmids
were African (98%). All the TEM-135 isolates displayed high-level ciprofloxacin and tetracycline resistance.
Conclusions: The high proportion of blaTEM-135 alleles (27%) demonstrates that this variant is circulating within
several gonococcal lineages. Only a single specific mutation near the b-lactamase active site could result in
TEM-135 evolving into an ESBL. This is concerning particularly because the TEM-135 isolates were associated
with high-level ciprofloxacin and tetracycline resistance. It is encouraging that no further TEM alleles were
detected in this gonococcal population; however, vigilance is vital as an ESBL in N. gonorrhoeae would render
the last remaining option for monotherapy, ceftriaxone, useless.
Introduction
Gonorrhoea is amajor public health concern in England andWales
due to the increasing numbers of new cases (e.g. from 25577 in
2012 to 29291 in 2013)1 and the ability of the causative agent,
Neisseria gonorrhoeae, to develop resistance to all antimicrobial
agents used for treating gonorrhoea.2 Penicillinase-producing
N. gonorrhoeae (PPNG) strains were first detected in 1976 in
both the UK3 and the USA.4 The rapid dissemination of PPNG
strains with high-level, plasmid-mediated penicillin resistance,
combined with emergence of chromosomally mediated penicillin
resistance, rendered this once highly effective antimicrobial aban-
doned in the USA by 1987.5 PPNG strains continue to circulate glo-
bally.6–8 In 2012, the total penicillin resistance (chromosomally
mediated and plasmid-mediated resistance) in gonococci
in England and Wales, as determined by the Gonococcal
Resistance to Antimicrobial Surveillance Programme (GRASP),
was 14.6% and PPNG prevalence was 4.6%.9 This PPNG level is
low compared with many countries in, e.g. South-East Asia,
where PPNG rates may be as high as 100%.6
PPNG strains traditionally produce TEM-1 b-lactamase, with
the encoding blaTEM gene located on one of seven different plas-
mids,10 all of which share a high degree of sequence homology.11
This TEM-1 penicillinase hydrolyses penicillins, but is not active
against extended-spectrum cephalosporins, such as cefixime
and ceftriaxone, which are currently used for gonorrhoea treat-
ment12 and are the last options for empirical antimicrobial mono-
therapy.2 The TEM-135 enzyme, which differs from TEM-1 by one
# The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com
J Antimicrob Chemother 2015; 70: 3238–3243
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amino acid substitution (M182T), was first identified in Salmonella
enterica subsp. enterica serovar Typhimurium from a rabbit in
Italy,13 but has been recently described in N. gonorrhoeae in sev-
eral studies.10,14–20 A recent study found that TEM-135 has been
present in the Toronto/Rio plasmid in N. gonorrhoeae since at least
1984.10 TEM-135 also lacks ESBL activity. However, the M182T
substitution increases enzyme stability21 and only one additional
change at any one of several key amino acid positions would be
needed to confer capacity to hydrolyse extended-spectrum
cephalosporins. A non-ESBL b-lactamase, TEM-220, with both
the M182Tand an A185T substitution has recently been identified
in aN. gonorrhoeae strain isolated in Argentina.19 ESBLs are preva-
lent worldwide in the Enterobacteriaceae and the increasing
prevalence of ESBL-producing Escherichia coli in the community
setting provides further opportunities for N. gonorrhoeae, a natur-
ally transformable species, to be exposed to ESBL-encoding genes
in the uro-genital tract.
We investigated the genetic diversity of blaTEM alleles, anti-
microbial susceptibility and molecular epidemiological character-
istics of PPNG isolates collected in England and Wales, to identify
the proportion and characteristics of TEM-1 and TEM-135 isolates
and to seek any circulating isolates with additional blaTEM alleles
that may have emerged due to the use of extended-spectrum
cephalosporins to treat gonorrhoea.
Materials and methods
Isolates submitted to GRASP in 20129 were tested for susceptibility to
penicillin G, ciprofloxacin, spectinomycin, azithromycin, tetracycline, ceftri-
axone and cefixime using the GRASP agar dilution method.22 The Oxoid
nitrocefin solution test (Oxoid, Basingstoke, UK) was used to detect
b-lactamase production.
The b-lactamase plasmid types were determined by PCR23 and the
blaTEM genes were amplified and sequenced as previously described.
15
N. gonorrhoeae multi-antigen sequence typing (NG-MAST) was performed
as previously described24 and the NG-MAST STs were established at
www.ng-mast.net. All sequence analysis was performed using Bionumerics
version 6.1 (Applied Maths, Sint-Martens-Latem, Belgium) and visualization
of phylograms was performed in FigTree version 1.4.2 (A. Rambaut,
University of Edinburgh, UK).
Geometricmeans of the MICswere calculated for three N. gonorrhoeae
categories (non-PPNG, PPNG with TEM-1 and PPNG with TEM-135). Linear
regression was used to study the relationship between the MICs and the
three different groups, as well as the relationship between TEM-1 and
TEM-135 isolates when the median MICs for the isolate groups differed
by at least two dilutions.
Results
Seventy-three PPNG isolates from 73 different episodes of infec-
tion were identified through GRASP in 2012 (4.6%, 73/1603).
Fifty-eight PPNG isolates were from men (79.5%), 15 were from
women (20.5%) and the median age of patients with a PPNG iso-
late was 28 years (range 18–70 years). Three different blaTEM
alleles were identified encoding two different mature penicilli-
nases. Fifty-three (73%) isolates produced TEM-1 enzyme, 39
(53%) with the classical allele and 14 (19%) with a variant that
differed from TEM-1 by one amino acid, in the signal peptide
region at position 14 [blaTEM-1 (P14S)].
25 Twenty PPNG (27%) iso-
lates produced TEM-135 (Figure 1).
MICs of penicillin G for all the PPNG isolates ranged from 1 to
.4 mg/L and were significantly higher than the penicillin MICs for
the non-PPNG isolates (P,0.001) (Table 1). The ciprofloxacin and
tetracycline MICs for the TEM-135 isolates were significantly higher
(P,0.001) than those for the TEM-1 isolates and the non-PPNG iso-
lates (Table 1). For the remaining antimicrobials, the median and
modal MICs for the TEM-135 isolates were either the same or
one MIC dilution higher than for isolates with TEM-1 (Table 1).
The blaTEM-135 allele was harboured on African, Asian and
Toronto/Rio plasmids (Figure 1). Four different NG-MAST STs were
identified in each of the TEM-135 PPNG groups with the Asian and
Toronto/Rio plasmids. The PPNG with TEM-135 on an African
TEM-135, n = 20 (27%)
TEM-135, Asian, n = 12
TEM-135, Toronto/Rio,
 n = 7
TEM-135, African, n = 1 ST217 (n = 1)
ST4995 (n = 7), ST5785 (n = 2),
ST10680 (n = 1), ST10686 (n = 1),
NT = 1
ST10681 (n = 2), ST5624 (n = 2),
ST10682 (n = 1), ST661 (n = 1),
NT = 1
NG-MAST STs of TEM-135
TEM-1 (P14S), n = 14 (19%)
ST5268 (n = 10)
ST26 (n = 1)
ST8669 (n = 1)
ST4644 (n = 1)
ST2025 (n = 1,
Asian)
TEM-1, n = 39 (53%)
23 different NG-
MAST STs
Figure 1. TEM enzyme distribution, b-lactamase plasmid type and NG-MAST STs of PPNG isolates from England and Wales (2012). NT, non-typeable.
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plasmid belonged to one NG-MAST ST (Figure 1). Other than an
Asian plasmid found in one isolate, the TEM-1-encoding plasmids
were African, in gonococcal isolates belonging to 27 different
NG-MAST STs (Figure 1). No overlap was seen among NG-MAST
STs of isolates with TEM-1 or TEM-135 penicillinases (Figure 1). A
phylogram created by NG-MAST concatenated porB and tbpB
alleles displayed two main clades; the smaller clade represented
isolates of the PorB1a (WI) serogroup, while the larger clade repre-
sented isolates of the PorB1b (WI/III) serogroup. The phylogram
additionally revealed that each individual NG-MAST ST from the
TEM-135 isolates (Figure 2) was ≥14 bp (1.6%) different from its
nearest ‘neighbours’ (Figure 2). According to a previously used def-
inition of NG-MAST genogroups (one of the two alleles identical
and the other ≥99% similar),26 this suggests that many of the
TEM-135 isolates were not closely related.
Discussion
This is the first study, to our knowledge, to reveal the genetic diver-
sity of blaTEM alleles andmolecular epidemiological characteristics
of PPNG strains circulating in England andWales. TEM-1 penicillin-
ase was the most common (found in 73% of the PPNG isolates).
However, the blaTEM-135 allele was identified in several gonococcal
lineages and three plasmid types, with the Asian plasmid type
predominating. These data differ from studies performed in
Thailand,16 Argentina,19 Australia20 and a global study,10 which
all showed the Toronto/Rio plasmid to be the most prevalent car-
rier of blaTEM-135. In accordance with previous studies, we found
that TEM-1 was predominantly encoded by the African plasmid
type,10,16,19,20 the Toronto/Rio plasmid did not harbour the
blaTEM-1 allele as was demonstrated in all but one
16 of the afore-
mentioned studies, and we also detected an association between
NG-MAST STs, the TEM enzyme and plasmid type.15,16,18,19
Comparedwith the TEM-1 and non-PPNG isolates, the TEM-135
isolates were all strikingly resistant to ciprofloxacin, whereas other
studies have not reported any significant difference between the
MICs of antimicrobials tested and the TEM-1 and TEM-135 iso-
lates.10,15,19 These UK TEM-135 isolates harboured three different
main plasmid types and represented dissimilar NG-MAST STs, so
the association with ciprofloxacin resistance is interesting,
although the number of TEM-135 isolates in this study was
quite small. WGS of these TEM-135 isolates might elucidate any
genetic relatedness between these TEM-135 isolates that could
not be distinguished from NG-MAST and plasmid typing.
Amino acid substitutions near the active site can increase the
activity of TEM enzymes by enlarging the active site and thereby
increasing the ability to hydrolyse extended-spectrum cephalos-
porins, which have larger oxyimino side chains. These substitu-
tions can come at a cost of destabilizing the enzyme and
lowering penicillinase activity.27,28 It was originally proposed
that M182T is always a secondary ‘stabilizing’ mutation or a ‘sup-
pressor’ of substitutions that decrease enzyme stability or disrupt
folding,21,28,29 because until TEM-135 was first described,13 the
M182T substitution was only found in combination with other
amino acid substitutions. Studies that have created M182T
mutants have revealed either slightly lower ampicillin resist-
ance/specific activity28,29 or no difference in activity;27 however,
the presence of M182T in addition to substitutions at single and
multiple positions results in restored activity and increasedTa
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stability.27–30 The recent global PPNG study10 revealed that the
degradation of ampicillin by TEM-1 and TEM-135 was indistin-
guishable using a relatively simple hydrolysis assay, indicating
no disadvantage of the M182T substitution.
TEM-135 has been circulating in gonococci since at least 1984
and so pre-dated the increased use of extended-spectrum cepha-
losporins for gonorrhoea treatment.10 Increased stability con-
ferred by M182T far from the active site, in the hinge region
between the two b-lactamase domains,21 may have allowed
this variant to become fixed in the population. Alternatively,
M182Tmaysimply be a natural polymorphism that confers no dis-
advantage and so ismaintainedwithin the gonococcal population
as an efficient penicillin resistance mechanism. Our single-year
study does not indicate when TEM-135 emerged in the gonococ-
cal population in England and Wales. Further sequencing of plas-
mids with TEM-135 and genomes from historical isolates may
help in answering this question, as well as to determine whether
TEM-135 has spread among the different b-lactamase plasmid
types by horizontal transfer or has occurred in situ through SNPs
in TEM-1. The three TEM variants detected in this collection of
gonococci from England and Wales, TEM-135, TEM-1 and TEM-1
(P14S), have all been detected elsewhere.10
Even though extended-spectrum cephalosporin use may not
have selected for TEM-135 in N. gonorrhoeae,10 the fact remains
that just a specific SNP near the b-lactamase active site in this
already stable enzyme could result in TEM-135 evolving into an
ESBL. Currently, there are three ESBLs that differ from TEM-135
by only one amino acid substitution (TEM-20, TEM-106 and
TEM-126).31 Even though resistance and decreased susceptibility
to extended-spectrum cephalosporins in gonococci has, to date,
been chromosomally mediated,2 it is not unreasonable to foresee
the emergence of further mutations in the TEM-1 or TEM-135
5624__TEM-135__cluster_Toronto*
10682__TEM-135__single_Toronto*
10692__TEM-1__single_African
586__TEM-1__single_African
5785__TEM-135__cluster_Asian*
10680__TEM-135__single_Asian*
4995__TEM-135__cluster_Asian*
10678__TEM-1__cluster_African
10686__TEM-135__single_Asian*
10689__TEM-1__single_African
8996__TEM-1__single_African
5793__TEM-1__single_African
217__TEM-135__single_African*
10681__TEM-135__cluster_Toronto*
10683__TEM-1__single_African
4849__TEM-1__single_African
4644__TEM-1-P14S__single_African
661__TEM-135__single_Toronto*
8669__TEM-1-P14S__single_African
5268__TEM-1-P14S__cluster_African
26__TEM-1-P14S__single_African
6974__TEM-1__single_African
10693__TEM-1__single_African
10691__TEM-1__single_African
1612__TEM-1__single_African
10685__TEM-1__single_African
10688__TEM-1__single_African
10687__TEM-1__single_African
10679__TEM-1__single_African
1582__TEM-1__single_African
3.0
8512__TEM-1__single_African
10690__TEM-1__single_African
8671__TEM-1__single_African
2025__TEM-1-P14S__single_Asian
10684__TEM-1__cluster_African
1780__TEM-1__cluster_African
8997__TEM-1__cluster_African
Figure 2. Phylogram of concatenated porB and tbpB alleles (880 bp) from PPNG isolates from England andWales (2012). Node labels: NG-MAST ST_TEM
enzyme_single ST or cluster (at least two isolates)_plasmid type. Asterisks show NG-MAST STs from TEM-135 isolates.
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enzymes in N. gonorrhoeae, selected by increasing extended-
spectrum cephalosporin dosages. The potential emergence of
an ESBL in the TEM-135 gonococcal population, in the UK and
additional countries, is of additional concern as these isolates
already display high-level ciprofloxacin and tetracycline resist-
ance. This situation therefore requires monitoring as the emer-
gence and spread of an ESBL in N. gonorrhoeae would render
the last remaining treatment option for gonorrhoea, i.e. ceftriax-
one, useless and would be a public health emergency.
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